ticlopidine has been researched along with Coronary Thrombosis in 496 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Coronary Thrombosis: Coagulation of blood in any of the CORONARY VESSELS. The presence of a blood clot (THROMBUS) often leads to MYOCARDIAL INFARCTION.
Excerpt | Relevance | Reference |
---|---|---|
"In smokers, a double-dose clopidogrel regimen reduced major cardiovascular events and stent thrombosis after percutaneous coronary intervention, with no increase in major bleeding." | 9.24 | Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. ( Bossard, M; Faxon, DP; Fox, KAA; Gao, P; Granger, CB; Jolly, SS; Mehta, SR; Montalescot, G; Natarajan, MK; Niemela, K; Steg, PG; Tanguay, JF; Widimsky, P; Yusuf, S, 2017) |
"In CHAMPION PHOENIX, cangrelor reduced ischaemic events with no significant increase in GUSTO-defined severe bleeding." | 9.22 | The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. ( Bhatt, DL; Blankenship, JC; Deliargyris, EN; Généreux, P; Gibson, CM; Gutierrez, JA; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016) |
"The CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention) trial demonstrated that cangrelor significantly reduced periprocedural ischemic events in all-comer percutaneous coronary intervention with a modest increase in mild and moderate bleeding." | 9.22 | Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. ( Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016) |
"Ticagrelor reduces thrombotic events compared with clopidogrel in patients with acute coronary syndrome, but may also increase bleeding complications." | 9.19 | Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor. ( Albertsson, P; Dellborg, M; Hansson, EC; Jeppsson, A; Rexius, H, 2014) |
"Ticagrelor compared with clopidogrel reduces the incidence of stent thrombosis in patients with acute coronary syndromes, with consistent benefit across a broad range of patient, stent, and treatment characteristics." | 9.17 | Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. ( Emanuelsson, H; Harrington, RA; James, SK; Katus, HA; Lewis, BS; Mahaffey, KW; Maurer, G; Meier, B; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM, 2013) |
"The study aimed to compare the antiplatelet action of ticagrelor with prasugrel in acute coronary syndrome (ACS) patients with high on-treatment platelet reactivity (HTPR) while on clopidogrel after percutaneous coronary intervention (PCI)." | 9.16 | Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. ( Alexopoulos, D; Damelou, A; Davlouros, P; Galati, A; Hahalis, G; Kassimis, G; Makris, G; Mavronasiou, E; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I, 2012) |
"Residual platelet reactivity (RPR) after clopidogrel loading, measured by the VerifyNow assay, has been shown to predict 12-month clinical events in patients with acute coronary syndromes." | 9.15 | Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. - Impact on intracoronary thrombus burden and myocardial perfusion-. ( Archontakis, S; Gafou, A; Kalogeras, KI; Kariori, MG; Moldovan, C; Papaioannou, TG; Stefanadis, C; Tzamalis, P; Vavuranakis, M; Vrachatis, DA, 2011) |
" On-clopidogrel platelet reactivity was investigated in patients with previous angiographically confirmed STh, myocardial infarction (MI), and controls." | 9.15 | Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Siegbahn, A; Varenhorst, C; Wallentin, L, 2011) |
"The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI." | 9.14 | Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009) |
"Aspirin and clopidogrel are recommended for patients with acute coronary syndromes (ACS) or undergoing coronary stenting." | 9.14 | Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. ( Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Finkelstein, A; Harrington, RA; Husted, S; James, S; Katus, H; Kilhamn, J; Olofsson, S; Steg, PG; Storey, RF; Wallentin, L; Weaver, WD, 2010) |
"Dual antiplatelet therapy with aspirin plus a P2Y(12) receptor inhibitor is the cornerstone of treatment for patients with acute coronary syndrome and in those undergoing percutaneous coronary intervention." | 8.89 | Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. ( Angiolillo, DJ; Azmoon, S, 2013) |
" In this article we focus on the use of clopidogrel in the contemporary management of coronary artery disease." | 8.84 | Contemporary use of clopidogrel in patients with coronary artery disease. ( Beckman, JA; Parikh, SA, 2007) |
"One of the most unusual causes of thrombotic thrombocytopenic purpura (TTP), a life-threatening disease, is ticlopidine hydrochloride, an antiplatelet agent used to prevent strokes in high-risk populations or following coronary artery stent placement." | 8.80 | Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. ( Bennett, CL; Bennett, RH; Davidson, CJ; Feldman, MD; Raisch, DW; Weinberg, PD, 1999) |
"PROMETHEUS was a multicentre observational study that compared clopidogrel vs prasugrel in acute coronary syndrome patients who underwent PCI (n = 19,914)." | 7.88 | Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. ( Aquino, M; Baber, U; Baker, BA; Chandrasekhar, J; Dangas, G; DeFranco, A; Effron, MB; Farhan, S; Ge, Z; Henry, TD; Kapadia, S; Keller, S; Kini, AS; Mehran, R; Muhlestein, JB; Pocock, S; Rao, S; Sartori, S; Sorrentino, S; Strauss, C; Toma, C; Vogel, B; Weintraub, W; Weiss, S, 2018) |
"Among patients in the CHAMPION trials with a prior cerebrovascular event at least 1 year before the percutaneous coronary intervention, the efficacy and bleeding profile of cangrelor compared with clopidogrel was similar to that in the overall trial." | 7.85 | Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD, 2017) |
"There are limited data about long-term outcomes for biodegradable polymer biolimus-eluting stent (BES) versus durable polymer everolimus-eluting stent (EES) in patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI)." | 7.81 | Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction. ( Choi, JH; Choi, RK; Choi, SH; Choi, YJ; Gwon, HC; Hahn, JY; Jang, HJ; Kim, JS; Kim, TH; Lee, HJ; Lee, SH; Park, JS; Park, TK; Roh, YM; Shim, WH; Song, YB; Yang, JH; Yu, CW, 2015) |
"This study sought to assess the usefulness of clopidogrel-pathway genotyping and on-treatment platelet reactivity (OTR) testing in predicting major adverse cardiac events (MACE) in stable coronary artery disease (CAD) patients receiving drug-eluting stents (DES) under dual antiplatelet (clopidogrel plus aspirin) therapy." | 7.79 | Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. ( Briguori, C; Condorelli, G; De Micco, F; Focaccio, A; Latronico, MV; Pagnotta, P; Papa, L; Roncarati, R; Visconti, G; Viviani Anselmi, C, 2013) |
"CYP2C19*17 carrier status is significantly associated with enhanced response to clopidogrel and an increased risk of bleeding." | 7.76 | Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. ( Braun, S; Gebhard, D; Kastrati, A; Koch, W; Morath, T; Schömig, A; Schuster, T; Sibbing, D; Stegherr, J; von Beckerath, N, 2010) |
" The present study was designed to assess the predictive value of adenosine diphosphate (ADP)-induced platelet aggregation (ADP-Ag) and the Platelet Reactivity Index of vasodilator-stimulated phosphoprotein for the occurrence of stent thrombosis in patients admitted for non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention." | 7.75 | Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. ( Alessi, MC; Bali, L; Bonnet, JL; Castelli, C; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J, 2009) |
"The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)." | 7.73 | Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006) |
"The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes." | 7.72 | Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004) |
"We report 3 cases of fatal neutropenia and thrombocytopenia associated with ticlopidine after coronary stenting." | 7.70 | Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. ( Ball, MW; Linnemeier, TJ; Szto, GY, 1999) |
" We report the successful use of ticlopidine, together with aspirin, in a 7-month-old infant with Kawasaki disease complicated by a thrombus in a giant coronary aneurysm that failed to resolve with thrombolytic therapy." | 7.70 | Ticlopidine plus aspirin for coronary thrombosis in Kawasaki disease. ( Baker, AL; Neufeld, EJ; Newburger, JW; O'Brien, M; Parness, IA; Sundel, RP, 2000) |
"The incidence of thrombocytopenia with ticlopidine and clopidogrel when used in conjunction with abciximab has not been systematically addressed." | 7.70 | Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine. ( Dillon, JC; Dillon, WC; Eckert, GJ; Ritchie, ME, 2000) |
"We examined the antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 [(WxB)F1] male mice with myocardial infarction (MI) and systemic lupus erythematosus (SLE)." | 7.69 | Antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 male mice with myocardial infarction and systemic lupus erythematosus. ( Fujiwara, H; Nakamura, Y; Shibata, Y; Suzuka, H; Tanaka, M; Yoshifusa, H, 1995) |
" The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months." | 6.74 | Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009) |
"In conclusion, in a dog coronary thrombosis model, ticagrelor blocks ADP-induced platelet activation and aggregation; prevents platelet-mediated thrombosis; prolongs reperfusion time and reduces re-occlusion and cyclic flow variation; and significantly decreases infarct size and rapidly restores myocardial tissue perfusion." | 5.36 | Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. ( Huang, Y; Khalil, M; Penn, MS; van Giezen, JJ; Wang, K; Wiktor, D; Zhou, X, 2010) |
"Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h." | 5.35 | Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008) |
"The DAPT (Dual Antiplatelet Therapy) study randomized 11,648 patients free from ischemic and bleeding events 12 months after coronary stenting to continued thienopyridine plus aspirin therapy for an additional 18 months versus aspirin therapy alone." | 5.24 | Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. ( Apruzzese, PK; Cutlip, DE; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW, 2017) |
"The ITALIC (Is There a Life for DES After Discontinuation of Clopidogrel) trial showed that rates of bleeding and thrombotic events at 1 year were much the same with 6 versus 12 months of DAPT after percutaneous coronary intervention with second-generation drug-eluting stents." | 5.24 | 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel). ( Armengaud, J; Barragan, P; Ben Amer, H; Berlan, J; Blanchard, D; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Didier, R; Druelles, P; Dupouy, P; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J, 2017) |
"In smokers, a double-dose clopidogrel regimen reduced major cardiovascular events and stent thrombosis after percutaneous coronary intervention, with no increase in major bleeding." | 5.24 | Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. ( Bossard, M; Faxon, DP; Fox, KAA; Gao, P; Granger, CB; Jolly, SS; Mehta, SR; Montalescot, G; Natarajan, MK; Niemela, K; Steg, PG; Tanguay, JF; Widimsky, P; Yusuf, S, 2017) |
"Thienopyridine plus aspirin beyond 1 year after coronary stenting reduces myocardial infarction (MI) risk and increases bleeding risk in comparison with aspirin alone." | 5.24 | Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). ( Cutlip, DE; D'Agostino, RB; Hsieh, WH; Kereiakes, DJ; Massaro, JM; Mauri, L; Stefanescu Schmidt, AC; Yeh, RW, 2017) |
"In CHAMPION PHOENIX, cangrelor reduced ischaemic events with no significant increase in GUSTO-defined severe bleeding." | 5.22 | The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. ( Bhatt, DL; Blankenship, JC; Deliargyris, EN; Généreux, P; Gibson, CM; Gutierrez, JA; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016) |
"Among patients with STEMI undergoing PPCI, ticagrelor reduces the incidence of MACCE and the composite end point of cardiovascular death, nonfatal MI, and stroke compared with clopidogrel." | 5.22 | Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. ( Jing, Q; Li, R; Liu, P; Liu, Y; Tang, X; Wang, Q; Zhang, P, 2016) |
"Compared with 12-month DAPT, 6-month DAPT did not increase the composite events of cardiac death, myocardial infarction, stroke, or TIMI major bleeding at 1 year in patients who underwent everolimus-eluting stent implantation." | 5.22 | 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial. ( Choi, D; Her, AY; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Shin, DH, 2016) |
"Despite broad differences in clinical profiles and indications for percutaneous coronary intervention by region in a large global cardiovascular clinical trial, cangrelor consistently reduced rates of ischemic end points compared with clopidogrel without an excess in severe bleeding in both the US and non-US subgroups." | 5.22 | Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; Vaduganathan, M; White, HD, 2016) |
"The CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention) trial demonstrated that cangrelor significantly reduced periprocedural ischemic events in all-comer percutaneous coronary intervention with a modest increase in mild and moderate bleeding." | 5.22 | Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. ( Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016) |
"We evaluated the impact of clopidogrel 150 mg/d in patients with chronic kidney disease (CKD) having clopidogrel resistance (CR) after percutaneous coronary intervention (PCI); 1076 consecutive patients with coronary artery disease (CAD) having CKD were enrolled." | 5.20 | High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention. ( Han, H; Li, Y; Liang, J; Liu, W; Liu, Y; Shi, D; Wang, Z; Yang, L; Zhang, L; Zhao, Y; Zhou, Y, 2015) |
"The aim of this study was to examine the efficacy and bleeding outcomes of cangrelor in patients in the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]) who underwent percutaneous coronary intervention with bivalirudin." | 5.20 | Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). ( Bhatt, DL; Cortese, B; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Liu, T; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD; Wilensky, M, 2015) |
"The relationships between Q waves that appear during the acute phase of ST-elevation myocardial infarction (STEMI), clinical characteristics, ST-segment resolution (STRes), and clopidogrel therapy in patients treated with fibrinolysis are not well described." | 5.19 | Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial. ( Cannon, CP; Gibson, CM; Giugliano, RP; Morrow, DA; Sabatine, MS; Scirica, BM; Sloan, S; Waks, JW; Wiviott, SD, 2014) |
"Ticagrelor reduces thrombotic events compared with clopidogrel in patients with acute coronary syndrome, but may also increase bleeding complications." | 5.19 | Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor. ( Albertsson, P; Dellborg, M; Hansson, EC; Jeppsson, A; Rexius, H, 2014) |
"Definite/probable ST and MB (TIMI major and Bleeding Academic Research Consortium (BARC) ≥ 3) were compared in 2 subsequent trials with similar inclusion criteria but different DAPT duration, that is, BASKET (6 months; n = 557) and BASKET-PROVE (12 months; n = 2,314), between months 0 to 6 (DAPT in both trials), 7 to 12 (DAPT in BASKET-PROVE only), and 13 to 24 (aspirin in both trials) using propensity score-adjusted, time-stratified Cox proportional hazard models." | 5.19 | Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations. ( Alber, H; Bonetti, PO; Eberli, F; Erne, P; Galatius, S; Jeger, RV; Kaiser, CA; Pedrazzini, G; Pfisterer, ME; Rickli, H; Sørensen, R; von Felten, S, 2014) |
"The PLATO (Platelet Inhibition and Patient Outcomes) angiographic substudy sought to compare the efficacy of ticagrelor versus clopidogrel with respect to angiographic outcomes before and after PCI in the setting of acute coronary syndrome." | 5.17 | Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). ( Emanuelsson, H; Gibson, CM; Harrington, RA; Horrow, J; James, SK; Katus, H; Kunadian, V; Maya, J; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM; Wu, J; Zorkun, C, 2013) |
"Ticagrelor compared with clopidogrel reduces the incidence of stent thrombosis in patients with acute coronary syndromes, with consistent benefit across a broad range of patient, stent, and treatment characteristics." | 5.17 | Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. ( Emanuelsson, H; Harrington, RA; James, SK; Katus, HA; Lewis, BS; Mahaffey, KW; Maurer, G; Meier, B; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM, 2013) |
"The study aimed to compare the antiplatelet action of ticagrelor with prasugrel in acute coronary syndrome (ACS) patients with high on-treatment platelet reactivity (HTPR) while on clopidogrel after percutaneous coronary intervention (PCI)." | 5.16 | Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. ( Alexopoulos, D; Damelou, A; Davlouros, P; Galati, A; Hahalis, G; Kassimis, G; Makris, G; Mavronasiou, E; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I, 2012) |
"The Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial included 3602 patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention who were randomized to heparin plus a glycoprotein IIb/IIIa inhibitor (GPI) (n=1802) versus bivalirudin monotherapy (n=1800)." | 5.15 | Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. ( Brodie, BR; Caixeta, A; Cristea, E; Dangas, GD; Dudek, D; Guagliumi, G; Lansky, AJ; Mehran, R; Möeckel, M; Parise, H; Peruga, JZ; Stone, GW; Witzenbichler, B, 2011) |
"Residual platelet reactivity (RPR) after clopidogrel loading, measured by the VerifyNow assay, has been shown to predict 12-month clinical events in patients with acute coronary syndromes." | 5.15 | Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. - Impact on intracoronary thrombus burden and myocardial perfusion-. ( Archontakis, S; Gafou, A; Kalogeras, KI; Kariori, MG; Moldovan, C; Papaioannou, TG; Stefanadis, C; Tzamalis, P; Vavuranakis, M; Vrachatis, DA, 2011) |
" On-clopidogrel platelet reactivity was investigated in patients with previous angiographically confirmed STh, myocardial infarction (MI), and controls." | 5.15 | Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Siegbahn, A; Varenhorst, C; Wallentin, L, 2011) |
"We screened 1277 patients to enroll 93 aspirin, 147 clopidogrel, and 23 dual poor responders, based on a point-of-care assay, who underwent elective coronary angioplasty at 10 European sites for stable or low-risk unstable coronary artery disease." | 5.14 | Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho ( Angiolillo, DJ; Brugaletta, S; Campo, G; Colangelo, S; de Cesare, N; Ferrari, R; Furgieri, A; Hamon, M; Meliga, E; Parrinello, G; Percoco, G; Repetto, A; Sabatè, M; Valgimigli, M; Vranckx, P, 2009) |
"The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI." | 5.14 | Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009) |
"Aspirin and clopidogrel are recommended for patients with acute coronary syndromes (ACS) or undergoing coronary stenting." | 5.14 | Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. ( Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Finkelstein, A; Harrington, RA; Husted, S; James, S; Katus, H; Kilhamn, J; Olofsson, S; Steg, PG; Storey, RF; Wallentin, L; Weaver, WD, 2010) |
" The Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) showed an overall reduction in ischemic events with more intensive antiplatelet therapy with prasugrel than with clopidogrel but with more bleeding." | 5.13 | Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial I ( Angiolillo, DJ; Antman, EM; Braunwald, E; Corbalan, R; Dalby, AJ; Goodman, SG; McCabe, CH; Meisel, S; Murphy, SA; Purdy, DA; Verheugt, FW; Wiviott, SD, 2008) |
"In elective stenting without clopidogrel pretreatment, use of a GPIIb/IIIa inhibitor produces superior platelet inhibition and lower myocardial necrosis compared with high-dose (600 mg) or standard-dose (300 mg) clopidogrel loading alone." | 5.11 | Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. ( Bliden, KP; Gurbel, PA; Hayes, KM; Tantry, US; Yoho, JA; Zaman, KA, 2005) |
" Furthermore, the simpler dosing regimen, the absence of neutropenia, and the lower frequency of other side effects make it a safe alternative to ticlopidine." | 5.09 | Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. ( Collins, M; Colombo, A; Iyer, S; Kreps, E; Maida, R; Moses, JW; Moussa, I; Oetgen, M; Roubin, G; Wang, X, 1999) |
"Compared with standard clopidogrel therapy, individualized intensified antiplatelet therapy on the basis of platelet reactivity testing reduces the incidence of cardiovascular events in patient undergoing PCI, without increasing the risk of bleeding." | 4.95 | Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. ( Huang, C; Wang, Y; Wu, Y; Xu, W; Yan, H; Zhang, L; Zhou, Y; Zhu, J; Zhu, W, 2017) |
"The association between DAPT interruption and the rates of stent thrombosis (ST) and cardiac death/target-vessel myocardial infarction (CD/TVMI) in patients receiving a Resolute zotarolimus-eluting stent (R-ZES) was analysed in 4896 patients from the pooled RESOLUTE clinical programme." | 4.90 | Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. ( Belardi, JA; Brar, S; Kirtane, AJ; Liu, M; Rothman, M; Silber, S; Windecker, S, 2014) |
"Dual antiplatelet therapy with aspirin plus a P2Y(12) receptor inhibitor is the cornerstone of treatment for patients with acute coronary syndrome and in those undergoing percutaneous coronary intervention." | 4.89 | Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. ( Angiolillo, DJ; Azmoon, S, 2013) |
"P2Y12 adenosine di-phosphate (ADP) receptor antagonists are critical to reduce thrombotic recurrences in acute coronary syndromes patients and for those undergoing percutaneous coronary revascularization." | 4.88 | Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome? ( Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A, 2012) |
"Clopidogrel has become part of the mainstay of therapy for acute coronary syndromes and in patients post stenting." | 4.87 | Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy. ( Dart, AM; Fernando, H; Peter, K; Shaw, JA, 2011) |
" In this article we focus on the use of clopidogrel in the contemporary management of coronary artery disease." | 4.84 | Contemporary use of clopidogrel in patients with coronary artery disease. ( Beckman, JA; Parikh, SA, 2007) |
"The clinical benefit of the combination of aspirin plus clopidogrel over aspirin alone to prevent recurrent events after acute coronary syndrome is obviously a key step of the past few years in the management of coronary artery disease." | 4.84 | [Management coronary syndrome in the acute phase]. ( Collet, JP; Montalescot, G, 2007) |
"The purpose of this article was to determine the incidence of in-stent thrombosis (IST) after coronary stent implantation in patients with cocaine abuse." | 4.84 | Increased incidence of in-stent thrombosis related to cocaine use: case series and review of literature. ( Arora, R; Bahekar, A; Handa, K; Khosla, S; Khraisat, A; Singh, S; Trivedi, A, 2007) |
"The current standard of care for the treatment of arterial thrombosis includes anticoagulants and three classes of antiplatelet agents--aspirin, thienopyridines and glycoprotein IIb-IIIa antagonists." | 4.82 | Therapeutic approaches in arterial thrombosis. ( Andre, P; Conley, PB; Phillips, DR; Sinha, U, 2005) |
"One of the most unusual causes of thrombotic thrombocytopenic purpura (TTP), a life-threatening disease, is ticlopidine hydrochloride, an antiplatelet agent used to prevent strokes in high-risk populations or following coronary artery stent placement." | 4.80 | Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. ( Bennett, CL; Bennett, RH; Davidson, CJ; Feldman, MD; Raisch, DW; Weinberg, PD, 1999) |
"PROMETHEUS was a multicentre observational study that compared clopidogrel vs prasugrel in acute coronary syndrome patients who underwent PCI (n = 19,914)." | 3.88 | Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. ( Aquino, M; Baber, U; Baker, BA; Chandrasekhar, J; Dangas, G; DeFranco, A; Effron, MB; Farhan, S; Ge, Z; Henry, TD; Kapadia, S; Keller, S; Kini, AS; Mehran, R; Muhlestein, JB; Pocock, S; Rao, S; Sartori, S; Sorrentino, S; Strauss, C; Toma, C; Vogel, B; Weintraub, W; Weiss, S, 2018) |
"The present study confirms the strong relationship of high platelet reactivity on clopidogrel to 2-year ischemic and bleeding outcomes after DES." | 3.85 | Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. ( Ben-Yehuda, O; Brodie, BR; Cox, DA; Duffy, PL; Généreux, P; Gurbel, PA; Henry, TD; Kirtane, AJ; Litherland, C; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Rinaldi, MJ; Simonton, CA; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B, 2017) |
"In clopidogrel treated PCI patients, the 2-year adjusted risk of MACE and NACE was significantly higher in PPI users driven by higher TLR compared to non-PPI users, without a difference in bleeding." | 3.85 | Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. ( Aquino, M; Ariti, C; Baber, U; Bansilal, S; Chandrasekhar, J; Chieffo, A; Cohen, D; Colombo, A; Dangas, G; Faggioni, M; Farhan, S; Gabriel Steg, P; Giustino, G; Henry, T; Kini, A; Mehran, R; Michael Gibson, C; Moliterno, D; Pocock, S; Saporito, R; Sartori, S; Stuckey, T; Vogel, B; Witzenbichler, B, 2017) |
"Among patients in the CHAMPION trials with a prior cerebrovascular event at least 1 year before the percutaneous coronary intervention, the efficacy and bleeding profile of cangrelor compared with clopidogrel was similar to that in the overall trial." | 3.85 | Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD, 2017) |
"Dual-antiplatelet therapy with aspirin and clopidogrel after percutaneous coronary intervention reduces the risk for coronary thrombotic events (CTEs) at the expense of increasing risk for major bleeding (MB)." | 3.83 | Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. ( Ariti, C; Baber, U; Chieffo, A; Cohen, DJ; Colombo, A; Dangas, G; Gibson, CM; Giustino, G; Henry, TD; Kini, AS; Kirtane, AJ; Krucoff, MW; Litherland, C; Mehran, R; Moliterno, DJ; Pocock, S; Sartori, S; Steg, PG; Stone, GW; Weisz, G; Witzenbichler, B, 2016) |
"There are limited data about long-term outcomes for biodegradable polymer biolimus-eluting stent (BES) versus durable polymer everolimus-eluting stent (EES) in patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI)." | 3.81 | Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction. ( Choi, JH; Choi, RK; Choi, SH; Choi, YJ; Gwon, HC; Hahn, JY; Jang, HJ; Kim, JS; Kim, TH; Lee, HJ; Lee, SH; Park, JS; Park, TK; Roh, YM; Shim, WH; Song, YB; Yang, JH; Yu, CW, 2015) |
"Patients with high PR on clopidogrel have a greater incidence of adverse ischemic events after stent implantation, whereas low PR may increase bleeding." | 3.81 | Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents). ( Brodie, BR; Cox, DA; Duffy, PL; Généreux, P; Henry, TD; Kirtane, AJ; Maehara, A; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Parikh, PB; Parvataneni, R; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B; Xu, K, 2015) |
" This investigation aimed to evaluate the effect of hypothermia on the pharmacodynamic response of aspirin and clopidogrel in patients (n = 20) with ST elevation myocardial infarction undergoing primary PCI." | 3.80 | Impact of mild hypothermia on platelet responsiveness to aspirin and clopidogrel: an in vitro pharmacodynamic investigation. ( Angiolillo, DJ; Ariza, A; Cequier, A; Ferreiro, JL; Gómez-Hospital, JA; Gómez-Lara, J; Gracida, M; Homs, S; Lorente, V; Marcano, AL; Rivera, K; Romaguera, R; Roura, G; Sánchez-Elvira, G; Sánchez-Salado, JC; Sosa, SG; Teruel, L, 2014) |
"The choice of antiplatelet therapy after acute coronary syndrome (ACS) is complicated: Ticagrelor and prasugrel are novel alternatives to clopidogrel, patients with some genotypes may not respond to clopidogrel, and low-cost generic formulations of clopidogrel are available." | 3.80 | Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. ( Boothroyd, DB; Dudley, RA; Garber, AM; Hlatky, MA; Kazi, DS; Mell, MW; Moshkevich, S; Owens, DK; Rhee, C; Shah, RU, 2014) |
"A 36 year-old man, who had undergone a paclitaxel-eluting stent deployment into the left main (LM) coronary artery three years before, was admitted after successful resuscitation following out-of-hospital cardiac arrest due to an acute ST-segment elevation myocardial infarction." | 3.79 | Thrombocytosis as a potential cause of a very late stent thrombosis in the left main coronary artery. ( Janus, M; Lesiak, M; Lukawski, K; Prech, M, 2013) |
" Whether the bolus dose alone is sufficient for ST-elevation myocardial infarction patients receiving a high loading dose of clopidogrel is unknown." | 3.79 | Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction. ( Berglund, U; Janzon, M; Nilsson, L, 2013) |
"The current study sought to evaluate the clinical impact of newly reported genetic variations and their association with clopidogrel high on-treatment platelet reactivity (HTPR) in acute coronary syndrome (ACS) patients after drug-eluting stent (DES) implantation." | 3.79 | The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. ( Han, YL; Kang, J; Li, Y; Liang, ZY; Yan, CH; Zhang, XL, 2013) |
"This study sought to assess the usefulness of clopidogrel-pathway genotyping and on-treatment platelet reactivity (OTR) testing in predicting major adverse cardiac events (MACE) in stable coronary artery disease (CAD) patients receiving drug-eluting stents (DES) under dual antiplatelet (clopidogrel plus aspirin) therapy." | 3.79 | Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. ( Briguori, C; Condorelli, G; De Micco, F; Focaccio, A; Latronico, MV; Pagnotta, P; Papa, L; Roncarati, R; Visconti, G; Viviani Anselmi, C, 2013) |
" We examined the influence of previously described polymorphisms, related to aspirin and clopidogrel resistance, on treatment outcome in a real life unselected population of patients presenting with ST-segment elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention." | 3.79 | Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction. ( Boden, H; Guchelaar, HJ; Heijmans, BT; Jukema, JW; Putter, H; Schalij, MJ; Trompet, S; van der Hoeven, BL; Verschuren, JJ; Wessels, JA, 2013) |
"CYP2C19*17 carrier status is significantly associated with enhanced response to clopidogrel and an increased risk of bleeding." | 3.76 | Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. ( Braun, S; Gebhard, D; Kastrati, A; Koch, W; Morath, T; Schömig, A; Schuster, T; Sibbing, D; Stegherr, J; von Beckerath, N, 2010) |
" The present study was designed to assess the predictive value of adenosine diphosphate (ADP)-induced platelet aggregation (ADP-Ag) and the Platelet Reactivity Index of vasodilator-stimulated phosphoprotein for the occurrence of stent thrombosis in patients admitted for non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention." | 3.75 | Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. ( Alessi, MC; Bali, L; Bonnet, JL; Castelli, C; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J, 2009) |
"Clopidogrel is widely used in patients with acute coronary syndromes and following percutaneous coronary intervention with stent implantation." | 3.75 | Potential Interaction between clopidogrel and proton pump inhibitors. ( Howard, PA; Vacek, JL, 2009) |
" We describe a case of very late paclitaxel-eluting stent thrombosis despite 21 months of clopidogrel treatment, which occurred just 2 weeks after its withdrawal, causing an acute coronary syndrome that was promptly resolved with an urgent invasive strategy." | 3.74 | Very late paclitaxel-eluting stent thrombosis despite 21 months of clopidogrel treatment after percutaneous coronary intervention. ( Bucciarelli-Ducci, C; Colantonio, R; Fedele, F; Mancone, M; Sangiorgi, GM; Sardella, G, 2007) |
"We describe a case of an 81-year-old man with acute ST-elevation myocardial infarction (STEMI), who received a loading dose of clopidogrel (300 mg) and aspirin (ASA) (300 mg) prior to primary coronary intervention of critical left anterior descending coronary artery stenosis." | 3.74 | [Suspected clopidogrel resistance associated with recurrent coronary stent thrombosis--a case report]. ( Knapp, M; Musiał, WJ; Prokop, JB; Sawicki, R; Sobkowicz, B; Tomaszuk-Kazberuk, A; Usowicz-Szaryńska, M, 2007) |
"To model the 2-year cost-effectiveness of secondary prevention with clopidogrel versus aspirin (acetylsalicylic acid) (ASS) in German patients with myocardial infarction (MI), ischaemic stroke (IS) or diagnosed with peripheral arterial disease (PAD), based on CAPRIE trial data and from the perspective of German third party payers (TPP)." | 3.74 | Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany. ( Berger, K; Diener, HC; Hessel, F; Kreuzer, J; Smala, A, 2008) |
"The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)." | 3.73 | Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006) |
"The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes." | 3.72 | Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004) |
"We report 3 cases of fatal neutropenia and thrombocytopenia associated with ticlopidine after coronary stenting." | 3.70 | Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. ( Ball, MW; Linnemeier, TJ; Szto, GY, 1999) |
" We report the successful use of ticlopidine, together with aspirin, in a 7-month-old infant with Kawasaki disease complicated by a thrombus in a giant coronary aneurysm that failed to resolve with thrombolytic therapy." | 3.70 | Ticlopidine plus aspirin for coronary thrombosis in Kawasaki disease. ( Baker, AL; Neufeld, EJ; Newburger, JW; O'Brien, M; Parness, IA; Sundel, RP, 2000) |
"The incidence of thrombocytopenia with ticlopidine and clopidogrel when used in conjunction with abciximab has not been systematically addressed." | 3.70 | Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine. ( Dillon, JC; Dillon, WC; Eckert, GJ; Ritchie, ME, 2000) |
"We examined the antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 [(WxB)F1] male mice with myocardial infarction (MI) and systemic lupus erythematosus (SLE)." | 3.69 | Antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 male mice with myocardial infarction and systemic lupus erythematosus. ( Fujiwara, H; Nakamura, Y; Shibata, Y; Suzuka, H; Tanaka, M; Yoshifusa, H, 1995) |
"Aspirin was to be given indefinitely, and clopidogrel/ticlopidine for ≥ 3 months or up to 12 months after implantation." | 2.79 | Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type. ( Al Kurdi, M; Boersma, E; Camenzind, E; Mauri, L; Ordoubadi, FF; Rademaker-Havinga, T; Steg, PG; Suttorp, MJ; Wijns, W, 2014) |
" Following this randomized pilot study, it may be justified to perform a large-scale randomized study comparing 50- and 75-mg dosing of clopidogrel in Japanese patients undergoing coronary stent implantation." | 2.79 | Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial. ( Fujimoto, Y; Iwata, Y; Kadohira, T; Kitahara, H; Kobayashi, Y; Morino, T; Ohkubo, K; Sugimoto, K, 2014) |
" Two 7-day treatments were separated by 14-day washout periods: (a) PA32540 + clopidogrel (300 mg loading/75 mg maintenance) 10 hours later and (b) synchronous dosing of clopidogrel + EC aspirin (81 mg) + EC omeprazole (40 mg)." | 2.78 | Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. ( Antonino, M; Bliden, KP; Chai, S; Fort, JG; Gesheff, M; Gesheff, T; Gurbel, PA; Jeong, YH; Shuldiner, A; Tantry, US; Zhang, Y, 2013) |
"Pantoprazole treatment does not impair the efficacy of dual antiplatelet therapy in patients with SAP after PCI." | 2.77 | Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention. ( Chmiel, A; Gąsior, Z; Gieszczyk, K; Haberka, M; Kunecki, M; Kyrcz-Krzemień, S; Lasota, B; Mizia, M; Mizia-Stec, K; Najda, J, 2012) |
" (2) Clopidogrel may be under dosed in obese patients." | 2.75 | Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. ( Bode, C; Diehl, P; Halscheid, C; Helbing, T; Moser, M; Olivier, C, 2010) |
"tirofiban may allow temporary withdrawal of oral clopidogrel without increasing the risk of bleeding." | 2.75 | Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. ( Barlocco, F; Caracciolo, M; D'Urbano, M; De Servi, S; Klugmann, S; Mariani, G; Nichelatti, M; Savonitto, S, 2010) |
" Some recent studies have suggested that a higher clopidogrel maintenance dosage could enhance ex vivo platelet inhibition and thereby overcome resistance to clopidogrel." | 2.75 | High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients. ( Carrie, D; Galinier, M; Lapeyre-Mestre, M; Montastruc, JL; Pathak, A; Tavassoli, N; Voisin, S, 2010) |
" The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months." | 2.74 | Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009) |
"Cilostazol is a potent antiplatelet agent with less serious side effects." | 2.69 | Comparison of cilostazol versus ticlopidine therapy after stent implantation. ( Hong, MK; Kim, HS; Kim, JJ; Lee, CW; Lee, HJ; Park, HK; Park, SJ; Park, SW, 1999) |
"Ticlopidine-plus-aspirin has become standard antiplatelet therapy for the prevention of thrombotic complications after coronary stenting." | 2.69 | Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. ( Aguirre, FV; Ligon, RW; Lucore, CL; Mishkel, GJ; Rocha-Singh, KJ, 1999) |
" A new therapeutic regimen of ticlopidine and aspirin without further heparin after coronary stenting in patients without AMI has been shown to be safe and reduce the incidence of stent thrombosis." | 2.69 | A safe and effective regimen without heparin therapy after successful primary coronary stenting in patients with acute myocardial infarction. ( Chang, HW; Chen, MC; Fang, CY; Hang, CL; Hsieh, KY; Wu, CJ; Yip, HK, 2000) |
"Ticlopidine therapy was discontinued in 1." | 2.68 | Combined antiplatelet therapy with ticlopidine and aspirin. A simplified approach to intracoronary stent management. ( Bauters, C; Bedossa, M; Bertrand, ME; Bonnet, JL; Danchin, N; Grollier, G; Lablanche, JM; Leclercq, C; McFadden, EP; Vahanian, A; Van Belle, E, 1996) |
"Ticagrelor is a novel ADP receptor blocker that has shown greater, more rapid and more consistent platelet inhibition than clopidogrel." | 2.53 | Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis? ( Duraj, L; Fedor, M; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Stančiaková, L; Staško, J, 2016) |
"Clinical trials enrolling STEMI patients were identified and relevant data was extracted." | 2.53 | Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis. ( Baber, U; Berger, PB; Currier, J; Dave, RH; Henry, TD; Mehran, R; Nayyar, P; Rafique, AM; Tobis, J; Wang, TY, 2016) |
" The included end-points were major adverse cardiovascular event (MACE), target lesion revascularization (TLR), target vessel revascularization (TVR), death, myocardial infarction (MI), stent thrombosis, bleeding and other drug adverse events." | 2.50 | Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. ( Chen, Y; Huang, X; Tang, Y; Xie, Y; Zhang, Y, 2014) |
" In contrast to aspirin, the response to clopidogrel is highly variable and reflects the bioavailability of the active metabolite and not "resistance" of the receptor to inhibition." | 2.44 | Aspirin and clopidogrel resistance. ( Fitzgerald, DJ; Maree, A, 2007) |
" This approach may be in the future influenced by further progress in drug-eluting stents development and by prospectively acquired information on long-term administration of clopidogrel to such patients." | 2.44 | [Late coronary stent thrombosis and clopidogrel]. ( Herman, A; Matejka, J; Varvarovský, I, 2007) |
"Ticlopidine is an inhibitor of platelets function in vivo." | 2.43 | [Place of ticlopidine in antiplatelet treatment]. ( Goch, A; Goch, JH; Wlazłowski, R, 2005) |
"We report a case of multiple coronary thrombosis involving the left anterior descending artery and circumflex artery and stent implantation to the subtotally stenotic right renal artery in a women with unstable angina pectoris, essential thrombocytosis and previous history of renal artery trombosis." | 2.43 | Multiple coronary thrombosis and stent implantation to the subtotally occluded right renal artery in a patient with essential thrombocytosis: a case report with review. ( Bugra, Z; Ekmekci, A; Meric, M; Ozben, B; Umman, S, 2006) |
"Aspirin is a weak antiplatelet agent; however, its side effects can cause in tolerance, and between 15% and 45% of patients are resistant to its antiplatelet effects." | 2.40 | The thienopyridines in coronary artery disease. ( Berger, PB, 1999) |
"Major bleeding was a significant correlate of DAPT ANA within 6 months." | 1.42 | Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. ( Cutlip, DE; Dauerman, HL; Kereiakes, DJ; Mauri, L; Stoler, R, 2015) |
" Use of β-adrenergic blockers is recommended in most guidelines, but the clinical trials to support this recommendation were performed more than 30 years ago, and routine long-term use may not be relevant to modern treatment, except when there is cardiac failure or left ventricular dysfunction." | 1.40 | Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome. ( Judkins, C; Thompson, AG; Thompson, PL, 2014) |
" In conclusion, compared with immediate PCI, d-PCI after ATT in selected, stabilized patients with ACS and a large intracoronary thrombus and without an urgent need for revascularization is probably safe and associated with a reduction in thrombotic burden, angiographic complications, and the need of revascularization." | 1.39 | Safety and efficacy of intense antithrombotic treatment and percutaneous coronary intervention deferral in patients with large intracoronary thrombus. ( Alfonso, F; Bañuelos, C; Echavarría-Pinto, M; Escaned, J; Fernández, C; Fernandez-Ortiz, A; García, E; Gonzalo, N; Gorgadze, T; Hernández, R; Ibañez, B; Jiménez-Quevedo, P; Lopes, R; Macaya, C; Nuñez-Gil, IJ, 2013) |
"Bleeding has emerged as a predictor of early and late mortality after percutaneous coronary interventions." | 1.38 | Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation. ( Angiolillo, DJ; Capodanno, D; Gavazzi, A; Guagliumi, G; Lettieri, C; Musumeci, G; Romano, M; Rosiello, R; Rossini, R; Valsecchi, O, 2012) |
" The aim of this study was to assess the impact of CCB therapy on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stent placement." | 1.37 | Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. ( Bernlochner, I; Kastrati, A; Mehilli, J; Morath, T; Neumann, L; Sarafoff, N; Schömig, A; Sibbing, D, 2011) |
"Systemic lupus erythematosus is a chronic inflammatory disorder that predisposes to acute coronary thrombosis." | 1.37 | Effective management of acute coronary thrombosis in a young woman with lupus using aggressive medical therapy. ( Matthai, WH; Patel, PJ; Untereker, WJ, 2011) |
"Needle injury induces atherosclerotic plaque rupture with exposure of plaque material and formation of a thrombus that is larger, nearly occlusive and more stable as compared to that formed by application of ultrasounds." | 1.37 | Comparison of two murine models of thrombosis induced by atherosclerotic plaque injury. ( Gachet, C; Hechler, B, 2011) |
" The effect of aspirin dosing was evaluated using χ(2) , Cochran-Mantel-Haenszel, and homogeneity testing." | 1.37 | Influence of low-dose aspirin (81 mg) on the incidence of definite stent thrombosis in patients receiving bare-metal and drug-eluting stents. ( Columbo, J; Cui, J; Davis, M; Giugliano, GR; Lotfi, A; Mulvey, S; Schweiger, M; Wartak, S, 2011) |
"The TRUE registry demonstrated that SES in the treatment of bare-metal stent ISR is efficacious (5% of target lesion revascularization [TLR]) and safe (stent thrombosis <1%) at 9 months." | 1.36 | Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years. ( Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Fineschi, M; Gori, T; Grotti, S; Liistro, F; Pierli, C, 2010) |
"Only amlodipine was associated with clopidogrel poor-response." | 1.36 | The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. ( Breet, NJ; de Boer, A; Deneer, VH; Hackeng, CM; Harmsze, AM; Klungel, OH; Robijns, K; Ruven, HJ; Ten Berg, JM; van Werkum, JW, 2010) |
"In conclusion, in a dog coronary thrombosis model, ticagrelor blocks ADP-induced platelet activation and aggregation; prevents platelet-mediated thrombosis; prolongs reperfusion time and reduces re-occlusion and cyclic flow variation; and significantly decreases infarct size and rapidly restores myocardial tissue perfusion." | 1.36 | Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. ( Huang, Y; Khalil, M; Penn, MS; van Giezen, JJ; Wang, K; Wiktor, D; Zhou, X, 2010) |
"The underlying disease was paroxysmal nocturnal hemoglobinuria (PNH), a stem cell defect characterized by episodes of complement-induced hemolysis and thromboembolic events." | 1.36 | [Between thrombosis and bleeding - a case of paroxysmal nocturnal hemoglobinuria]. ( Reinhart, WH, 2010) |
" In 199 patients treated with DAT alone (control group) and 103 patients treated with rabeprazole plus DAT (rabeprazole group), we examined the incidences of GI bleeding and major adverse cardiac events (MACE) including stent thrombosis." | 1.36 | [Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study]. ( Chubachi, H; Ikee, R; Miyasaka, Y; Saito, S; Yasu, T, 2010) |
"Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h." | 1.35 | Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008) |
"Myocardial infarction is common in patients with a history of coronary artery disease." | 1.35 | [Severe myocardial infarction due to late and very late stent thrombosis after coronary artery stenting with drug-eluting stents]. ( Erdmann, E; Flesch, M; Krausgrill, B, 2008) |
"Aspirin effect was assessed using the VerifyNow Aspirin Assay, and the effect of clopidogrel was assessed using the VerifyNow P2Y12 Assay and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P)." | 1.35 | Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. ( Beauzile, P; Bonello, L; Gavini, R; Gurbel, P; Kaneshige, K; Kent, K; Pichard, AD; Pinto Slottow, TL; Satler, LF; Scheinowitz, M; Suddath, WO; Sushinsky, SJ; Tantry, U; Torguson, R; Waksman, R; Xue, Z, 2009) |
" Investigation of alternative clopidogrel dosing regimens to reduce ischaemic events in high-risk patients identified by this assay is warranted." | 1.35 | Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. ( Endemann, S; Ernst, A; Gollapudi, RR; Levisay, JP; Price, MJ; Sawhney, NS; Schatz, RA; Stinis, CT; Teirstein, PS; Valencia, R, 2008) |
"Ticlopidine can cause rare but serious side effects, especially during the first 3 months of treatment." | 1.34 | Optimal antiplatelet treatment for percutaneous coronary intervention: clopidogrel vs. ticlopidine. ( Almsherqi, ZA; Deng, Y; McLachlan, CS; Mossop, P, 2007) |
"Ticlopidine has a relative high rate of side-effects." | 1.34 | Incidence of side-effects of ticlopidine after sirolimus-eluting stent implantation. ( Fukushima, K; Kobayashi, Y; Komuro, I; Kuroda, N; Miyazaki, A; Nakamura, Y; Nakayama, T; Okuno, T; Sakakibara, M; Shimizu, Y, 2007) |
" We assessed the cumulative incidence of major adverse cardiac events (death, acute myocardial infarction, and target-vessel revascularization) and angiographic stent thrombosis during 2-year follow-up." | 1.34 | Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. ( Aurier, E; Benassi, A; Cremonesi, A; Grilli, R; Guastaroba, P; Magnavacchi, P; Manari, A; Maresta, A; Marzocchi, A; Percoco, G; Piovaccari, G; Saia, F; Varani, E, 2007) |
" Prasugrel is orally more potent and acts more rapidly than clopidogrel, allowing lower oral dosing despite of similar in vitro activity of the active metabolites." | 1.34 | [Prasugrel, a new thienopyridine]. ( Huber, K; Schrör, K, 2007) |
"ticlopidine) treatment remained the sole predictor of TSO (OR: 5." | 1.33 | Increased long term rates of stent thrombosis and mortality in patients given clopidogrel as compared to ticlopidine following coronary stent implantation. ( Amit, G; Cafri, C; Gilutz, H; Ilia, R; Wolak, A; Zahger, D, 2005) |
" Clopidogrel was studied in two dosing regimens representing either a clinical pretreatment regimen (PTR) of 4." | 1.33 | Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis. ( Brooks, JM; Crandall, DL; Hennan, JK; Leik, CE; Morgan, GA; Schaub, RG; Shaw, GD; Swillo, RE; Vlasuk, GP, 2006) |
" An adequate dosage of ticlopidine (250 mg twice daily) and aspirin (100 mg/day) led to a lower rate of stent thrombosis (6 of 2,189 cases) than inadequate dosages or missing therapy (12 of 343 cases)." | 1.32 | Influence of residual stenosis after percutaneous coronary intervention with stent implantation on development of restenosis and stent thrombosis. ( Hambrecht, R; Hentschel, B; Hüttl, T; Lauer, B; Niebauer, J; Schuler, G; Sick, P; Thiele, H, 2003) |
" We sought to establish an optimal clopidogrel dosing regimen for sustained platelet inhibition in stented patients." | 1.32 | Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. ( Alford, AB; Bell, CR; Cummings, CC; Gurbel, PA; Meister, AF; Serebruany, VL, 2003) |
"Reduced anticoagulation with antiplatelet therapy alone after coronary stenting, despite infrequent use of intravascular ultrasound, is an effective and safe strategy with a low rate of vascular complications, a relatively short hospital stay and a low incidence of clinical manifestations of stent thrombosis." | 1.30 | Antiplatelet therapy alone is safe and effective after coronary stenting: observations of a transition in practice. ( Buller, CE; Chauhan, A; Moscovich, MD; Penn, IM; Ricci, DR; Zubaid, M, 1997) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (0.40) | 18.7374 |
1990's | 49 (9.88) | 18.2507 |
2000's | 229 (46.17) | 29.6817 |
2010's | 215 (43.35) | 24.3611 |
2020's | 1 (0.20) | 2.80 |
Authors | Studies |
---|---|
Capodanno, D | 3 |
Stefanini, GG | 1 |
Vicenzi, M | 1 |
Nikolaou, NI | 1 |
Secemsky, EA | 1 |
Yeh, RW | 2 |
Kereiakes, DJ | 4 |
Cutlip, DE | 6 |
Steg, PG | 14 |
Massaro, JM | 2 |
Apruzzese, PK | 1 |
Mauri, L | 4 |
Felix, CM | 1 |
Vlachojannis, GJ | 1 |
IJsselmuiden, AJJ | 1 |
Fam, JM | 1 |
Smits, PC | 1 |
Lansink, WJ | 1 |
Diletti, R | 1 |
Zijlstra, F | 3 |
Regar, ES | 1 |
Boersma, E | 2 |
Onuma, Y | 2 |
van Geuns, RJM | 1 |
Zhou, Y | 2 |
Wang, Y | 1 |
Wu, Y | 1 |
Huang, C | 1 |
Yan, H | 1 |
Zhu, W | 1 |
Xu, W | 1 |
Zhang, L | 3 |
Zhu, J | 2 |
Didier, R | 1 |
Morice, MC | 3 |
Barragan, P | 7 |
Noryani, AAL | 1 |
Noor, HA | 1 |
Majwal, T | 1 |
Hovasse, T | 1 |
Castellant, P | 1 |
Schneeberger, M | 1 |
Maillard, L | 1 |
Bressolette, E | 1 |
Wojcik, J | 1 |
Delarche, N | 2 |
Blanchard, D | 1 |
Jouve, B | 1 |
Ormezzano, O | 2 |
Paganelli, F | 7 |
Levy, G | 1 |
Sainsous, J | 3 |
Carrie, D | 3 |
Furber, A | 1 |
Berlan, J | 1 |
Darremont, O | 1 |
Le Breton, H | 1 |
Lyuycx-Bore, A | 1 |
Gommeaux, A | 1 |
Cassat, C | 1 |
Kermarrec, A | 1 |
Cazaux, P | 2 |
Druelles, P | 1 |
Dauphin, R | 1 |
Armengaud, J | 1 |
Dupouy, P | 2 |
Champagnac, D | 1 |
Ohlmann, P | 1 |
Ben Amer, H | 1 |
Kiss, RG | 2 |
Ungi, I | 1 |
Gilard, M | 2 |
Jiang, M | 1 |
You, JHS | 1 |
Baber, U | 8 |
Chandrasekhar, J | 3 |
Sartori, S | 5 |
Aquino, M | 3 |
Kini, AS | 3 |
Kapadia, S | 2 |
Weintraub, W | 2 |
Muhlestein, JB | 3 |
Vogel, B | 3 |
Faggioni, M | 2 |
Farhan, S | 3 |
Weiss, S | 2 |
Strauss, C | 2 |
Toma, C | 2 |
DeFranco, A | 2 |
Baker, BA | 2 |
Keller, S | 2 |
Effron, MB | 3 |
Henry, TD | 8 |
Rao, S | 2 |
Pocock, S | 4 |
Dangas, G | 6 |
Mehran, R | 13 |
Stuckey, TD | 5 |
Kirtane, AJ | 10 |
Brodie, BR | 6 |
Witzenbichler, B | 8 |
Litherland, C | 2 |
Weisz, G | 6 |
Rinaldi, MJ | 6 |
Neumann, FJ | 7 |
Metzger, DC | 5 |
Cox, DA | 4 |
Duffy, PL | 4 |
Mazzaferri, EL | 4 |
Gurbel, PA | 9 |
Généreux, P | 5 |
Ben-Yehuda, O | 3 |
Simonton, CA | 2 |
Stone, GW | 16 |
Harada, Y | 1 |
Michel, J | 1 |
Lohaus, R | 1 |
Mayer, K | 3 |
Emmer, R | 1 |
Lahmann, AL | 1 |
Colleran, R | 1 |
Giacoppo, D | 1 |
Wolk, A | 1 |
Ten Berg, JM | 8 |
Han, Y | 1 |
Adriaenssens, T | 1 |
Tölg, R | 1 |
Seyfarth, M | 2 |
Maeng, M | 2 |
Zrenner, B | 1 |
Jacobshagen, C | 1 |
Wöhrle, J | 1 |
Kufner, S | 1 |
Morath, T | 6 |
Ibrahim, T | 1 |
Bernlochner, I | 4 |
Fischer, M | 1 |
Schunkert, H | 3 |
Laugwitz, KL | 4 |
Mehilli, J | 5 |
Byrne, RA | 4 |
Kastrati, A | 9 |
Schulz-Schüpke, S | 1 |
Zafar, MU | 1 |
Smith, DA | 1 |
Contreras, J | 1 |
Rey-Mendoza, J | 1 |
Linares-Koloffon, CA | 1 |
Escolar, G | 1 |
Fuster, V | 1 |
Badimon, JJ | 1 |
Piccolo, R | 2 |
Feres, F | 2 |
Abizaid, A | 3 |
Hong, MK | 7 |
Kim, HS | 3 |
Colombo, A | 17 |
Bhatt, DL | 10 |
Palmerini, T | 3 |
Windecker, S | 4 |
Valgimigli, M | 7 |
Bossard, M | 1 |
Granger, CB | 2 |
Tanguay, JF | 1 |
Montalescot, G | 8 |
Faxon, DP | 2 |
Jolly, SS | 1 |
Widimsky, P | 3 |
Niemela, K | 1 |
Natarajan, MK | 1 |
Gao, P | 1 |
Fox, KAA | 1 |
Yusuf, S | 2 |
Mehta, SR | 2 |
Sorrentino, S | 1 |
Ge, Z | 1 |
Almalla, M | 1 |
Schröder, J | 1 |
Hennings, V | 1 |
Marx, N | 1 |
Hoffmann, R | 1 |
Rinfret, S | 1 |
Rodés-Cabau, J | 2 |
Bagur, R | 1 |
Déry, JP | 2 |
Dorais, M | 1 |
Larose, E | 2 |
Barbeau, G | 1 |
Gleeton, O | 2 |
Nguyen, CM | 2 |
Noël, B | 2 |
Proulx, G | 2 |
Roy, L | 2 |
Taillon, I | 1 |
De Larochellière, R | 2 |
Bertrand, OF | 2 |
Echavarría-Pinto, M | 1 |
Lopes, R | 1 |
Gorgadze, T | 1 |
Gonzalo, N | 1 |
Hernández, R | 3 |
Jiménez-Quevedo, P | 4 |
Alfonso, F | 5 |
Bañuelos, C | 3 |
Nuñez-Gil, IJ | 1 |
Ibañez, B | 1 |
Fernández, C | 2 |
Fernandez-Ortiz, A | 3 |
García, E | 1 |
Macaya, C | 5 |
Escaned, J | 3 |
Prech, M | 1 |
Janus, M | 1 |
Lukawski, K | 1 |
Lesiak, M | 1 |
Storey, RF | 6 |
Park, J | 1 |
Shin, DH | 2 |
Kim, BK | 2 |
Her, AY | 2 |
Kim, YH | 4 |
Choi, HH | 1 |
Kim, JS | 3 |
Ko, YG | 2 |
Choi, D | 2 |
Jang, Y | 2 |
Berglund, U | 1 |
Nilsson, L | 1 |
Janzon, M | 1 |
Cano, P | 1 |
Consuegra-Sánchez, L | 1 |
Conesa, P | 1 |
Torres-Moreno, D | 1 |
Jaulent, L | 1 |
Dau, D | 1 |
Picó, F | 1 |
Villegas, M | 1 |
Tantry, US | 7 |
Kunadian, V | 1 |
James, SK | 3 |
Wojdyla, DM | 3 |
Zorkun, C | 1 |
Wu, J | 1 |
Katus, H | 2 |
Emanuelsson, H | 5 |
Horrow, J | 1 |
Maya, J | 1 |
Wallentin, L | 6 |
Harrington, RA | 11 |
Gibson, CM | 11 |
Liang, ZY | 1 |
Han, YL | 2 |
Zhang, XL | 1 |
Li, Y | 4 |
Yan, CH | 1 |
Kang, J | 1 |
Katus, HA | 3 |
Mahaffey, KW | 9 |
Meier, B | 3 |
Lewis, BS | 2 |
Maurer, G | 2 |
Cuisset, T | 6 |
Grosdidier, C | 1 |
Loundou, AD | 1 |
Quilici, J | 4 |
Loosveld, M | 1 |
Camoin, L | 2 |
Pankert, M | 2 |
Beguin, S | 1 |
Lambert, M | 1 |
Morange, PE | 2 |
Bonnet, JL | 5 |
Alessi, MC | 3 |
Suh, SY | 1 |
Kang, WC | 1 |
Oh, PC | 1 |
Choi, H | 1 |
Moon, CI | 1 |
Lee, K | 1 |
Han, SH | 1 |
Ahn, T | 1 |
Choi, IS | 1 |
Shin, EK | 1 |
Park, KW | 1 |
Kang, SH | 1 |
Park, JJ | 1 |
Yang, HM | 1 |
Kang, HJ | 1 |
Koo, BK | 2 |
Park, BE | 1 |
Cha, KS | 1 |
Rhew, JY | 1 |
Jeon, HK | 1 |
Shin, ES | 1 |
Oh, JH | 1 |
Jeong, MH | 5 |
Kim, S | 1 |
Hwang, KK | 1 |
Yoon, JH | 2 |
Lee, SY | 1 |
Park, TH | 1 |
Moon, KW | 1 |
Kwon, HM | 1 |
Chae, IH | 2 |
Mao, L | 1 |
Jian, C | 1 |
Changzhi, L | 1 |
Dan, H | 1 |
Suihua, H | 1 |
Wenyi, T | 1 |
Wei, W | 1 |
Chen, Y | 1 |
Zhang, Y | 2 |
Tang, Y | 1 |
Huang, X | 1 |
Xie, Y | 1 |
Musumeci, G | 2 |
Limbruno, U | 2 |
Viviani Anselmi, C | 1 |
Briguori, C | 2 |
Roncarati, R | 1 |
Papa, L | 1 |
Visconti, G | 1 |
Focaccio, A | 1 |
De Micco, F | 1 |
Latronico, MV | 1 |
Pagnotta, P | 1 |
Condorelli, G | 1 |
Tebaldi, M | 2 |
Borghesi, M | 1 |
Vranckx, P | 3 |
Campo, G | 4 |
Tumscitz, C | 1 |
Cangiano, E | 1 |
Minarelli, M | 1 |
Scalone, A | 1 |
Cavazza, C | 1 |
Marchesini, J | 1 |
Parrinello, G | 2 |
Ferreiro, JL | 1 |
Sánchez-Salado, JC | 1 |
Gracida, M | 1 |
Marcano, AL | 1 |
Roura, G | 1 |
Ariza, A | 1 |
Gómez-Lara, J | 1 |
Lorente, V | 1 |
Romaguera, R | 1 |
Homs, S | 1 |
Sánchez-Elvira, G | 1 |
Teruel, L | 1 |
Rivera, K | 1 |
Sosa, SG | 1 |
Gómez-Hospital, JA | 1 |
Angiolillo, DJ | 12 |
Cequier, A | 2 |
Deharo, P | 1 |
Bonnet, G | 1 |
Verdier, V | 1 |
Morange, P | 1 |
Waks, JW | 1 |
Sabatine, MS | 3 |
Cannon, CP | 4 |
Morrow, DA | 2 |
Wiviott, SD | 2 |
Giugliano, RP | 1 |
Sloan, S | 1 |
Scirica, BM | 1 |
Hansson, EC | 1 |
Rexius, H | 1 |
Dellborg, M | 2 |
Albertsson, P | 1 |
Jeppsson, A | 1 |
Silber, S | 1 |
Belardi, JA | 1 |
Liu, M | 1 |
Brar, S | 1 |
Rothman, M | 1 |
Camenzind, E | 1 |
Wijns, W | 3 |
Rademaker-Havinga, T | 1 |
Ordoubadi, FF | 1 |
Suttorp, MJ | 3 |
Al Kurdi, M | 1 |
Sabouret, P | 2 |
Taiel-Sartral, M | 1 |
Murray, AM | 1 |
Keville, N | 1 |
Gray, S | 1 |
Schulz, S | 5 |
Braun, S | 4 |
Hausleiter, J | 3 |
Massberg, S | 4 |
Sibbing, D | 8 |
Kazi, DS | 1 |
Garber, AM | 1 |
Shah, RU | 1 |
Dudley, RA | 1 |
Mell, MW | 1 |
Rhee, C | 1 |
Moshkevich, S | 1 |
Boothroyd, DB | 1 |
Owens, DK | 1 |
Hlatky, MA | 1 |
Ho, HH | 1 |
Er Ching, M | 1 |
Ong, PJ | 1 |
Ooi, YW | 1 |
Rangé, G | 2 |
Yayehd, K | 1 |
Belle, L | 2 |
Thuaire, C | 1 |
Richard, P | 1 |
Barbou, F | 1 |
Köning, R | 1 |
Chassaing, S | 1 |
Teiger, E | 1 |
Berthier, R | 1 |
Decomis, MP | 1 |
Claudel, JP | 1 |
Brunel, P | 1 |
De Poli, F | 1 |
Beygui, F | 3 |
Albert, F | 1 |
Collet, JP | 6 |
Davlouros, P | 2 |
Gkizas, V | 1 |
Deftereos, S | 1 |
Giannopoulos, G | 1 |
Alexopoulos, D | 2 |
Ayers, J | 1 |
Mandell, R | 1 |
Sanghvi, K | 1 |
Aboujaoude, R | 1 |
Hsi, DH | 1 |
Roguin, A | 1 |
Musallam, A | 1 |
Liang, J | 1 |
Wang, Z | 1 |
Shi, D | 1 |
Liu, Y | 2 |
Zhao, Y | 1 |
Han, H | 1 |
Liu, W | 1 |
Yang, L | 1 |
Legrand, V | 1 |
Chenu, P | 1 |
Vrolix, M | 1 |
Martinez, C | 1 |
Dens, J | 1 |
Gach, O | 1 |
Boland, J | 1 |
Claeys, MJ | 1 |
Magne, J | 1 |
Barbato, E | 1 |
Parekh, P | 1 |
Agrawal, N | 1 |
Vasavada, A | 1 |
Vinchurkar, M | 1 |
Thim, T | 1 |
Johansen, MB | 1 |
Chisholm, GE | 1 |
Schmidt, M | 1 |
Kaltoft, A | 1 |
Sørensen, HT | 1 |
Thuesen, L | 2 |
Kristensen, SD | 3 |
Bøtker, HE | 1 |
Krusell, LR | 1 |
Lassen, JF | 1 |
Thayssen, P | 1 |
Jensen, LO | 1 |
Tilsted, HH | 1 |
Orban, M | 2 |
Hadamitzky, M | 1 |
Hoppmann, P | 1 |
Tiroch, K | 1 |
Ramaiola, I | 1 |
Padró, T | 1 |
Peña, E | 1 |
Juan-Babot, O | 1 |
Cubedo, J | 1 |
Martin-Yuste, V | 1 |
Sabate, M | 7 |
Badimon, L | 1 |
Siller-Matula, JM | 1 |
Trenk, D | 2 |
Schrör, K | 3 |
Gawaz, M | 6 |
Huber, K | 4 |
Calabrò, P | 1 |
Piscione, F | 2 |
De Servi, S | 2 |
Cattaneo, M | 3 |
Maffeo, D | 1 |
Toso, A | 1 |
Bartorelli, A | 1 |
Palmieri, C | 1 |
De Carlo, M | 2 |
Barozzi, C | 1 |
Tomasi, L | 1 |
Della Riva, D | 1 |
Mariani, A | 1 |
Taglieri, N | 1 |
Reggiani, LB | 1 |
Bianchi, R | 1 |
De Rosa, R | 1 |
Mariani, M | 1 |
Podda, G | 1 |
Thompson, PL | 1 |
Thompson, AG | 1 |
Judkins, C | 1 |
Mendolicchio, GL | 1 |
Zavalloni, D | 2 |
Bacci, M | 1 |
Roveda, M | 1 |
Quagliuolo, V | 1 |
Anselmi, CV | 1 |
Rota, LL | 1 |
Ruggeri, ZM | 1 |
Jeger, RV | 1 |
Pfisterer, ME | 1 |
Sørensen, R | 1 |
von Felten, S | 1 |
Alber, H | 1 |
Bonetti, PO | 1 |
Eberli, F | 1 |
Erne, P | 1 |
Pedrazzini, G | 1 |
Rickli, H | 1 |
Galatius, S | 1 |
Kaiser, CA | 1 |
Shimohama, T | 1 |
Ako, J | 2 |
Lee, HJ | 2 |
Park, TK | 1 |
Song, YB | 1 |
Choi, YJ | 1 |
Yu, CW | 1 |
Yang, JH | 1 |
Hahn, JY | 1 |
Choi, SH | 1 |
Choi, RK | 1 |
Choi, JH | 1 |
Park, JS | 1 |
Kim, TH | 1 |
Jang, HJ | 1 |
Lee, SH | 2 |
Shim, WH | 1 |
Roh, YM | 1 |
Gwon, HC | 1 |
Stoler, R | 1 |
Dauerman, HL | 3 |
White, HD | 6 |
Hamm, CW | 5 |
Price, MJ | 9 |
Cortese, B | 2 |
Wilensky, M | 1 |
Deliargyris, EN | 5 |
Liu, T | 1 |
Prats, J | 5 |
Zalewski, J | 1 |
Bogaert, J | 1 |
Sadowski, M | 1 |
Woznicka, O | 1 |
Doulaptsis, K | 1 |
Ntoumpanaki, M | 1 |
Ząbczyk, M | 1 |
Nessler, J | 1 |
Undas, A | 1 |
Ichikawa, M | 1 |
Takei, Y | 1 |
Hamasaki, T | 1 |
Kijima, Y | 1 |
Sueta, D | 1 |
Hokimoto, S | 2 |
Enomoto, K | 1 |
Ono, T | 1 |
Tabata, T | 1 |
Kajiwara, I | 1 |
Kaikita, K | 1 |
Saruwatari, J | 1 |
Oniki, K | 1 |
Nakagawa, K | 1 |
Ogawa, H | 2 |
Perzborn, E | 1 |
Heitmeier, S | 1 |
Laux, V | 1 |
Rutledge, DR | 1 |
Caixeta, A | 2 |
Kedhi, E | 1 |
Hermiller, JB | 1 |
Wang, J | 2 |
Krucoff, MW | 2 |
Jones-McMeans, J | 1 |
Sudhir, K | 1 |
Serruys, PW | 1 |
Mele, M | 1 |
Martimucci, M | 1 |
Maggi, A | 1 |
Villella, A | 1 |
Villella, M | 1 |
Langialonga, T | 1 |
Azzalini, L | 1 |
Al-Hawwas, M | 1 |
L'Allier, PL | 3 |
Wei, YQ | 1 |
Wang, DG | 1 |
Yang, H | 1 |
Cao, H | 1 |
Samoš, M | 1 |
Fedor, M | 1 |
Kovář, F | 1 |
Duraj, L | 1 |
Stančiaková, L | 1 |
Galajda, P | 1 |
Staško, J | 1 |
Kubisz, P | 1 |
Mokáň, M | 1 |
Valenti, R | 3 |
Marcucci, R | 4 |
Comito, V | 1 |
Marrani, M | 1 |
Cantini, G | 1 |
Migliorini, A | 2 |
Parodi, G | 2 |
Gensini, GF | 3 |
Abbate, R | 3 |
Antoniucci, D | 4 |
Gutierrez, JA | 1 |
Blankenship, JC | 1 |
Kim, YS | 1 |
Lee, SR | 1 |
Yahagi, K | 1 |
Virmani, R | 2 |
Kesavamoorthy, B | 1 |
Khalaf, H | 1 |
Al Meman, AA | 1 |
Rasool, S | 1 |
Gouffran, G | 1 |
Rosencher, J | 1 |
Bougouin, W | 1 |
Jakamy, R | 1 |
Joffre, J | 1 |
Lamhaut, L | 1 |
Dumas, F | 1 |
Cariou, A | 1 |
Varenne, O | 1 |
Parikh, PB | 1 |
Xu, K | 2 |
Parvataneni, R | 2 |
Maehara, A | 3 |
Bonello, L | 9 |
Dignat-George, F | 4 |
Laine, M | 3 |
Tang, X | 1 |
Li, R | 1 |
Jing, Q | 1 |
Wang, Q | 1 |
Liu, P | 1 |
Zhang, P | 1 |
Crimi, G | 1 |
Leonardi, S | 1 |
Costa, F | 1 |
Adamo, M | 1 |
Ariotti, S | 2 |
Giustino, G | 2 |
Cohen, DJ | 3 |
Ariti, C | 2 |
Moliterno, DJ | 2 |
Chieffo, A | 3 |
Rafique, AM | 1 |
Nayyar, P | 1 |
Wang, TY | 1 |
Berger, PB | 8 |
Tobis, J | 3 |
Currier, J | 1 |
Dave, RH | 1 |
Hong, SJ | 1 |
Vaduganathan, M | 1 |
Brener, SJ | 1 |
Essandoh, MK | 1 |
Dalia, AA | 1 |
George, BS | 1 |
Flores, AS | 1 |
Otey, AJ | 1 |
Broderick, TM | 1 |
Rao, SV | 1 |
Gargiulo, G | 1 |
Santucci, A | 1 |
Baldo, A | 1 |
Franzone, A | 1 |
Magnani, G | 1 |
Marino, M | 1 |
Esposito, G | 1 |
Ren, F | 1 |
Mu, N | 1 |
Zhang, X | 2 |
Tan, J | 2 |
Li, L | 1 |
Zhang, C | 1 |
Dong, M | 1 |
Bansilal, S | 1 |
Kini, A | 2 |
Saporito, R | 1 |
Michael Gibson, C | 1 |
Cohen, D | 1 |
Moliterno, D | 1 |
Stuckey, T | 2 |
Henry, T | 1 |
Gabriel Steg, P | 1 |
Abtan, J | 2 |
Abnousi, F | 1 |
Kukula, K | 1 |
Klopotowski, M | 1 |
Kunicki, P | 1 |
Jamiolkowski, J | 1 |
Debski, A | 1 |
Bekta, P | 1 |
Chmielak, Z | 1 |
Witkowski, A | 1 |
Sawlani, NN | 1 |
Yu, J | 1 |
Ooi, SY | 1 |
Stefanescu Schmidt, AC | 1 |
D'Agostino, RB | 1 |
Hsieh, WH | 1 |
Jiménez-Brítez, G | 1 |
Freixa, X | 1 |
Flores-Umanzor, E | 1 |
San Antonio, R | 1 |
Caixal, G | 1 |
Garcia, J | 1 |
Hernandez-Enriquez, M | 1 |
Andrea, R | 1 |
Regueiro, A | 1 |
Masotti, M | 1 |
Brugaletta, S | 3 |
Martin, V | 1 |
Gupta, R | 1 |
Ozan, MO | 1 |
Lim, SY | 1 |
Kim, KS | 3 |
Joo, SJ | 1 |
Jeong, YH | 3 |
Kim, IS | 1 |
Choi, BR | 1 |
Kwak, CH | 2 |
Hwang, JY | 2 |
Camoin-Jau, L | 4 |
Antonino, MJ | 1 |
Acar, G | 1 |
Sökmen, G | 1 |
Nacar, AB | 1 |
Tuncer, C | 1 |
Newsome, LT | 1 |
Weller, RS | 1 |
Gerancher, JC | 1 |
Kutcher, MA | 1 |
Royster, RL | 1 |
Fukushima, K | 3 |
Kobayashi, Y | 4 |
Kitahara, H | 3 |
Iwata, Y | 3 |
Nakayama, T | 2 |
Kuroda, N | 3 |
Ooyama, M | 1 |
Nomura, F | 1 |
Komuro, I | 3 |
Ibrahim, K | 1 |
Hass, N | 1 |
Kolschmann, S | 1 |
Strasser, RH | 1 |
Braun-Dullaeus, RC | 1 |
Barthwal, R | 1 |
Herman, BA | 1 |
Braunwald, E | 2 |
Meisel, S | 1 |
Dalby, AJ | 1 |
Verheugt, FW | 1 |
Goodman, SG | 2 |
Corbalan, R | 1 |
Purdy, DA | 1 |
Murphy, SA | 4 |
McCabe, CH | 2 |
Antman, EM | 3 |
Asano, T | 1 |
Ishio, N | 1 |
Maltz, LA | 1 |
Gauvreau, K | 1 |
Connor, JA | 1 |
Jenkins, KJ | 1 |
Williams, DO | 1 |
Abbott, JD | 1 |
Krausgrill, B | 1 |
Erdmann, E | 3 |
Flesch, M | 1 |
Horowitz, JD | 1 |
Chirkov, YY | 1 |
Biondi-Zoccai, G | 1 |
Lotrionte, M | 1 |
Sheiban, I | 3 |
Ivandic, BT | 1 |
Kurz, K | 1 |
Keck, F | 1 |
Staritz, P | 1 |
Lehrke, S | 1 |
Giannitsis, E | 1 |
Vlaar, PJ | 1 |
Svilaas, T | 1 |
Damman, K | 1 |
de Smet, BJ | 1 |
Tijssen, JG | 1 |
Hillege, HL | 1 |
Serebruany, VL | 4 |
Goto, S | 1 |
Pérez-Vizcayno, MJ | 2 |
Bethencourt, A | 1 |
Martí, V | 1 |
López-Mínguez, JR | 1 |
Angel, J | 1 |
Iñiguez, A | 2 |
Morís, C | 1 |
Suárez, A | 2 |
Wang, ZJ | 1 |
Zhou, YJ | 1 |
Liu, YY | 1 |
Yu, M | 1 |
Shi, DM | 1 |
Zhao, YX | 1 |
Guo, YH | 1 |
Cheng, WJ | 1 |
Jia, de A | 1 |
Cao, Z | 1 |
Nie, B | 1 |
Ge, HL | 1 |
Yang, SW | 1 |
Yan, ZX | 1 |
Armero, S | 2 |
Com, O | 1 |
Arques, S | 1 |
Burignat-Bonello, C | 1 |
Giacomoni, MP | 1 |
Bonello, R | 1 |
Collet, F | 1 |
Rossi, P | 1 |
Jang, SW | 1 |
Kim, DB | 1 |
Kwon, BJ | 1 |
Shin, D | 1 |
Her, SH | 1 |
Park, CS | 1 |
Park, HJ | 1 |
Park, MW | 1 |
Cho, EJ | 1 |
Rho, TH | 1 |
Kim, JH | 2 |
De Labriolle, A | 1 |
Scheinowitz, M | 2 |
Lemesle, G | 1 |
Roy, P | 3 |
Steinberg, DH | 3 |
Pinto Slottow, TL | 4 |
Pakala, R | 1 |
Pichard, AD | 5 |
Waksman, R | 7 |
Conroy, MM | 1 |
Bolsin, SN | 2 |
Kremneva, LV | 1 |
Shalaev, SV | 1 |
Lozano, I | 1 |
Martín, D | 1 |
Torres, F | 1 |
Avanzas, P | 1 |
Rondán, J | 1 |
García-Ruiz, JM | 1 |
Hernández, E | 2 |
Bayón, J | 1 |
Vegas, JM | 1 |
Espolita, A | 1 |
Torguson, R | 3 |
Okabe, T | 2 |
Kaneshige, K | 2 |
Xue, Z | 3 |
Satler, LF | 3 |
Kent, KM | 1 |
Suddath, WO | 2 |
Lindsay, J | 1 |
Giusti, B | 1 |
Gori, AM | 1 |
Saracini, C | 1 |
Sestini, I | 1 |
Paniccia, R | 1 |
Buonamici, P | 2 |
Pattullo, SJ | 1 |
Jayasinghe, R | 1 |
Iijima, R | 1 |
Schömig, A | 8 |
Merkely, B | 1 |
Tóth-Zsamboki, E | 1 |
Becker, D | 1 |
Beres, BJ | 1 |
Szabó, G | 1 |
Vargova, K | 1 |
Fülöp, G | 1 |
Kerecsen, G | 1 |
Preda, I | 1 |
Spaulding, C | 1 |
Micheli, A | 1 |
Picchi, A | 1 |
Ben-Dor, I | 2 |
Ikari, Y | 2 |
Kotani, J | 2 |
Kozuma, K | 2 |
Kyo, E | 2 |
Nakamura, M | 3 |
Yokoi, H | 2 |
Wozakowska-Kapłon, B | 1 |
Młodnicki, M | 1 |
Gutkowski, W | 1 |
Cola, C | 1 |
Martín Yuste, V | 1 |
Campos, B | 1 |
Costa, JR | 1 |
Costa, R | 1 |
Tanajura, LF | 1 |
Mattos, LA | 1 |
Staico, R | 1 |
Siqueira, D | 1 |
Sousa, AG | 1 |
Bonan, R | 1 |
Sousa, JE | 1 |
Liu, X | 1 |
Doi, H | 1 |
Mintz, GS | 2 |
Costa, Jde R | 1 |
Sano, K | 1 |
Dangas, GD | 2 |
Lansky, AJ | 3 |
Kreps, EM | 1 |
Collins, M | 2 |
Fahy, M | 1 |
Moses, JW | 4 |
Leon, MB | 2 |
Otake, H | 2 |
Shite, J | 2 |
Shinke, T | 2 |
Tanino, Y | 2 |
Ogasawara, D | 2 |
Sawada, T | 2 |
Miyoshi, N | 1 |
Kato, H | 2 |
Honda, Y | 1 |
Fitzgerald, PJ | 1 |
Hirata, K | 2 |
Motovska, Z | 2 |
Ruiz, M | 2 |
Cazares, M | 1 |
Makarov, LM | 1 |
Güray, Y | 1 |
Güray, U | 1 |
Korkmaz, S | 1 |
Carrescia, C | 1 |
Carletti, R | 1 |
Ferrari, R | 2 |
de Cesare, N | 1 |
Meliga, E | 1 |
Furgieri, A | 1 |
Hamon, M | 2 |
Repetto, A | 1 |
Colangelo, S | 1 |
Percoco, G | 2 |
Chen, KY | 1 |
Rha, SW | 1 |
Li, YJ | 1 |
Poddar, KL | 1 |
Jin, Z | 1 |
Minami, Y | 1 |
Wang, L | 1 |
Kim, EJ | 1 |
Park, CG | 1 |
Seo, HS | 1 |
Oh, DJ | 2 |
Ahn, YK | 1 |
Hong, TJ | 2 |
Kim, YJ | 1 |
Hur, SH | 1 |
Seong, IW | 2 |
Chae, JK | 1 |
Cho, MC | 1 |
Bae, JH | 1 |
Choi, DH | 1 |
Jang, YS | 2 |
Kim, CJ | 1 |
Chung, WS | 1 |
Seung, KB | 2 |
Park, SJ | 5 |
Perez, G | 1 |
Rodriguez-Granillo, AM | 1 |
Mieres, J | 1 |
Llaurado, C | 1 |
Rubilar, B | 1 |
Risau, G | 1 |
Fernandez-Pereira, C | 1 |
Rodriguez, AE | 1 |
Milicic, D | 1 |
Skoric, B | 1 |
Lovric, D | 1 |
Gavini, R | 1 |
Beauzile, P | 1 |
Sushinsky, SJ | 1 |
Tantry, U | 1 |
Kent, K | 1 |
Gurbel, P | 1 |
Heestermans, AA | 2 |
Van Werkum, JW | 8 |
Hamm, C | 2 |
Dill, T | 1 |
Gosselink, AT | 2 |
De Boer, MJ | 1 |
Van Houwelingen, G | 1 |
Hoorntje, JC | 1 |
Koopmans, PC | 1 |
Van 't Hof, AW | 2 |
El-Menyar, A | 1 |
Hussein, H | 1 |
Al Suwaidi, J | 1 |
Ergelen, M | 1 |
Uyarel, H | 1 |
Osmonov, D | 1 |
Ayhan, E | 1 |
Akkaya, E | 1 |
Soylu, O | 1 |
Orhan, AL | 1 |
Sayar, N | 1 |
Bozbay, M | 1 |
Turer, A | 1 |
Yildirim, E | 1 |
Yekeler, I | 1 |
Santiago-Díaz, P | 1 |
Arrebola-Moreno, AL | 1 |
Ramírez-Hernández, JA | 1 |
Melgares-Moreno, R | 1 |
Frere, C | 1 |
Gaborit, B | 1 |
Castelli, C | 1 |
Poyet, R | 1 |
Bali, L | 1 |
Zomer, AC | 1 |
Zwart, B | 1 |
Tanzilli, G | 1 |
Greco, C | 1 |
Pelliccia, F | 1 |
Pasceri, V | 2 |
Barillà, F | 1 |
Paravati, V | 1 |
Pannitteri, G | 1 |
Gaudio, C | 1 |
Mangieri, E | 1 |
Lee, CW | 3 |
Park, DW | 1 |
Kim, JJ | 4 |
Park, SW | 4 |
Yun, SC | 1 |
Lee, JH | 1 |
Lee, NH | 1 |
Cho, YH | 1 |
Cheong, SS | 1 |
Lim, DS | 1 |
Yang, JY | 1 |
Lee, SG | 1 |
Yoon, J | 1 |
Popescu, WM | 1 |
Giuliani, G | 1 |
Cerisano, G | 1 |
Carrabba, N | 1 |
Howard, PA | 1 |
Vacek, JL | 1 |
Diehl, P | 1 |
Olivier, C | 1 |
Halscheid, C | 1 |
Helbing, T | 1 |
Bode, C | 1 |
Moser, M | 1 |
Chhatriwalla, AK | 1 |
Gerber, RT | 1 |
Savonitto, S | 1 |
D'Urbano, M | 1 |
Caracciolo, M | 1 |
Barlocco, F | 1 |
Mariani, G | 1 |
Nichelatti, M | 1 |
Klugmann, S | 1 |
Sielski, J | 2 |
Wałek, P | 1 |
Polewczyk, A | 2 |
Janion, M | 2 |
Xue, F | 1 |
Yang, XJ | 1 |
Cheng, XJ | 1 |
Hui, J | 1 |
Jiang, TB | 1 |
Chen, T | 1 |
Liu, ZH | 1 |
Song, JP | 1 |
Jiang, WP | 1 |
Koch, W | 1 |
Gebhard, D | 1 |
Schuster, T | 1 |
Stegherr, J | 1 |
von Beckerath, N | 1 |
Steinhubl, SR | 7 |
Tavassoli, N | 1 |
Voisin, S | 1 |
Lapeyre-Mestre, M | 1 |
Galinier, M | 1 |
Montastruc, JL | 1 |
Pathak, A | 1 |
Akhter, M | 1 |
Kothari, S | 1 |
Sharma, SK | 1 |
Nie, R | 1 |
Luo, N | 1 |
Liistro, F | 2 |
Fineschi, M | 2 |
Grotti, S | 1 |
Angioli, P | 1 |
Carrera, A | 1 |
Ducci, K | 1 |
Gori, T | 2 |
Falsini, G | 1 |
Pierli, C | 1 |
Bolognese, L | 1 |
Balbi, M | 1 |
Fedele, M | 1 |
Bezante, GP | 1 |
Brunelli, C | 1 |
Barsotti, A | 1 |
Harmsze, AM | 1 |
Robijns, K | 1 |
Breet, NJ | 3 |
Hackeng, CM | 2 |
Ruven, HJ | 1 |
Klungel, OH | 1 |
de Boer, A | 1 |
Deneer, VH | 1 |
Johansen, M | 1 |
Afshari, A | 1 |
Kristensen, BB | 1 |
Piatek, L | 1 |
Piatek, K | 1 |
Saidi, Y | 1 |
Guesmi, F | 1 |
Landolsi, M | 1 |
Trabelsi, S | 1 |
Khemiri, K | 1 |
Ounalli, K | 1 |
Dziri, C | 1 |
Houissa, M | 1 |
Schwartz, RS | 1 |
Eshtehardi, P | 2 |
Cook, S | 1 |
Billinger, M | 1 |
Togni, M | 1 |
Garachemani, A | 1 |
Hess, OM | 1 |
Wenaweser, P | 1 |
Shen, WF | 1 |
Chen, JL | 1 |
Gao, LJ | 1 |
Yang, YJ | 1 |
Li, JJ | 1 |
Qiao, SB | 1 |
Xu, B | 2 |
Huang, JH | 1 |
Yao, M | 1 |
Qin, XW | 1 |
Liu, HB | 1 |
Wu, YJ | 1 |
Yuan, JQ | 1 |
Chen, J | 2 |
You, SJ | 1 |
Dai, J | 1 |
Gao, RL | 2 |
Geisler, T | 3 |
Mueller, K | 1 |
Aichele, S | 1 |
Bigalke, B | 3 |
Stellos, K | 1 |
Htun, P | 1 |
Ninci, E | 1 |
Fateh-Moghadam, S | 1 |
May, AE | 2 |
Paikin, JS | 1 |
Eikelboom, JW | 1 |
Cairns, JA | 1 |
Hirsh, J | 2 |
Hulot, JS | 2 |
Silvain, J | 3 |
Pena, A | 1 |
Bellemain-Appaix, A | 1 |
Barthélémy, O | 2 |
Cayla, G | 3 |
Hövelborn, T | 1 |
Wessely, R | 1 |
Karabay, CY | 1 |
Can, MM | 1 |
Tanboğa, IH | 1 |
Ahmet, G | 1 |
Bitigen, A | 1 |
Serebruany, V | 1 |
Wang, K | 1 |
Zhou, X | 1 |
Huang, Y | 1 |
Khalil, M | 1 |
Wiktor, D | 1 |
van Giezen, JJ | 1 |
Penn, MS | 1 |
Blindt, R | 1 |
Becker, R | 1 |
Gachet, C | 2 |
Jennings, LK | 1 |
Kereiakes, D | 1 |
Llau, JV | 1 |
Ferrandis, R | 1 |
Sierra, P | 1 |
Gómez-Luque, A | 1 |
Solheim, S | 1 |
Seljeflot, I | 1 |
Lunde, K | 1 |
Bjørnerheim, R | 1 |
Aakhus, S | 1 |
Forfang, K | 1 |
Arnesen, H | 1 |
James, S | 2 |
Ardissino, D | 1 |
Becker, RC | 3 |
Finkelstein, A | 1 |
Husted, S | 1 |
Kilhamn, J | 1 |
Olofsson, S | 1 |
Weaver, WD | 1 |
Reinhart, WH | 1 |
Gentilomo, C | 1 |
Huang, YS | 1 |
Raffini, L | 1 |
Yasu, T | 1 |
Ikee, R | 1 |
Miyasaka, Y | 1 |
Chubachi, H | 1 |
Saito, S | 1 |
Tomasello, SD | 1 |
Tello-Montoliu, A | 2 |
Park, KH | 1 |
Lee, MG | 1 |
Ko, JS | 1 |
Sim, DS | 1 |
Yoon, NS | 1 |
Yoon, HJ | 1 |
Hong, YJ | 1 |
Kim, KH | 1 |
Park, HW | 1 |
Ahn, Y | 1 |
Cho, JG | 1 |
Park, JC | 1 |
Kang, JC | 2 |
Rechner, AR | 1 |
Ivandic, B | 1 |
Frey, N | 1 |
Ota, Y | 1 |
Nagai, Y | 1 |
Katsuta, Y | 1 |
Nozaki, E | 1 |
Onodera, T | 1 |
Dolgin, E | 1 |
Campbell, KL | 1 |
Cohn, JR | 1 |
Fischman, DL | 1 |
Walinsky, P | 1 |
Mallya, R | 1 |
Jaffrani, W | 1 |
Savage, MP | 1 |
Patti, G | 2 |
Vizzi, V | 1 |
Ricottini, E | 1 |
Di Sciascio, G | 1 |
Jung, HJ | 1 |
Sir, JJ | 1 |
Barison, A | 1 |
Bellini, F | 1 |
Capozza, PF | 1 |
Lunardini, A | 1 |
Petronio, AS | 1 |
Bakhai, A | 1 |
Ferrieres, J | 1 |
Schmitt, C | 1 |
Sartral, M | 1 |
Belger, M | 1 |
Zeymer, U | 1 |
Juel, J | 1 |
Jensen, SE | 1 |
Bouman, HJ | 1 |
ten Cate, H | 1 |
Sarafoff, N | 1 |
Neumann, L | 1 |
Patel, PJ | 1 |
Matthai, WH | 1 |
Untereker, WJ | 1 |
Hara, M | 1 |
Nishino, M | 1 |
Taniike, M | 1 |
Makino, N | 1 |
Egami, Y | 1 |
Shutta, R | 1 |
Tanouchi, J | 1 |
Yamada, Y | 1 |
Hechler, B | 1 |
Parise, H | 1 |
Cristea, E | 1 |
Guagliumi, G | 3 |
Peruga, JZ | 1 |
Dudek, D | 1 |
Möeckel, M | 1 |
Briongos Figuero, S | 1 |
Salido-Tahoces, L | 1 |
de Juan-Bagudá, J | 1 |
Martí-Sánchez, D | 1 |
Grove, EL | 1 |
Würtz, M | 1 |
Hvas, AM | 1 |
Fernando, H | 1 |
Dart, AM | 1 |
Peter, K | 1 |
Shaw, JA | 1 |
Vavuranakis, M | 1 |
Vrachatis, DA | 1 |
Papaioannou, TG | 1 |
Archontakis, S | 1 |
Kalogeras, KI | 1 |
Kariori, MG | 1 |
Gafou, A | 1 |
Moldovan, C | 1 |
Tzamalis, P | 1 |
Stefanadis, C | 1 |
Cassese, S | 1 |
De Luca, G | 1 |
Villari, B | 1 |
Berti, S | 1 |
Bellone, P | 1 |
Alfieri, A | 1 |
Montinaro, A | 1 |
Quaranta, G | 1 |
Marraccini, P | 1 |
Lotfi, A | 1 |
Cui, J | 1 |
Wartak, S | 1 |
Columbo, J | 1 |
Mulvey, S | 1 |
Davis, M | 1 |
Schweiger, M | 1 |
Giugliano, GR | 1 |
Yan, BP | 1 |
Ajani, AE | 1 |
Clark, DJ | 1 |
Duffy, SJ | 1 |
Andrianopoulos, N | 1 |
Brennan, AL | 1 |
Loane, P | 1 |
Reid, CM | 1 |
Nusca, A | 1 |
Curzen, N | 2 |
Sambu, N | 2 |
Varenhorst, C | 1 |
Koul, S | 1 |
Erlinge, D | 1 |
Lagerqvist, B | 1 |
Siegbahn, A | 1 |
Barone-Rochette, G | 2 |
Foote, A | 1 |
Motreff, P | 2 |
Vanzetto, G | 2 |
Quesada, JL | 1 |
Danchin, N | 2 |
Machecourt, J | 2 |
Zakhem, B | 1 |
Garg, P | 1 |
Davis, G | 1 |
Wilson, JI | 1 |
Sivananthan, M | 1 |
Sharma, S | 1 |
Forrester, JS | 2 |
Rossini, R | 1 |
Lettieri, C | 1 |
Romano, M | 1 |
Rosiello, R | 1 |
Valsecchi, O | 1 |
Gavazzi, A | 1 |
Luo, Y | 1 |
Zhao, YT | 1 |
Verdo, A | 1 |
Qi, WG | 1 |
Zhang, DF | 1 |
Hu, B | 1 |
Odvodyova, D | 1 |
Fischerova, M | 1 |
Stepankova, S | 1 |
Maly, M | 1 |
Morawska, P | 1 |
Hermanides, RS | 1 |
Ottervanger, JP | 1 |
van Houwelingen, KG | 1 |
Dambrink, JH | 1 |
Ishida, M | 1 |
Watanabe, H | 1 |
Iino, K | 1 |
Okawa, M | 1 |
Kosaka, T | 1 |
Ito, H | 1 |
Granada, JF | 1 |
French, PA | 1 |
Smyth, SS | 2 |
Kern, MJ | 1 |
Parrett, BM | 1 |
Woo, A | 1 |
Buntic, R | 1 |
Singer, M | 1 |
Elmariah, S | 1 |
Jang, IK | 1 |
Warner, TD | 1 |
Mitchell, JA | 1 |
Kirkby, NS | 1 |
Radhakrishnan, A | 1 |
Dent, H | 1 |
Calver, AL | 1 |
Corbett, S | 1 |
Gray, H | 1 |
Simpson, IA | 1 |
Subban, V | 1 |
Kalidoss, L | 1 |
Sankardas, MA | 1 |
Azmoon, S | 1 |
Park, Y | 1 |
Muse, WC | 1 |
Kwon, TJ | 1 |
Koh, JS | 1 |
Hwang, SJ | 1 |
Canpolat, U | 1 |
Yorgun, H | 1 |
Atalar, E | 1 |
Mizia-Stec, K | 1 |
Haberka, M | 1 |
Mizia, M | 1 |
Lasota, B | 1 |
Kunecki, M | 1 |
Gieszczyk, K | 1 |
Chmiel, A | 1 |
Najda, J | 1 |
Kyrcz-Krzemień, S | 1 |
Gąsior, Z | 1 |
O'Connor, SA | 2 |
Bessereau, J | 1 |
Sébastien, A | 1 |
Galati, A | 1 |
Xanthopoulou, I | 1 |
Mavronasiou, E | 1 |
Kassimis, G | 1 |
Theodoropoulos, KC | 1 |
Makris, G | 1 |
Damelou, A | 1 |
Tsigkas, G | 1 |
Hahalis, G | 1 |
Tai, BC | 1 |
Sia, W | 1 |
Phua, QH | 1 |
Richards, MA | 1 |
Low, A | 1 |
Chan, KH | 1 |
Teo, SG | 1 |
Sim, TB | 1 |
Lee, CH | 1 |
Roe, MT | 1 |
Yeo, TC | 1 |
Tan, HC | 1 |
Chan, MY | 1 |
Colantonio, R | 2 |
Rotolo, F | 1 |
Monti, F | 1 |
Boggi, A | 1 |
Serdoz, R | 2 |
Rollini, F | 1 |
El Mallah, W | 1 |
Klein, AJ | 1 |
Brilakis, ES | 1 |
Verschuren, JJ | 1 |
Boden, H | 1 |
Wessels, JA | 1 |
van der Hoeven, BL | 1 |
Trompet, S | 1 |
Heijmans, BT | 1 |
Putter, H | 1 |
Guchelaar, HJ | 1 |
Schalij, MJ | 2 |
Jukema, JW | 1 |
Zou, JJ | 1 |
Xie, HG | 1 |
Chen, SL | 1 |
Lin, L | 1 |
Zhao, YY | 1 |
Xu, HM | 1 |
Lin, S | 1 |
Zhang, J | 1 |
Wang, GJ | 1 |
Brodie, B | 1 |
Pokharel, Y | 1 |
Garg, A | 1 |
Kissling, G | 1 |
Hansen, C | 1 |
Milks, S | 1 |
Cooper, M | 1 |
McAlhany, C | 1 |
Biscaglia, S | 1 |
Elhadad, S | 1 |
Pouillot, C | 1 |
Henry, P | 1 |
Boueri, Z | 1 |
Van Belle, E | 2 |
Rousseau, H | 1 |
Aubry, P | 2 |
Monségu, J | 1 |
Kerneis, M | 1 |
Saint-Etienne, C | 1 |
Vicaut, E | 1 |
Peyrol, M | 1 |
Sbragia, P | 1 |
Thuny, F | 1 |
Bennett, MR | 1 |
Yang, LX | 1 |
Liu, HL | 1 |
Qu, P | 1 |
Li, WM | 1 |
Jiang, TM | 1 |
Li, SM | 1 |
Jing, QM | 1 |
Zhang, QY | 1 |
Aradi, D | 1 |
Komócsi, A | 1 |
Vorobcsuk, A | 1 |
Yamagishi, M | 1 |
Ueno, T | 1 |
Hara, K | 2 |
Ishiwata, S | 1 |
Itoh, T | 1 |
Hamanaka, I | 1 |
Wakatsuki, T | 2 |
Sugano, T | 1 |
Kawai, K | 1 |
Kimura, T | 1 |
Ohkubo, K | 1 |
Fujimoto, Y | 1 |
Kadohira, T | 1 |
Sugimoto, K | 1 |
Morino, T | 1 |
Bliden, KP | 3 |
Fort, JG | 1 |
Shuldiner, A | 1 |
Chai, S | 1 |
Gesheff, T | 1 |
Antonino, M | 1 |
Gesheff, M | 1 |
Carlquist, JF | 1 |
Knight, S | 1 |
Horne, BD | 1 |
Huntinghouse, JA | 1 |
Rollo, JS | 1 |
May, H | 1 |
Anderson, JL | 1 |
Singh, M | 1 |
Bolla, VH | 1 |
Berg, R | 1 |
Shatin, D | 1 |
Schech, SD | 1 |
Brinker, A | 1 |
Mahadevan, VS | 1 |
Khan, MM | 1 |
Adgey, JA | 1 |
Burzotta, F | 1 |
Sabatier, R | 1 |
Prati, F | 1 |
Boccanelli, A | 1 |
Grollier, G | 2 |
Orford, JL | 1 |
Lennon, R | 1 |
Melby, S | 2 |
Fasseas, P | 1 |
Bell, MR | 2 |
Rihal, CS | 2 |
Holmes, DR | 6 |
Fitchett, D | 1 |
Gupta, M | 1 |
Langer, A | 1 |
Krötz, F | 1 |
Schiele, TM | 1 |
Zahler, S | 1 |
König, A | 1 |
Rieber, J | 1 |
Kantlehner, R | 1 |
Pöllinger, B | 1 |
Dühmke, E | 1 |
Theisen, K | 1 |
Sohn, HY | 1 |
Klauss, V | 1 |
Sick, P | 1 |
Hüttl, T | 1 |
Niebauer, J | 1 |
Thiele, H | 1 |
Lauer, B | 1 |
Hambrecht, R | 1 |
Hentschel, B | 1 |
Schuler, G | 1 |
Cummings, CC | 1 |
Bell, CR | 1 |
Alford, AB | 1 |
Meister, AF | 1 |
Boden, WE | 1 |
Pepine, CJ | 1 |
Bouvier, JL | 3 |
Roquebert, PO | 2 |
Macaluso, G | 1 |
Commeau, P | 1 |
Comet, B | 3 |
Lafont, A | 1 |
Walter, U | 1 |
Eigenthaler, M | 2 |
Voskoboĭ, VI | 1 |
Rebrov, AP | 1 |
Rogan, SV | 1 |
Arablinskiĭ, AV | 1 |
Solov'ev, OP | 1 |
Rott, D | 1 |
Dai, H | 1 |
Tao, Q | 1 |
Zhang, F | 1 |
Zheng, L | 1 |
Qiu, Y | 1 |
Lee, SW | 1 |
Song, JM | 1 |
Han, KH | 1 |
Kang, DH | 1 |
Song, JK | 1 |
Ludwig, J | 1 |
Spanos, V | 1 |
Louvard, Y | 1 |
Desmedt, B | 1 |
Di Mario, C | 4 |
Weltermann, A | 1 |
Fritsch, P | 1 |
Kyrle, PA | 1 |
Schoenauer, V | 1 |
Heinze, G | 1 |
Wojta, J | 1 |
Christ, G | 1 |
Schömig, E | 1 |
Lepäntalo, A | 1 |
Virtanen, KS | 1 |
Heikkilä, J | 1 |
Wartiovaara, U | 1 |
Lassila, R | 1 |
Bernardo, E | 2 |
Stranieri, C | 1 |
Trabetti, E | 1 |
Pignatti, PF | 1 |
Helø, OH | 1 |
Madsen, JK | 1 |
Kastrup, J | 1 |
Matetzky, S | 2 |
Shenkman, B | 1 |
Guetta, V | 1 |
Shechter, M | 1 |
Beinart, R | 1 |
Bienart, R | 1 |
Goldenberg, I | 1 |
Novikov, I | 1 |
Pres, H | 1 |
Savion, N | 1 |
Varon, D | 1 |
Hod, H | 2 |
Müller, I | 2 |
Besta, F | 1 |
Tsakiris, DA | 1 |
Schneider, C | 1 |
Patrono, C | 1 |
Coller, B | 1 |
FitzGerald, GA | 1 |
Roth, G | 1 |
Ezekowitz, M | 1 |
Meade, TW | 1 |
O'Connor, CM | 1 |
Vorchheimer, DA | 1 |
Guyatt, GH | 1 |
Zimarino, M | 3 |
Renda, G | 2 |
Maddestra, N | 1 |
De Caterina, R | 2 |
Schwimmbeck, PL | 1 |
Schulman, SP | 1 |
Schleinitz, MD | 1 |
Olkin, I | 1 |
Heidenreich, PA | 1 |
Danna, P | 1 |
Piccaluga, E | 1 |
Viecca, M | 1 |
von Mach, MA | 1 |
Eich, A | 1 |
Weilemann, LS | 1 |
Münzel, T | 2 |
Zaman, KA | 1 |
Yoho, JA | 1 |
Hayes, KM | 1 |
Leopold, JA | 1 |
Bavry, AA | 1 |
Kumbhani, DJ | 1 |
Helton, TJ | 1 |
Kunz, I | 1 |
Spada, S | 1 |
Sütsch, G | 1 |
Ruggieri, F | 1 |
Karvouni, E | 1 |
Korovesis, S | 1 |
Katritsis, DG | 1 |
Wyss, CA | 1 |
Roffi, M | 1 |
Biondi-Zoccai, GG | 2 |
Sangiorgi, GM | 2 |
Vittori, G | 1 |
Falchetti, E | 1 |
Margheri, M | 1 |
Barbagallo, R | 1 |
Tamburino, C | 2 |
Remigi, E | 1 |
Iakovou, I | 1 |
Agostoni, P | 1 |
Tsagalou, E | 1 |
Melzi, G | 1 |
Michev, I | 1 |
Airoldi, F | 1 |
Montorfano, M | 1 |
Carlino, M | 1 |
Wolak, A | 1 |
Amit, G | 1 |
Cafri, C | 1 |
Gilutz, H | 1 |
Ilia, R | 1 |
Zahger, D | 1 |
Phillips, DR | 1 |
Conley, PB | 1 |
Sinha, U | 1 |
Andre, P | 1 |
Wlazłowski, R | 1 |
Goch, A | 1 |
Goch, JH | 1 |
Leiva-Pons, JL | 1 |
Keltai, M | 1 |
Almsherqi, ZA | 1 |
McLachlan, CS | 1 |
Mossop, P | 1 |
Deng, Y | 1 |
Bierbach, B | 1 |
Horstick, G | 1 |
Berg, O | 1 |
Heimann, A | 1 |
Vahl, CF | 1 |
Kempski, O | 1 |
Darius, H | 1 |
Brügemann, J | 1 |
van Gelder, IC | 1 |
van der Meer, J | 1 |
Boztosun, B | 1 |
Gunes, Y | 1 |
Kirma, C | 1 |
Barutcu, I | 1 |
Hennan, JK | 1 |
Swillo, RE | 1 |
Morgan, GA | 1 |
Leik, CE | 1 |
Brooks, JM | 1 |
Shaw, GD | 1 |
Schaub, RG | 1 |
Crandall, DL | 1 |
Vlasuk, GP | 1 |
Vats, HS | 1 |
Hocking, WG | 1 |
Rezkalla, SH | 1 |
Templin, C | 1 |
Schaefer, A | 1 |
Stumme, B | 1 |
Drexler, H | 1 |
von Depka, M | 1 |
Olivier, AC | 1 |
Hollman, JL | 1 |
Fuchigami, S | 1 |
Oshima, S | 1 |
Noda, K | 1 |
Fukushima, H | 1 |
Yoshida, T | 1 |
Takushi, Y | 1 |
Ozben, B | 1 |
Ekmekci, A | 1 |
Bugra, Z | 1 |
Umman, S | 1 |
Meric, M | 1 |
Oo, TH | 1 |
Patel, TN | 1 |
Kreindel, M | 1 |
Lincoff, AM | 1 |
Vafai, JJ | 1 |
Aroesty, JM | 1 |
Granitskiĭ, NA | 1 |
Ishikawa, T | 1 |
Mutoh, M | 1 |
Fuda, Y | 1 |
Sakamoto, H | 1 |
Okada, H | 1 |
Higashitani, M | 1 |
Nakano, Y | 1 |
Yamaguchi, J | 1 |
Enta, K | 1 |
Satoh, T | 1 |
Imai, K | 1 |
Horie, T | 1 |
Mochizuki, S | 1 |
Plokker, HW | 1 |
Nesto, RW | 1 |
Gaku, N | 1 |
Kengo, T | 1 |
Aoki, J | 1 |
Yamamoto, H | 1 |
Higashikuni, Y | 1 |
Nakajima, H | 1 |
Chrissoheris, MP | 1 |
Mruthyunjayanna, V | 1 |
Donohue, TJ | 1 |
Yang, J | 1 |
Wang, N | 1 |
Xu, J | 1 |
Ling, F | 1 |
Zhou, L | 1 |
Ye, X | 1 |
Münzel, TF | 1 |
Post, F | 1 |
Sharifkazemi, MB | 1 |
Zamirian, M | 1 |
Aslani, A | 1 |
Matsumoto, D | 1 |
Paredes, OL | 1 |
Yokoyama, M | 1 |
Bochenek, A | 1 |
Wilczyński, M | 1 |
Pfisterer, M | 1 |
Brunner-La Rocca, HP | 1 |
Buser, PT | 1 |
Rickenbacher, P | 1 |
Hunziker, P | 1 |
Mueller, C | 1 |
Jeger, R | 1 |
Bader, F | 1 |
Osswald, S | 1 |
Kaiser, C | 1 |
Califf, RM | 1 |
Wiper, AJ | 1 |
Roberts, DH | 1 |
Antoniou, S | 1 |
Rothman, MT | 1 |
Chassot, PG | 2 |
Delabays, A | 2 |
Ravussin, P | 1 |
Spahn, DR | 2 |
Glowczynska, R | 1 |
Malek, LA | 1 |
Spiewak, M | 1 |
Filipiak, KJ | 1 |
Grabowski, M | 1 |
Kisiel, B | 1 |
Kochman, J | 1 |
Kostrzewa, G | 1 |
Ploski, R | 1 |
Opolski, G | 1 |
Hamdalla, H | 1 |
Eshaghian, S | 1 |
Kaul, S | 1 |
Amin, S | 1 |
Shah, PK | 2 |
Diamond, GA | 1 |
Okuno, T | 1 |
Nakamura, Y | 2 |
Sakakibara, M | 1 |
Miyazaki, A | 1 |
Shimizu, Y | 1 |
Seesing, TH | 1 |
Bal, ET | 1 |
den Heijer, P | 1 |
Grinius, V | 1 |
Navickas, R | 1 |
Unikas, R | 1 |
Bartorelli, AL | 1 |
Trabattoni, D | 1 |
Galassi, A | 1 |
Piovaccari, G | 2 |
Benassi, A | 2 |
Sangiorgio, P | 1 |
Chierchia, S | 1 |
Reimers, B | 3 |
Finn, AV | 1 |
Joner, M | 1 |
Nakazawa, G | 1 |
Kolodgie, F | 1 |
Newell, J | 1 |
John, MC | 1 |
Gold, HK | 1 |
Lee, JS | 1 |
Dunn, SP | 1 |
Marshall, HM | 1 |
Cohen, MG | 1 |
Schäfer, A | 1 |
Bonz, AW | 1 |
Bauersachs, J | 1 |
Karlsson, G | 1 |
Rehman, J | 1 |
Kalaria, V | 1 |
Breall, JA | 1 |
Fefer, P | 1 |
Tamura, A | 1 |
Watanabe, T | 1 |
Shinozaki, K | 1 |
Kotoku, M | 1 |
Yano, S | 1 |
Kadota, J | 1 |
Majdoub, MA | 1 |
Sauguet, A | 1 |
Tchetche, D | 1 |
Ducrocq, G | 2 |
Benamer, H | 1 |
Himbert, D | 1 |
Feldman, LJ | 1 |
Juliard, JM | 1 |
Digne, F | 1 |
Gérardin, B | 1 |
Pillière, R | 1 |
Estagnasié, P | 1 |
Dib, JC | 1 |
Terdjman, M | 1 |
Grinda, JM | 1 |
Dubois, C | 1 |
Baer, FM | 1 |
Tie, S | 1 |
Wong, CK | 1 |
Yap, J | 1 |
Wilkins, G | 1 |
Williams, M | 1 |
Kay, P | 1 |
Gladding, P | 1 |
Webster, M | 1 |
Marzocchi, A | 1 |
Saia, F | 1 |
Manari, A | 1 |
Aurier, E | 1 |
Cremonesi, A | 1 |
Varani, E | 1 |
Magnavacchi, P | 1 |
Guastaroba, P | 1 |
Grilli, R | 1 |
Maresta, A | 1 |
Kapp, M | 1 |
Göhring-Frischholz, K | 1 |
Daub, K | 1 |
Dösch, C | 1 |
Langer, H | 1 |
Herdeg, C | 1 |
Belli, G | 1 |
Rossi, M | 1 |
Presbitero, P | 1 |
Kupferwasser, LI | 1 |
Amorn, AM | 1 |
Kapoor, N | 1 |
Lee, MS | 1 |
Kar, S | 1 |
Cercek, B | 1 |
Dohad, S | 1 |
Mirocha, J | 1 |
Makkar, RR | 1 |
Parikh, SA | 1 |
Beckman, JA | 1 |
Sardella, G | 1 |
Bucciarelli-Ducci, C | 1 |
Mancone, M | 1 |
Fedele, F | 1 |
Tomaszuk-Kazberuk, A | 1 |
Sobkowicz, B | 1 |
Usowicz-Szaryńska, M | 1 |
Prokop, JB | 1 |
Knapp, M | 1 |
Sawicki, R | 1 |
Musiał, WJ | 1 |
Augoustides, JG | 1 |
Joyal, D | 1 |
Rudski, L | 1 |
Smith, K | 1 |
Ferguson, JJ | 3 |
Wilson, JM | 1 |
Diez, J | 1 |
Grube, E | 1 |
Dawkins, KD | 1 |
Banning, AP | 2 |
Zmudka, K | 1 |
Hauptman, K | 1 |
Marco, J | 1 |
Popma, JJ | 2 |
Buellesfeld, L | 1 |
Koglin, J | 1 |
Russell, ME | 1 |
Fitzgerald, DJ | 1 |
Maree, A | 1 |
Berger, K | 1 |
Hessel, F | 1 |
Kreuzer, J | 1 |
Smala, A | 1 |
Diener, HC | 1 |
Varvarovský, I | 1 |
Matejka, J | 1 |
Herman, A | 1 |
Conroy, M | 1 |
Black, SA | 1 |
Orford, N | 1 |
Kaya, MG | 1 |
Durakoglugil, E | 1 |
Yalcin, R | 1 |
Singh, S | 1 |
Arora, R | 1 |
Khraisat, A | 1 |
Handa, K | 1 |
Bahekar, A | 1 |
Trivedi, A | 1 |
Khosla, S | 1 |
Kirsch, M | 1 |
Vermes, E | 1 |
Boval, B | 1 |
Drouet, L | 1 |
Loisance, D | 1 |
Dupliakov, DV | 1 |
Endemann, S | 1 |
Gollapudi, RR | 1 |
Valencia, R | 1 |
Stinis, CT | 1 |
Levisay, JP | 1 |
Ernst, A | 1 |
Sawhney, NS | 1 |
Schatz, RA | 1 |
Teirstein, PS | 2 |
Ryding, AD | 1 |
Faurie, B | 1 |
Costerousse, O | 1 |
Beyar, R | 1 |
Nikolsky, E | 1 |
Bollati, M | 1 |
Gambino, A | 1 |
Lombardi, P | 1 |
Eslami, M | 1 |
Moayed, DA | 1 |
Pranno, N | 1 |
Noble, S | 1 |
Ibrahim, R | 1 |
Grégoire, JC | 1 |
Azzari, F | 1 |
Nozza, A | 1 |
Berry, C | 1 |
Doucet, S | 1 |
Labarthe, B | 1 |
Théroux, P | 1 |
Tardif, JC | 1 |
Piana, RN | 1 |
Caputo, RP | 1 |
Gordon, PC | 1 |
Lopez, JJ | 1 |
Ryan, TJ | 1 |
Kiernan, FJ | 1 |
Ho, KK | 2 |
Sharma, M | 1 |
Yeghiazarians, Y | 1 |
Sullebarger, JT | 1 |
Wymer, N | 1 |
Holloway, D | 1 |
Polack, B | 1 |
Bertrand, B | 1 |
Andrade, J | 1 |
Al Ali, A | 1 |
Saw, J | 1 |
Wong, GC | 1 |
King, SB | 1 |
Suzuka, H | 1 |
Fujiwara, H | 1 |
Tanaka, M | 1 |
Yoshifusa, H | 1 |
Shibata, Y | 1 |
Silvestri, M | 3 |
Siméoni, JB | 2 |
Villain, P | 2 |
Pietri, P | 2 |
Quatre, JM | 1 |
Bayet, G | 1 |
Rozenman, Y | 2 |
Lotan, C | 2 |
Mosseri, M | 2 |
Gotsman, MS | 2 |
Hall, P | 3 |
Nakamura, S | 3 |
Almagor, Y | 2 |
Maiello, L | 3 |
Martini, G | 4 |
Gaglione, A | 2 |
Goldberg, SL | 1 |
Tobis, JM | 2 |
White, BP | 1 |
Sullivan, AT | 1 |
Lumley, P | 1 |
Yao, SK | 2 |
Ober, JC | 2 |
Maffrand, JP | 2 |
Anderson, HV | 2 |
Buja, LM | 2 |
Willerson, JT | 3 |
Charmasson, C | 1 |
Bremondy, M | 1 |
Hasin, Y | 1 |
Lablanche, JM | 1 |
McFadden, EP | 1 |
Bedossa, M | 1 |
Leclercq, C | 1 |
Vahanian, A | 1 |
Bauters, C | 1 |
Bertrand, ME | 2 |
Pan, M | 1 |
Suárez de Lezo, J | 1 |
Velasco, F | 1 |
Romero, M | 1 |
Medina, A | 1 |
Segura, J | 1 |
Pavlovic, D | 1 |
Melian, F | 1 |
Gallardo, A | 1 |
Zayas, R | 1 |
Torres, A | 1 |
Moussa, I | 4 |
Akiyama, T | 1 |
Tiecco, F | 1 |
Di Maggio, M | 1 |
Chotinaiwattarakul, C | 1 |
Mahanonda, N | 1 |
Kangkagate, C | 1 |
Chaithiraphan, S | 1 |
Cho, SY | 1 |
Kim, KB | 1 |
Oh, BH | 1 |
Zubaid, M | 1 |
Penn, IM | 1 |
Buller, CE | 2 |
Moscovich, MD | 1 |
Ricci, DR | 1 |
Chauhan, A | 1 |
Hall, D | 1 |
Hobson, AG | 1 |
Sowinski, KM | 1 |
Moses, J | 1 |
Di Francesco, L | 1 |
Weber, AA | 1 |
Heublein, B | 1 |
Ozbek, C | 1 |
Pethig, K | 1 |
Elsner, M | 1 |
Peifer, A | 1 |
Drexler, M | 1 |
Wenzel, C | 1 |
Hebbeker, C | 1 |
Kasper, W | 1 |
Oemrawsingh, PV | 1 |
Udayachalerm, W | 1 |
van der Wall, EE | 1 |
Bruschke, AV | 1 |
Zidar, JP | 3 |
Buchwald, AB | 1 |
Alvarez, JM | 1 |
Harper, RW | 1 |
Peverill, RE | 1 |
Urban, P | 1 |
Rupprecht, HJ | 1 |
Kiemeneij, F | 1 |
Fontanelli, A | 1 |
Pieper, M | 1 |
Wesseling, T | 1 |
Sagnard, L | 1 |
Szto, GY | 1 |
Linnemeier, TJ | 2 |
Ball, MW | 1 |
Oetgen, M | 1 |
Roubin, G | 1 |
Wang, X | 1 |
Iyer, S | 1 |
Maida, R | 1 |
Kreps, E | 1 |
Topol, EJ | 2 |
McCullough, PA | 1 |
Marks, KR | 1 |
de Carvalho, HC | 1 |
Park, HK | 1 |
Zoldhelyi, P | 1 |
Jauhar, R | 1 |
Bergman, G | 1 |
Savino, S | 1 |
Deutsch, E | 2 |
Shaknovich, A | 1 |
Parikh, M | 1 |
Sanborn, TA | 1 |
Tcheng, JE | 1 |
Kong, DF | 1 |
Bennett, CL | 1 |
Davidson, CJ | 1 |
Raisch, DW | 1 |
Weinberg, PD | 1 |
Bennett, RH | 1 |
Feldman, MD | 1 |
Mishkel, GJ | 1 |
Aguirre, FV | 1 |
Ligon, RW | 1 |
Rocha-Singh, KJ | 1 |
Lucore, CL | 1 |
Ting, H | 1 |
Barsness, G | 1 |
Garratt, K | 1 |
Bellot, V | 1 |
Mathew, V | 1 |
Hammes, L | 1 |
Grill, D | 1 |
Klein, LW | 1 |
Calvin, JE | 1 |
Avran, A | 1 |
Fourcade, L | 1 |
Bory, M | 1 |
Müller, C | 1 |
Büttner, HJ | 1 |
Petersen, J | 1 |
Roskamm, H | 1 |
Miller, JL | 1 |
Prost, C | 1 |
Veyre, B | 1 |
Ollivier, L | 1 |
Daurat, MO | 1 |
Vial, T | 1 |
Augey, F | 1 |
Cohen, M | 1 |
O'Brien, M | 1 |
Parness, IA | 1 |
Neufeld, EJ | 1 |
Baker, AL | 1 |
Sundel, RP | 1 |
Newburger, JW | 1 |
Dillon, WC | 1 |
Eckert, GJ | 1 |
Dillon, JC | 1 |
Ritchie, ME | 1 |
Pascual Figal, DA | 1 |
Valdés Chávarri, M | 1 |
Ruipérez, JA | 1 |
Cortés, R | 1 |
López Pálop, R | 1 |
Picó Aracil, F | 1 |
García Alberola, A | 1 |
Kleiman, NS | 1 |
Grazeiadei, N | 1 |
Maresh, K | 1 |
Taylor, RJ | 1 |
Frederick, B | 1 |
Lance, ET | 1 |
Jordan, RE | 1 |
Mascelli, MA | 1 |
Rüdiger, S | 1 |
Wolf, B | 1 |
Pogatsa-Murray, G | 1 |
Van De Graaff, E | 1 |
Yip, HK | 1 |
Chang, HW | 1 |
Wu, CJ | 1 |
Chen, MC | 1 |
Hang, CL | 1 |
Fang, CY | 1 |
Hsieh, KY | 1 |
Baim, DS | 1 |
Carrozza, JP | 1 |
Chauhan, MS | 1 |
Rodriguez, O | 1 |
Kuntz, RE | 1 |
Kandzari, DE | 1 |
Behar, VS | 1 |
Sketch, MH | 1 |
Shimshak, T | 1 |
Broderick, T | 1 |
Young, J | 1 |
Runyon, JP | 1 |
Safian, RD | 1 |
Kern, M | 1 |
Taniuchi, M | 2 |
Kurz, HI | 1 |
Lasala, JM | 2 |
Kitai, T | 1 |
Nishikawa, M | 1 |
Tanigawa, T | 1 |
Okinaka, T | 1 |
Wada, H | 1 |
Shiku, H | 1 |
Ikeda, Y | 1 |
Ito, M | 1 |
Isaka, N | 1 |
Nakano, T | 1 |
Timurkaynak, T | 1 |
Goksen, I | 1 |
Cengel, A | 1 |
Dortlemez, O | 1 |
Lowe, HC | 1 |
Kumar, RK | 1 |
Chesterman, CN | 1 |
Fahmy, RG | 1 |
Khachigian, LM | 1 |
Cosmi, B | 1 |
Rubboli, A | 1 |
Castelvetri, C | 1 |
Milandri, M | 1 |
Batchelor, WB | 1 |
Meier, S | 1 |
Hasselblad, V | 1 |
Fry, ET | 2 |
Ross, AM | 1 |
Binanay, CA | 1 |
Ellis, SG | 1 |
Hasa, AA | 1 |
Schmaier, AH | 1 |
Warnock, M | 1 |
Normolle, D | 1 |
Driscoll, E | 1 |
Lucchesi, BR | 1 |
Werns, SW | 1 |
Bahit, MC | 1 |
Gobeil, F | 1 |
Juneau, C | 1 |
Plante, S | 1 |
Meier, SJ | 1 |
Batchelor, W | 1 |
Reed, MD | 1 |
Bell, D | 1 |
Hata, K | 1 |
Kitada, N | 1 |
Gomyo, T | 1 |
Hamanaka, M | 1 |
Koganei, A | 1 |
Kan, Z | 1 |
Kawaguchi, S | 1 |
Amemiya, T | 1 |
Tomoda, H | 1 |
Yokota, I | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Comparative Study of the Antithrombotic Effects of Ticagrelor and Clopidogrel in Type 2 Diabetic Patients[NCT01823510] | Phase 4 | 20 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.[NCT00335452] | Phase 3 | 25,086 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
Telephone Contacts to Improve Adherence to Dual Anti-Platelet Therapy Following Drug-Eluting Stent Implantation; A Randomized Controlled-Trial[NCT01134679] | 300 participants (Actual) | Interventional | 2009-06-30 | Completed | |||
A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872] | Phase 3 | 18,624 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI With Biologically Active Stents (P2BiTO) Registry[NCT01967615] | 4,500 participants (Actual) | Observational | 2015-01-31 | Completed | |||
The Use of BRILInta to Optimize ANTiplatelet Therapy (BRILIANT) Registry: The BRILIANT KOREA Registry[NCT02521038] | 2,000 participants (Anticipated) | Observational [Patient Registry] | 2015-07-31 | Recruiting | |||
Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet [NCT01267734] | Phase 4 | 3,750 participants (Anticipated) | Interventional | 2010-06-30 | Recruiting | ||
Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286] | Phase 4 | 1,700 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
Short-term Outcomes of Elective High-risk PCI With Extracorporeal Membrane Oxygenation Support: a Single-centre Registry[NCT05387902] | 25 participants (Actual) | Observational [Patient Registry] | 2022-02-03 | Completed | |||
RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population[NCT00752128] | 2,349 participants (Actual) | Observational | 2008-08-31 | Completed | |||
Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835] | 1,492 participants (Anticipated) | Observational [Patient Registry] | 2019-08-01 | Recruiting | |||
A Clinical Evaluation of the Medtronic Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2mm[NCT00726453] | 1,516 participants (Actual) | Interventional | 2008-07-31 | Completed | |||
The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries[NCT00927940] | 100 participants (Actual) | Interventional | 2009-03-31 | Completed | |||
RESOLUTE-III All-comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention[NCT00617084] | Phase 4 | 2,292 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
PROTECT Trial: Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial[NCT00476957] | Phase 4 | 8,709 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
Evaluation of the Occurence of Thrombotic and Bleeding Events After Coronary Angioplasty With Stent According to Aspirin and Clopidogrel Platelet Reactivity Assessed by a Point of Care Assay in the Cathlab (the Verifynow French Registry)[NCT00753753] | 1,001 participants (Actual) | Observational | 2008-02-29 | Completed | |||
EDUCATE: a Prospective, Multi-center Study Designed to Collect Real-world Safety and Clinical Outcomes in Subjects Receiving One or More Endeavor Zotarolimus-Eluting Stents and Either Clopidogrel and Aspirin or Prasugrel and Aspirin as Part of a Dual Anti[NCT01069003] | Phase 4 | 2,272 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
Platelet Function in Resuscitated Patients-2[NCT03445546] | 25 participants (Actual) | Observational | 2016-05-01 | Completed | |||
A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions[NCT00180310] | Phase 3 | 300 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions[NCT00402272] | Phase 4 | 2,700 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
SPIRIT III: A Clinical Evaluation of the Investigational Device XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) in the Treatment of Subjects With de Novo Native Coronary Artery Lesions[NCT00180479] | Phase 3 | 1,002 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions[NCT00496938] | Phase 4 | 1,600 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-Arm Study[NCT00631228] | 1,000 participants (Actual) | Observational | 2008-06-30 | Completed | |||
XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study[NCT00676520] | 8,053 participants (Actual) | Observational | 2008-07-31 | Completed | |||
SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions[NCT00307047] | Phase 3 | 3,687 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)[NCT01156571] | Phase 3 | 11,145 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA Trial)[NCT04654052] | Phase 4 | 634 participants (Anticipated) | Interventional | 2021-07-02 | Recruiting | ||
Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents[NCT00638794] | 8,575 participants (Actual) | Observational | 2008-01-31 | Completed | |||
Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients: An Observational Single-Arm Study (The PARIS Registry)[NCT00998127] | 5,031 participants (Actual) | Observational | 2009-06-30 | Completed | |||
Impact of IntraVascular UltraSound Guidance on Outcomes of Xience Prime Stents in Long Lesions (IVUS-XPL Study)[NCT01308281] | 1,079 participants (Actual) | Interventional | 2010-10-31 | Completed | |||
A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938] | Phase 4 | 25,682 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention[NCT00097591] | Phase 3 | 13,619 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
Prospective Study of Bioresorbable Vascular Scaffold Treatment With Scoring Balloon Pre-dilatation in Patients With In-stent Restenosis[NCT03069066] | Phase 4 | 100 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial[NCT01239953] | Phase 4 | 190 participants (Actual) | Interventional | 2010-01-31 | Active, not recruiting | ||
RIBS IV (Restenosis Intra-stent of Drug-eluting Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial[NCT01239940] | Phase 4 | 310 participants (Anticipated) | Interventional | 2010-01-31 | Recruiting | ||
Prospective Study of Bioresorbable Vascular Scaffold Treatment in Patients With In-stent Restenosis[NCT02672878] | Phase 4 | 130 participants (Anticipated) | Interventional | 2014-04-30 | Not yet recruiting | ||
Observational Study of Treatment of Bioresorbable Vascular Scaffolds Restenosis[NCT03167424] | 100 participants (Anticipated) | Observational [Patient Registry] | 2016-05-31 | Recruiting | |||
Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel[NCT00398463] | Phase 4 | 263 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
A Randomized, Multicenter, Double-Blind, Study to Evaluate the Efficacy of Tirofiban HCl Versus Placebo in the Setting of Standard Therapies Among Subjects Undergoing Percutaneous Coronary Intervention[NCT01245725] | Phase 3 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to Study was not initiated, change in clinical development) | |||
Customized Choice of P2Y12 Oral Receptor Blocker Based on Phenotype Assessment Via Point of Care Testing[NCT01477775] | Phase 4 | 4,000 participants (Anticipated) | Interventional | 2012-01-31 | Recruiting | ||
Randomized, Prospective , Open Label, Phase 4 Trial of Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention With Drug-eluting Stent[NCT01261832] | Phase 4 | 951 participants (Anticipated) | Interventional | 2011-07-31 | Active, not recruiting | ||
Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization[NCT03953547] | 88 participants (Actual) | Observational | 2018-01-01 | Completed | |||
Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273] | 1,800 participants (Anticipated) | Observational [Patient Registry] | 2018-11-21 | Not yet recruiting | |||
ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy in Patients With ST-segment Elevation Myocardial Infarction[NCT01452139] | Phase 2/Phase 3 | 102 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435] | 889 participants (Actual) | Interventional | 2013-06-30 | Terminated (stopped due to Ethics Committe decision) | |||
Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)[NCT02428374] | Phase 4 | 300 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation (The RAPID GENE Study)[NCT01184300] | Phase 2/Phase 3 | 200 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093] | 280 participants (Actual) | Observational | 2014-06-30 | Completed | |||
Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel[NCT01643031] | Phase 4 | 500 participants (Anticipated) | Interventional | 2012-08-31 | Not yet recruiting | ||
Efficacy and Safety of Anticoagulant on Early Treatment of Post-STEMI Left Ventricular Thrombus: an Open, Prospective, Randomized and Multi-centers Trial.[NCT03764241] | Phase 3 | 280 participants (Anticipated) | Interventional | 2020-02-01 | Recruiting | ||
Efficacy and Safety of Anticoagulant on Early Prevention of Post-STEMI Left Ventricular Thrombus: an Open, Prospective, Randomized and Multi-centers Trial.[NCT03786757] | Phase 3 | 200 participants (Anticipated) | Interventional | 2019-04-01 | Not yet recruiting | ||
REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
Chinese People's Liberation Army General Hospital[NCT02798874] | 240 participants (Anticipated) | Interventional | 2016-05-31 | Enrolling by invitation | |||
Comparison of Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI Undergoing PPCI Evaluated by SPECT[NCT02233790] | Phase 4 | 600 participants (Anticipated) | Interventional | 2014-12-31 | Not yet recruiting | ||
The MAgnitude of Platelet Inhibition and the Pharmacokinetics of a 600 mg Loading Dose of Clopidogrel, in Different Patient CATegories (Stable Angina Versus Acute-coronary Syndromes Versus ST-elevated Myocardial Infarction).[NCT01012544] | Phase 4 | 187 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary An[NCT00433966] | Phase 3 | 3,602 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry[NCT02264912] | 2,016 participants (Actual) | Observational [Patient Registry] | 2008-07-31 | Completed | |||
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242] | Phase 4 | 9,006 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
Ticagrelor in Comparison to Prasugrel for Inhibition of Platelet Reactivity, in Patients With Acute Coronary Syndrome (ACS) Presenting Resistance to the Usual Clopidogrel Dose After PCI[NCT01360437] | Phase 3 | 44 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and a Interruption Versus Continuation of Double Antiplatelet Therapy, One Year After Stenting[NCT00827411] | Phase 4 | 2,500 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
Laboratory Implications of Non Obstructive Atherosclerotic Plaques Identified by Multiple Detector Coronary Angiotomography[NCT03632785] | 90 participants (Actual) | Observational | 2017-03-27 | Completed | |||
Randomized Comparison of Platelet Function Monitoring to Adjust Antiplatelet Therapy Versus a Common Antiplatelet Treatment for Intracranial Aneurysm Stent-assisted Coiling[NCT02224131] | Phase 4 | 1,856 participants (Anticipated) | Interventional | 2015-01-31 | Not yet recruiting | ||
ASS-Nonresponse Following Cardiac Surgery as Assessed With Multiple Electrode Aggregometry[NCT01824147] | 400 participants (Actual) | Observational | 2013-08-31 | Completed | |||
A Randomized, Open-Label, Cross-Over, Study to Evaluate the Inhibitory Effect of Clopidogrel, EC Aspirin 81 mg and EC Omeprazole 40 mg All Dosed Concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers[NCT01557335] | Phase 1 | 30 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
Revascularization With Paclitaxel-coated Balloon Angioplasty Versus Drug-eluting Stenting in Acute Myocardial Infarction - a Randomized Controlled Trial.[NCT02219802] | 120 participants (Anticipated) | Interventional | 2014-08-31 | Not yet recruiting | |||
SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis[NCT00697372] | Phase 4 | 150 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
Prospective Randomized Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions / BABILON Study (Paclitaxel-Coated Balloon in Bifurcated Lesions)[NCT01278186] | Phase 4 | 190 participants (Anticipated) | Interventional | 2010-06-30 | Active, not recruiting | ||
Prospective, Randomized, Single-Center Evaluation of the Cypher™ Sirolimus Eluting Coronary Stent System in the Treatment of Bifurcated Coronary Lesions[NCT00288535] | Phase 4 | 200 participants (Anticipated) | Interventional | 2005-03-31 | Recruiting | ||
Study of Lipid Core Plaque Shift at Sites of Native Coronary Artery Bifurcation[NCT00905671] | Phase 4 | 20 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis[NCT01200693] | Phase 4 | 80 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
Approaches to Chronic Occlusions With Sirolimus Stents-Cypher (ACROSS-Cypher) Total Occlusion Study of Coronary Arteries 4 Trial[NCT00378612] | Phase 3 | 200 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
Prospective Pilot Study- Does Mean Platelet Volume Change With Clopidogrel in Patients With Stable Angina Undergoing Percutaneous Coronary Intervention?[NCT02550301] | 100 participants (Anticipated) | Observational | 2015-09-30 | Not yet recruiting | |||
Biological Efficacy of Clopidogrel 600 mg Loading Dose Followed by 75 mg Maintenance Dose After Implantation of Drug-eluting Stents in Patients With Diabetes Mellitus or Metabolic Syndrome (SPACE)[NCT00298428] | 159 participants (Actual) | Interventional | 2006-05-31 | Completed | |||
Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI[NCT00889044] | Phase 3 | 30 participants (Anticipated) | Interventional | 2009-04-30 | Recruiting | ||
Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Abciximab And Bivalirudin in Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Interventions (ISAR-REACT-4)[NCT00373451] | Phase 4 | 1,721 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention[NCT01812330] | Phase 3 | 180 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
A Pilot Study of The Effects of a Single High Dose Bolus Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention[NCT00407771] | Phase 4 | 44 participants (Anticipated) | Interventional | 2007-11-30 | Not yet recruiting | ||
"Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing One-stop Hybrid Coronary Revascularization"[NCT02513004] | Phase 4 | 60 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
Spot Drug-Eluting vs Full Cover Stenting for Long Coronary Stenoses: a Randomized Clinical Study[NCT00738556] | 179 participants (Actual) | Interventional | 2003-01-31 | Completed | |||
Activity of Platelets After Inhibition and Cardiovascular Events: Drug Eluting Stent Implantation in Patients With Acute Coronary Syndrome: Optical Coherence Tomography Study[NCT01239654] | Phase 3 | 60 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
A Prospective Optical Coherence Tomography Study on Completeness of Strut Coverage and Vessel Wall Response at 3-6 and 9 Months Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease[NCT00704145] | Phase 4 | 30 participants (Anticipated) | Interventional | 2007-11-30 | Completed | ||
In-Vivo Vascular Response of Sirolimus-,Paclitaxel- and Zotarolimus-Eluting Stents in Long Lesions Requiring Overlapping. A Prospective, Randomized, Controlled Study Using Optical Coherence Tomography[NCT00693030] | Phase 4 | 77 participants (Anticipated) | Interventional | 2006-08-31 | Recruiting | ||
The Optical Coherence Tomography Drug Eluting Stent Investigation(OCTDESI)[NCT00776204] | 60 participants (Actual) | Interventional | 2008-05-31 | Completed | |||
Effect of TCFA on Neointimal Coverage After EXCEL Biodegradable Polymer-coated Sirolimus-eluting Stents Implantation at 9 Months Follow-up: Evaluated by Optical Coherence Tomography and Fractional Flow Reserve[NCT02384837] | 33 participants (Actual) | Observational | 2014-12-31 | Completed | |||
Prospective, Randomized, Controlled Arm Study Comparing the Coverage of the Zotarolimus-eluting Stent vs Bare Metal Stent Implanted in ST- Elevation Myocardial Infarction (STEMI).[NCT00704561] | 44 participants (Actual) | Interventional | 2008-04-30 | Completed | |||
A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss.The OCT-ORION Study[NCT01742507] | Phase 4 | 60 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265] | 31 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
Phase 4 Study of Randomized Comparison Among Oral Rapamycin Plus Bare Metal Stents Versus Drug Eluting Stents in de Novo Coronary Lesions.[NCT00552669] | Phase 4 | 200 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
A Multicenter, Open-labeled, Randomized Controlled Trial Comparing Three 2nd Generation Drug-Eluting Stents in Real-World Practice[NCT01397175] | 1,960 participants (Actual) | Interventional | 2013-01-16 | Terminated (stopped due to Slow enrollment) | |||
Vessel Injury in Relation With Strut Thickness Assessed by OCT (VISTA): A Comparison of Vascular Injury Induced by a Polymer Free Sirolimus and Probucol Eluting Stent and a Biodegradable-polymer Biolimus-eluting Stent[NCT03026465] | Phase 4 | 50 participants (Actual) | Interventional | 2017-02-16 | Completed | ||
Frequency Domain Imaging to Determine Stent Strut Coverage and Duration of Anti-Platelet Treatment After Endeavor Stent Placement[NCT01219894] | 0 participants (Actual) | Observational | 2010-11-30 | Withdrawn (stopped due to Number of patients to meet individual IDE requirements was not obtained.) | |||
Optical Frequency Domain Imaging (OFDI) Determined Stent Strut Coverage and Plaque Morphology After RESOLUTE Stent Placement in Non-Insulin Dependent Diabetics Presenting With Acute Coronary Syndrome (ACS)[NCT01794949] | 8 participants (Actual) | Interventional | 2013-09-30 | Completed | |||
Optimization of Antiplatelet Therapy With Clopidogrel on the Basis of the Extent of Platelet Inhibition in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy Undergoing PCI With Stent Implantation[NCT00774475] | Phase 3 | 442 participants (Anticipated) | Interventional | 2008-11-30 | Not yet recruiting | ||
A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET Trial A Drug Reduction Study for Patients With Acute Coronary Syndrome in the Unified Health System[NCT04360720] | Phase 3 | 3,400 participants (Anticipated) | Interventional | 2020-10-15 | Recruiting | ||
French Registry to Evaluate the Safety and Efficacy of the Diamondback 360TM Orbital Atherectomy System in the Preparation of Calcified Coronary Lesions Before Implantation of a Coronary Endoprothesis[NCT05417022] | 300 participants (Anticipated) | Observational [Patient Registry] | 2022-06-15 | Recruiting | |||
Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease. A Multicenter, Prospective, Randomized Controlled Trial.[NCT00380809] | Phase 4 | 240 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
Early and Long-Term Outcome of Elective Stenting of the Infarct-Related Artery in Patients With Viability in the Infarct-Area Early After Acute Myocardial Infarction. The VIAMI-Trial.[NCT00149591] | 300 participants | Interventional | 2001-04-30 | Active, not recruiting | |||
A Multicenter, Randomized Trial Evaluating 30-day and 6-month Clinical Outcomes With Three Different Treatment Strategies (Coronary Angioplasty + Abciximab, Intracoronary Stent + Abciximab, and Intracoronary Stent + Placebo) in Patients Undergoing Percuta[NCT00271401] | Phase 3 | 2,399 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2)[NCT00133003] | Phase 4 | 2,022 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
Value of Abciximab in Patients With AMI Undergoing PCI After High Dose Clopidogrel Pretreatment (BRAVE 3)[NCT00133250] | Phase 4 | 800 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)[NCT00140465] | Phase 4 | 60 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309] | 30 participants (Anticipated) | Interventional | 2006-04-30 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Platelet reactivity by measuring P2Y12 Reaction Unit using Accumetrics VerifyNow (NCT01823510)
Timeframe: up to 7 days
Intervention | percentage of baseline PRU (Mean) | ||
---|---|---|---|
2 hour post-loading dose | 6 hour post-loading dose | 5-7 days of maintenance dosing | |
Clopidogrel + Aspirin | 77.8 | 66.8 | 62.7 |
Ticagrelor + Aspirin | 14.8 | 8.2 | 14.5 |
Platelet reactivity by Multiplate Analyzer (NCT01823510)
Timeframe: up to 7 days
Intervention | percentage of baseline Unit (Mean) | ||
---|---|---|---|
2 hour post-loading dose | 6 hour post-loading dose | 5-7 days of maintenance dosing | |
Clopidogrel + Aspirin | 54.5 | 43.6 | 45.5 |
Ticagrelor + Aspirin | 20.5 | 20.6 | 24.2 |
Platelet reactivity index by Vasodilator-Stimulated Phosphoprotein phosphorylation (VASP) assay. (NCT01823510)
Timeframe: up to 7 days
Intervention | percentage of baseline PRI (Mean) | ||
---|---|---|---|
2 hour post-loading dose | 6 hour post-loading dose | 5-7 days of maintenance dosing | |
Clopidogrel + Aspirin | 85.8 | 82.5 | 68.4 |
Ticagrelor + Aspirin | 21.8 | 17.8 | 17.2 |
Thrombus formation in Badimon Perfusion Chamber high-shear) (ex vivo model of thrombosis). (NCT01823510)
Timeframe: up to 7 days
Intervention | percentage of baseline size (Mean) | ||
---|---|---|---|
2 hour post loading dose | 6 hours post loading dose | 5-7 days of maintenance dose | |
Clopidogrel + Aspirin | 84.4 | 79.8 | 82.6 |
Ticagrelor + Aspirin | 66.9 | 59.9 | 68.9 |
(NCT00335452)
Timeframe: 30 days
Intervention | participants (Number) |
---|---|
Clopidogrel 300/75/75 mg + ASA Low Dose | 267 |
Clopidogrel 300/75/75 mg + ASA High Dose | 290 |
Clopidogrel 600/150/75 mg + ASA Low Dose | 282 |
Clopidogrel 600/150/75 mg + ASA High Dose | 240 |
(NCT00335452)
Timeframe: 30 days
Intervention | participants (Number) | |||
---|---|---|---|---|
CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
Clopidogrel + ASA High Dose | 527 | 211 | 251 | 65 |
Clopidogrel + ASA Low Dose | 546 | 231 | 260 | 55 |
"The primary endpoint is the first occurrence of any of the following events:~Cardiovascular death (any death with a clear cardiovascular or unknown cause),~Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal)~Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal)~reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC)." (NCT00335452)
Timeframe: 30 days
Intervention | participants (Number) | |||
---|---|---|---|---|
CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
Clopidogrel 300/75/75 mg + ASA | 557 | 222 | 274 | 61 |
Clopidogrel 600/150/75 mg + ASA | 522 | 226 | 237 | 59 |
(NCT00335452)
Timeframe: 30 days
Intervention | participants (Number) | |||
---|---|---|---|---|
CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
Clopidogrel 300/75/75 mg + ASA | 392 | 132 | 225 | 35 |
Clopidogrel 600/150/75 mg + ASA | 330 | 130 | 172 | 28 |
(NCT00335452)
Timeframe: 30 days
Intervention | participants (Number) | ||
---|---|---|---|
Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
Clopidogrel + ASA High Dose | 282 | 216 | 73 |
Clopidogrel + ASA Low Dose | 285 | 215 | 74 |
Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC. (NCT00335452)
Timeframe: 30 days
Intervention | participants (Number) | ||
---|---|---|---|
Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
Clopidogrel 300/75/75 mg + ASA | 255 | 195 | 65 |
Clopidogrel 600/150/75 mg + ASA | 313 | 236 | 83 |
This includes definite stent thrombosis (confirmed by angiography or evidence of recent thrombus determined at autopsy or by examination of tissue retrieved following thrombectomy) and probable stent thrombosis (unexplained death having occurred after intracoronary stenting or, MI related to acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any obvious cause) after validation by the EAC. (NCT00335452)
Timeframe: 30 days
Intervention | participants (Number) | ||
---|---|---|---|
Stent trombosis | - Definite | - Probable | |
Clopidogrel 300/75/75 mg + ASA | 200 | 111 | 89 |
Clopidogrel 600/150/75 mg + ASA | 135 | 58 | 77 |
Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
Intervention | Participants (Number) |
---|---|
TICAGRELOR | 901 |
CLOPIDOGREL | 1065 |
Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months
Intervention | Participants (Number) |
---|---|
TICAGRELOR | 1290 |
CLOPIDOGREL | 1456 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
Intervention | Participants (Number) |
---|---|
TICAGRELOR | 569 |
CLOPIDOGREL | 668 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
Intervention | Participants (Number) |
---|---|
TICAGRELOR | 864 |
CLOPIDOGREL | 1014 |
Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
Intervention | Participants (Number) |
---|---|
TICAGRELOR | 961 |
CLOPIDOGREL | 929 |
Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
Intervention | Participants (Number) |
---|---|
TICAGRELOR | 619 |
CLOPIDOGREL | 654 |
Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
Intervention | Participants (Number) |
---|---|
TICAGRELOR | 329 |
CLOPIDOGREL | 341 |
Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
Intervention | Participants (Number) |
---|---|
TICAGRELOR | 399 |
CLOPIDOGREL | 506 |
Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
Intervention | Participants (Number) |
---|---|
TICAGRELOR | 353 |
CLOPIDOGREL | 442 |
Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
Intervention | Participants (Number) |
---|---|
TICAGRELOR | 1339 |
CLOPIDOGREL | 1215 |
Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
Intervention | Participants (Number) |
---|---|
TICAGRELOR | 504 |
CLOPIDOGREL | 593 |
Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
Intervention | Participants (Number) |
---|---|
TICAGRELOR | 362 |
CLOPIDOGREL | 306 |
Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
Intervention | Participants (Number) |
---|---|
TICAGRELOR | 235 |
CLOPIDOGREL | 180 |
Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
Intervention | Participants (Number) |
---|---|
TICAGRELOR | 125 |
CLOPIDOGREL | 106 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
Intervention | Participants (Number) |
---|---|
TICAGRELOR | 21 |
CLOPIDOGREL | 16 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
Intervention | Participants (Number) |
---|---|
TICAGRELOR | 84 |
CLOPIDOGREL | 51 |
(NCT00752128)
Timeframe: 12 Months
Intervention | percentage of participants (Number) |
---|---|
Cardiac Death or Target Vessel MI | 4.2 |
(NCT00752128)
Timeframe: 12 Months
Intervention | percentage of participants (Number) |
---|---|
Overall Stent Thrombosis (Definite and Probable-ARC) | 0.9 |
(NCT00726453)
Timeframe: 12 months
Intervention | percentage of participants (Number) |
---|---|
Primary Enrollment Group | 1.3 |
Major Adverse Cardiac Event (MACE) composite endpoint and each individual component (death, Target Vessel MI (Q wave and non-Q wave), emergent coronary bypass surgery (CABG), or clinically-driven repeat Target Lesion Revascularization (TLR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months
Intervention | percentage of participants (Number) |
---|---|
Primary Enrollment Group | 5.5 |
Stent Thrombosis (ST) (as determined by historic and ARC definitions). (NCT00726453)
Timeframe: 12 months
Intervention | percentage of participants (Number) |
---|---|
Primary Enrollment Group | 0.1 |
Target Lesion Failure (TLF) at 12 months post-procedure, defined as Cardiac Death, Target Vessel Myocardial Infarction (TVMI) (Q wave and non-Q wave) or clinically-driven Target Lesion Revascularization (TLR) by percutaneous or surgical methods. (NCT00726453)
Timeframe: 12 Months
Intervention | percentage of participants (Number) |
---|---|
Primary Enrollment Group | 4.7 |
Target Vessel Failure (TVF) composite endpoint and each individual component (Cardiac Death, Target Vessel MI, or clinically-driven Target Vessel Revascularization (TVR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months
Intervention | percentage of participants (Number) |
---|---|
Primary Enrollment Group | 6.3 |
Target Vessel MI (as determined by extended historical and ARC definitions). (NCT00726453)
Timeframe: 12 months
Intervention | percentage of eligible participants (Number) |
---|---|
Primary Enrollment Group | 1.4 |
The difference between the post-procedure immediate minimal lumen diameter (MLD) and follow up angigraphy MLD (NCT00927940)
Timeframe: Post procedure, 8 Months
Intervention | mm (Mean) |
---|---|
Zotarolimus Eluting Stent | 0.13 |
Major Secondary Endpoint Target lesion fature (TLF) is defined as cardiac death, target vessel myocardial infarction(Q wave and non-Q wave), or clinically-driven target lesion revascularization (TLR) by percutaneous or surgical methods. (NCT00927940)
Timeframe: 12 months
Intervention | percentage of participants with TLF (Number) |
---|---|
Zotarolims Eluting Stent | 4.0 |
In Stent Percent Diameter Stenosis at thirteen months. In Stent Percent Diameter Stenosis: measured percent of diameter stenosis at the region of the stent (calculated as 100x(RVD-MLD)/RVD using the mean values from 2 orthogonal views by QCA. RVD (Reference Vessel Diameter): average of normal segments within 10mm proximal and distal to target lesion from 2 orthogonal views using QCA. MLD (Minimal Lumen Diameter): average of 2 orthogonal views of the narrowest point wihtin the area of assessment. MLD measured during QCA by the angiographic core laboratory. (NCT00617084)
Timeframe: 13 Months
Intervention | Percentage diameter stenosis (Mean) |
---|---|
1. Resolute - 12-13 Months | 21.65 |
2. XIENCE V - 12-13 Months | 19.76 |
Percentage of participants that had either Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel)or Target Lesion Revascularization (TLR, clinically indicated) after one year. MI: Q MI if new pathological Q waves and chest pain, non Q MI if CK elevated more than two times normal, troponin elevated more than normal, according to ARC definitions. TLR, clinically indicated if associated with ischemic symptoms and angiographic min lumen diameter bigger than fifty percent by QCA or without symptoms and min lumen diameter bigger than seventy percent. Measure average. (NCT00617084)
Timeframe: 12 months
Intervention | percentage of participants (Number) |
---|---|
1. Resolute - 12-13 Months | 8.2 |
2. XIENCE V - 12-13 Months | 8.3 |
Definite or probable stent thrombosis rate. (NCT00476957)
Timeframe: 3 years
Intervention | participants (Number) |
---|---|
E-ZES | 61 |
C-SES | 75 |
Total death and large non-fatal myocardial infarctions Total death and non-fatal myocardial infarctions Cardiac death and large non-fatal MI Cardiac death and non-fatal myocardial infarctions (NCT00476957)
Timeframe: 3 years
Intervention | participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Total death and large non-fatal myocardial infarct | Total death and non-fatal myocardial infarctions | Cardiac death and large non-fatal MI | Cardiac death and non-fatal MI | Target lesion revascularization | Stroke | Bleeding events | |
C-SES | 255 | 360 | 174 | 282 | 156 | 72 | 184 |
E-ZES | 225 | 331 | 157 | 265 | 249 | 77 | 201 |
(NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)
Intervention | Percentage of participants (Number) |
---|---|
Placebo Arm | 1.8 |
Thienopyridine Therapy | 2.0 |
Surveillance Arm | 4.8 |
"All definite and probable Stent Thrombosis (ST) are adjudicated by an independent committee according to the definition based on Academic Research Consortium (ARC)~Definite is defined as angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region and at least 1 of the following: Acute ischemic symptoms, Ischemic ECG changes, Elevated cardiac biomarkers~Probable defined as any unexplained death within the first 30 days of procedure and any myocardial infarction, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)
Intervention | percentage of participants (Number) |
---|---|
Placebo Arm | 1.0 |
Thienopyridine Therapy | 0.5 |
Surveillance Arm | 2.4 |
(NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)
Intervention | Percentage of participants (Number) |
---|---|
Placebo Arm | 4.3 |
Thienopyridine Therapy | 4.8 |
Surveillance Arm | 16.9 |
Defined as stent intimal hyperplasia and calculated as 100*(Stent Volume - Lumen Volume)/Stent Volume by IVUS. (NCT00180479)
Timeframe: at 240 days
Intervention | percent of volume obstruction (Mean) |
---|---|
XIENCE V® EECSS | 6.91 |
TAXUS® EXPRESS2™ ECSS | 11.21 |
Successful delivery and deployment of 1st implanted study stent/s @ the intended target lesion and successful withdrawal of the stent delivery system with final residual stenosis < 50%. (NCT00180479)
Timeframe: In-hospital
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 98.3 |
TAXUS® EXPRESS2™ ECSS | 98.7 |
Successful delivery and deployment of study stent/s @ the intended target lesion and successful withdrawal of the stent delivery system with final residual stenosis < 50%. (NCT00180479)
Timeframe: In-hospital
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 98.5 |
TAXUS® EXPRESS2™ ECSS | 97.3 |
Distal MLD post-procedure minus distal MLD at follow-up (distal defined as within 5 mm of healthy tissue distal to stent placement) (NCT00180479)
Timeframe: 240 days
Intervention | millimeters (Mean) |
---|---|
XIENCE V® EECSS | 0.09 |
TAXUS® EXPRESS2™ ECSS | 0.10 |
Percent of subjects with a follow-up in-segment percent diameter stenosis of ≥ 50% per QCA (NCT00180479)
Timeframe: 240 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 4.7 |
TAXUS® EXPRESS2™ ECSS | 8.9 |
Within the margins of the stent, 5 mm proximal and 5 mm distal to the stent, the value calculated as 100 * (1 - in-segment MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA. (NCT00180479)
Timeframe: 240 days
Intervention | percent of in-segment diameter stenosis (Mean) |
---|---|
XIENCE V® EECSS | 18.77 |
TAXUS® EXPRESS2™ ECSS | 22.82 |
Percent of subjects with a follow-up in-stent percent diameter stenosis of ≥ 50% per quantitative coronary angiography (QCA) (NCT00180479)
Timeframe: at 240 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 2.3 |
TAXUS® EXPRESS2™ ECSS | 5.7 |
In-stent: Within the margins of the stent, the value calculated as 100 * (1 - in-stent MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA. (NCT00180479)
Timeframe: at 240 days
Intervention | percent diameter stenosis (Mean) |
---|---|
XIENCE V® EECSS | 5.92 |
TAXUS® EXPRESS2™ ECSS | 10.30 |
In-stent MLD post-procedure minus in-stent MLD at follow-up (in-stent defined as within the margins of the stent) (NCT00180479)
Timeframe: at 240 days
Intervention | millimeters (Mean) |
---|---|
XIENCE V® EECSS | 0.16 |
TAXUS® EXPRESS2™ ECSS | 0.30 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 1 year
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 6.0 |
TAXUS® EXPRESS2™ ECSS | 10.3 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 180 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 2.9 |
TAXUS® EXPRESS2™ ECSS | 5.2 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 270 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 5.0 |
TAXUS® EXPRESS2™ ECSS | 8.8 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 3 year
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 9.7 |
TAXUS® EXPRESS2™ ECSS | 16.4 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 30 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 1.3 |
TAXUS® EXPRESS2™ ECSS | 3.0 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 4 year
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 12.8 |
TAXUS® EXPRESS2™ ECSS | 18.5 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 5 years
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 14.4 |
TAXUS® EXPRESS2™ ECSS | 22.0 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 2 years
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 7.7 |
TAXUS® EXPRESS2™ ECSS | 13.8 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 1 years
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 3.4 |
TAXUS® EXPRESS2™ ECSS | 5.6 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 180 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 1.5 |
TAXUS® EXPRESS2™ ECSS | 2.1 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 2 years
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 5.7 |
TAXUS® EXPRESS2™ ECSS | 9.2 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 270 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 2.7 |
TAXUS® EXPRESS2™ ECSS | 5.0 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 3 year
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 5.7 |
TAXUS® EXPRESS2™ ECSS | 9.2 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 30 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 0.4 |
TAXUS® EXPRESS2™ ECSS | 0.3 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 4 year
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 8.0 |
TAXUS® EXPRESS2™ ECSS | 10.6 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 5 years
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 8.9 |
TAXUS® EXPRESS2™ ECSS | 12.9 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 1 year
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 3.1 |
TAXUS® EXPRESS2™ ECSS | 4.7 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 180 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 1.2 |
TAXUS® EXPRESS2™ ECSS | 1.8 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 2 years
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 4.9 |
TAXUS® EXPRESS2™ ECSS | 6.6 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 270 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 2.9 |
TAXUS® EXPRESS2™ ECSS | 4.1 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 3 years
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 6.7 |
TAXUS® EXPRESS2™ ECSS | 8.9 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 30 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 0.3 |
TAXUS® EXPRESS2™ ECSS | 0.9 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 4 years
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 7.8 |
TAXUS® EXPRESS2™ ECSS | 9.6 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 5 years
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 8.8 |
TAXUS® EXPRESS2™ ECSS | 11.9 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 270 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 7.2 |
TAXUS® EXPRESS2™ ECSS | 9.0 |
"Incomplete Apposition (Persisting & Late acquired): Failure to completely appose vessel wall w/ ≥1 strut separated from vessel wall w/ blood behind strut per ultrasound. Aneurysm: Abnormal vessel expansion ≥ 1.5 of reference vessel diameter. Thrombus: Protocol & ARC definition.~Persisting dissection @ follow-up, present post-procedure." (NCT00180479)
Timeframe: at 240 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 24.4 |
TAXUS® EXPRESS2™ ECSS | 14.0 |
In-segment minimal lumen diameter (MLD) post-procedure minus (-) in segment MLD at 240 day follow-up and 5 mm proximal and 5mm distal to the stent equals Late Loss. MLD defined: The average of two orthogonal views (when possible) of the narrowest point within the area of assessment. (NCT00180479)
Timeframe: 240 days
Intervention | millimeters (Mean) |
---|---|
XIENCE V® EECSS | 0.14 |
TAXUS® EXPRESS2™ ECSS | 0.28 |
Proximal Minimum Lumen Diameter (MLD) post-procedure minus proximal MLD at follow-up (proximal defined as within 5 mm of healthy tissue proximal to stent placement) (NCT00180479)
Timeframe: at 240 days
Intervention | millimeters (Mean) |
---|---|
XIENCE V® EECSS | 0.12 |
TAXUS® EXPRESS2™ ECSS | 0.20 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 1 year
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 8.6 |
TAXUS® EXPRESS2™ ECSS | 11.6 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 180 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 4.1 |
TAXUS® EXPRESS2™ ECSS | 5.5 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 2 year
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 11.3 |
TAXUS® EXPRESS2™ ECSS | 16.4 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 3 year
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 14.3 |
TAXUS® EXPRESS2™ ECSS | 20.0 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 30 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 1.6 |
TAXUS® EXPRESS2™ ECSS | 3.3 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 4 year
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 18.5 |
TAXUS® EXPRESS2™ ECSS | 22.5 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 5 years
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® EECSS | 20.3 |
TAXUS® EXPRESS2™ ECSS | 26.6 |
MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 1 year
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 6.3 |
MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 4.7 |
MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 3.3 |
(NCT00676520)
Timeframe: acute: post index procedure until hospital discharge
Intervention | percentage of lesions (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 99.8 |
MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 1 year
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 8.3 |
MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 5.8 |
MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 3.6 |
MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 1 year
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 14.9 |
MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 9.4 |
MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 4.3 |
MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 5.4 |
MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 3.6 |
MI= ARC (Academic Research Constortium) defined (NCT00676520)
Timeframe: 1 year
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 7.2 |
MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 1 year
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 9.4 |
MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 6.2 |
MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 3.5 |
MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 1 year
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 9.6 |
MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 6.3 |
MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 3.5 |
(NCT00676520)
Timeframe: at 1 year
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 2.6 |
(NCT00676520)
Timeframe: at 180 days
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 1.4 |
(NCT00676520)
Timeframe: at 30 days
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 0.4 |
"Patient is included if medications (both aspirin and thienopyridine) were taken for at least 1 day during the visit window. The visit window for 14-day visit is 7-21 days, 30-day visit is 23-37 days, 180-day visit is 166-194 days, 1-year visit is 323-407 days, and 2-year visit is 688-772 days.~Adjunctive antiplatelet therapy includes: Aspirin & Thienopyridines (Clopidogrel/Ticlopidine/Prasugrel).~Compliance refers to subjects following prescribed instructions for taking these medications. Therapy interruptions refer to any intervals during which the subject stops taking one or all of the prescribed medications." (NCT00676520)
Timeframe: at 1 year
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 79.9 |
"Patient is included if medications (both aspirin and thienopyridine) were taken for at least 1 day during the visit window. The visit window for 14-day visit is 7-21 days, 30-day visit is 23-37 days, 180-day visit is 166-194 days, 1-year visit is 323-407 days, and 2-year visit is 688-772 days.~Adjunctive antiplatelet therapy includes: Aspirin & Thienopyridines (Clopidogrel/Ticlopidine/Prasugrel).~Compliance refers to subjects following prescribed instructions for taking these medications. Therapy interruptions refer to any intervals during which the subject stops taking one or all of the prescribed medications." (NCT00676520)
Timeframe: at 14 days
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 89.4 |
"Patient is included if medications (both aspirin and thienopyridine) were taken for at least 1 day during the visit window. The visit window for 14-day visit is 7-21 days, 30-day visit is 23-37 days, 180-day visit is 166-194 days, 1-year visit is 323-407 days, and 2-year visit is 688-772 days.~Adjunctive antiplatelet therapy includes: Aspirin & Thienopyridines (Clopidogrel/Ticlopidine/Prasugrel).~Compliance refers to subjects following prescribed instructions for taking these medications. Therapy interruptions refer to any intervals during which the subject stops taking one or all of the prescribed medications." (NCT00676520)
Timeframe: at 180 days
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 86.4 |
"Patient is included if medications (both aspirin and thienopyridine) were taken for at least 1 day during the visit window. The visit window for 14-day visit is 7-21 days, 30-day visit is 23-37 days, 180-day visit is 166-194 days, 1-year visit is 323-407 days, and 2-year visit is 688-772 days.~Adjunctive antiplatelet therapy includes: Aspirin & Thienopyridines (Clopidogrel/Ticlopidine/Prasugrel).~Compliance refers to subjects following prescribed instructions for taking these medications. Therapy interruptions refer to any intervals during which the subject stops taking one or all of the prescribed medications." (NCT00676520)
Timeframe: at 30 days
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 89.2 |
Defined as patients who had at least 1 day without using either aspirin or thienopyridine from 1 to 407 days post index procedure. (NCT00676520)
Timeframe: 1 year
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 18.0 |
by TIMI flow (NCT00676520)
Timeframe: at 1 year
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 2.8 |
by TIMI flow (NCT00676520)
Timeframe: at 14 days
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 0.6 |
by TIMI flow (NCT00676520)
Timeframe: at 180 days
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 1.8 |
by TIMI flow (NCT00676520)
Timeframe: at 30 days
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 0.7 |
"SAQ: 19-item, 5-6-point Likert, questionnaire measuring 5 dimensions of coronary artery disease:~Anginal Stability: whether a patient's symptoms are changing over time. Anginal Frequency: how often a patient is having symptoms now Physical Limitation: how much a patient's condition is hampering his ability to do what he wants to do.~Treatment Satisfaction: how well a patient understands her care and what she thinks of it.~Disease Perception: the overall impact of a patient's condition on a patient's interpersonal relationships and state of mind.~Each dimension is assigns each response an ordinal value, beginning with 1 for the response at the lowest level of functioning, and summing across items within each of the 5 scales. Scale scores then transformed to 0-100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100." (NCT00676520)
Timeframe: at 1 year
Intervention | units on the SAQ scale (Mean) |
---|---|
Subjects Receiving the XIENCE V EECSS | 76.0 |
"SAQ: 19-item, 5-6-point Likert, questionnaire measuring 5 dimensions of coronary artery disease:~Anginal Stability: whether a patient's symptoms are changing over time. Anginal Frequency: how often a patient is having symptoms now Physical Limitation: how much a patient's condition is hampering his ability to do what he wants to do.~Treatment Satisfaction: how well a patient understands her care and what she thinks of it.~Disease Perception: the overall impact of a patient's condition on a patient's interpersonal relationships and state of mind.~Each dimension is assigns each response an ordinal value, beginning with 1 for the response at the lowest level of functioning, and summing across items within each of the 5 scales. Scale scores then transformed to 0-100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100." (NCT00676520)
Timeframe: at 180 days
Intervention | units on the SAQ scale (Mean) |
---|---|
Subjects Receiving the XIENCE V EECSS | 75.8 |
"SAQ: 19-item, 5-6-point Likert, questionnaire measuring 5 dimensions of coronary artery disease:~Anginal Stability: whether a patient's symptoms are changing over time. Anginal Frequency: how often a patient is having symptoms now Physical Limitation: how much a patient's condition is hampering his ability to do what he wants to do.~Treatment Satisfaction: how well a patient understands her care and what she thinks of it.~Disease Perception: the overall impact of a patient's condition on a patient's interpersonal relationships and state of mind.~Each dimension is assigns each response an ordinal value, beginning with 1 for the response at the lowest level of functioning, and summing across items within each of the 5 scales. Scale scores then transformed to 0-100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100." (NCT00676520)
Timeframe: at baseline
Intervention | units on the SAQ scale (Mean) |
---|---|
Subjects Receiving the XIENCE V EECSS | 70.0 |
(NCT00676520)
Timeframe: acute: post index procedure until hospital discharge
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 97.3 |
(NCT00676520)
Timeframe: at 1 year
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 9.2 |
(NCT00676520)
Timeframe: at 180 days
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 5.0 |
(NCT00676520)
Timeframe: at 30 days
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 1.1 |
"SAQ: 19-item, 5-6-point Likert, questionnaire measuring 5 dimensions of coronary artery disease:~Anginal Stability: whether a patient's symptoms are changing over time. Anginal Frequency: how often a patient is having symptoms now Physical Limitation: how much a patient's condition is hampering his ability to do what he wants to do.~Treatment Satisfaction: how well a patient understands her care and what she thinks of it.~Disease Perception: the overall impact of a patient's condition on a patient's interpersonal relationships and state of mind.~Each dimension is assigns each response an ordinal value, beginning with 1 for the response at the lowest level of functioning, and summing across items within each of the 5 scales. Scale scores then transformed to 0-100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100." (NCT00676520)
Timeframe: 1 year
Intervention | units on the SAQ scale (Mean) |
---|---|
Physical Limitations | 76.0 |
Angina Stability | 54.3 |
Angina Frequency | 90.7 |
Treatment Satisfaction | 92.2 |
Perception of Disease/Quality of Life | 78.0 |
"SAQ: 19-item, 5-6-point Likert, questionnaire measuring 5 dimensions of coronary artery disease:~Anginal Stability: whether a patient's symptoms are changing over time. Anginal Frequency: how often a patient is having symptoms now Physical Limitation: how much a patient's condition is hampering his ability to do what he wants to do.~Treatment Satisfaction: how well a patient understands her care and what she thinks of it.~Disease Perception: the overall impact of a patient's condition on a patient's interpersonal relationships and state of mind.~Each dimension is assigns each response an ordinal value, beginning with 1 for the response at the lowest level of functioning, and summing across items within each of the 5 scales. Scale scores then transformed to 0-100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100." (NCT00676520)
Timeframe: 180 days
Intervention | units on the SAQ scale (Mean) |
---|---|
Physical Limitations | 75.8 |
Angina Stability | 57.3 |
Angina Frequency | 90.1 |
Treatment Satisfaction | 91.4 |
Perception of Disease/Quality of Life | 76.8 |
"SAQ: 19-item, 5-6-point Likert, questionnaire measuring 5 dimensions of coronary artery disease:~Anginal Stability: whether a patient's symptoms are changing over time. Anginal Frequency: how often a patient is having symptoms now Physical Limitation: how much a patient's condition is hampering his ability to do what he wants to do.~Treatment Satisfaction: how well a patient understands her care and what she thinks of it.~Disease Perception: the overall impact of a patient's condition on a patient's interpersonal relationships and state of mind.~Each dimension is assigns each response an ordinal value, beginning with 1 for the response at the lowest level of functioning, and summing across items within each of the 5 scales. Scale scores then transformed to 0-100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100." (NCT00676520)
Timeframe: at baseline
Intervention | units on the SAQ scale (Mean) |
---|---|
Physical Limitations | 70.0 |
Angina Stability | 42.0 |
Angina Frequency | 73.1 |
Treatment Satisfaction | 98.1 |
Perception of Disease/Quality of Life | 55.3 |
"ARC Defines Stent Thrombosis in the following way:~Definite Stent Thrombosis: Angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region AND at least ONE of the following, additional criteria:~Acute ischemic symptoms Ischemic ECG changes Elevated cardiac biomarkers~Probable Stent Thrombosis: Any unexplained death within 30 days of stent implantation or any myocardial infarction, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause~Possible Stent Thrombosis Any unexplained death beyond 30 days~For further information on ARC definitions, please refer to the following website: http://circ.ahajournals.org/content/115/17/2344.full#sec-1" (NCT00676520)
Timeframe: up to 1 year
Intervention | percentage of participants (Number) |
---|---|
Subjects Receiving the XIENCE V EECSS | 0.81 |
Successful delivery and deployment of the first implanted study stent (in overlapping stent setting a successful delivery and deployment of the first and second study stents) at the intended target lesion and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable). Bailout subjects will be included as device success only if the above criteria for clinical device are met. (NCT00307047)
Timeframe: Acute: At time of index procedure
Intervention | Percent of success (Number) |
---|---|
XIENCE V® | 92.0 |
TAXUS™ EXPRESS 2™ | 90.7 |
Successful delivery and deployment of the study stent or stents at the intended target lesion and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable) and/or using any adjunctive device without the occurrence of major adverse cardiac event (MACE) during the hospital stay with a maximum of first seven days following the index procedure. In multiple lesion setting all lesions must meet clinical procedure success. (NCT00307047)
Timeframe: Acute: At time of index procedure
Intervention | Percentage of success (Number) |
---|---|
XIENCE V® | 98.6 |
TAXUS™ EXPRESS 2™ | 98.1 |
(NCT00307047)
Timeframe: 1 year
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 1.0 |
TAXUS™ EXPRESS 2™ | 1.3 |
(NCT00307047)
Timeframe: 180 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 0.5 |
TAXUS™ EXPRESS 2™ | 0.6 |
(NCT00307047)
Timeframe: 2 years
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 2.1 |
TAXUS™ EXPRESS 2™ | 2.7 |
(NCT00307047)
Timeframe: 270 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 0.7 |
TAXUS™ EXPRESS 2™ | 0.9 |
(NCT00307047)
Timeframe: 3 years
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 3.4 |
TAXUS™ EXPRESS 2™ | 5.2 |
(NCT00307047)
Timeframe: 30 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 0.0 |
TAXUS™ EXPRESS 2™ | 0.2 |
(NCT00307047)
Timeframe: 1 year
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 1.9 |
TAXUS™ EXPRESS 2™ | 3.1 |
(NCT00307047)
Timeframe: 180 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 1.6 |
TAXUS™ EXPRESS 2™ | 2.9 |
(NCT00307047)
Timeframe: 2 years
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 2.6 |
TAXUS™ EXPRESS 2™ | 3.9 |
(NCT00307047)
Timeframe: 270 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 1.8 |
TAXUS™ EXPRESS 2™ | 3.0 |
(NCT00307047)
Timeframe: 3 years
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 3.1 |
TAXUS™ EXPRESS 2™ | 4.7 |
(NCT00307047)
Timeframe: 30 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 1.5 |
TAXUS™ EXPRESS 2™ | 2.1 |
(NCT00307047)
Timeframe: 1 year
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 2.2 |
TAXUS™ EXPRESS 2™ | 3.2 |
(NCT00307047)
Timeframe: 180 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 1.8 |
TAXUS™ EXPRESS 2™ | 2.8 |
(NCT00307047)
Timeframe: 2 years
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 3.2 |
TAXUS™ EXPRESS 2™ | 4.3 |
(NCT00307047)
Timeframe: 270 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 2.1 |
TAXUS™ EXPRESS 2™ | 3.0 |
(NCT00307047)
Timeframe: 3 years
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 4.1 |
TAXUS™ EXPRESS 2™ | 5.5 |
(NCT00307047)
Timeframe: 30 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 1.5 |
TAXUS™ EXPRESS 2™ | 2.1 |
(NCT00307047)
Timeframe: 1 year
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 9.0 |
TAXUS™ EXPRESS 2™ | 10.5 |
(NCT00307047)
Timeframe: 180 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 5.5 |
TAXUS™ EXPRESS 2™ | 7.5 |
(NCT00307047)
Timeframe: 2 years
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 15.5 |
TAXUS™ EXPRESS 2™ | 16.2 |
(NCT00307047)
Timeframe: 270 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 7.2 |
TAXUS™ EXPRESS 2™ | 9.3 |
(NCT00307047)
Timeframe: 3 years
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 21.4 |
TAXUS™ EXPRESS 2™ | 22.5 |
(NCT00307047)
Timeframe: 30 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 2.4 |
TAXUS™ EXPRESS 2™ | 3.6 |
"ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: >24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: >1 year post~* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.~† Including primary as well as secondary late ST; secondary late ST is after a target segment revascularization." (NCT00307047)
Timeframe: 0-30 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 0.16 |
TAXUS™ EXPRESS 2™ | 0.74 |
"ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: >24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: >1 year post~* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.~† Including primary as well as secondary late ST; secondary late ST is after a target segment revascularization." (NCT00307047)
Timeframe: 0 -393 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 0.29 |
TAXUS™ EXPRESS 2™ | 1.10 |
"ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: >24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: >1 year post~* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.~† Including primary as well as secondary late ST; secondary late ST is after a target segment revascularization." (NCT00307047)
Timeframe: 0-1123 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 0.62 |
TAXUS™ EXPRESS 2™ | 1.73 |
"ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: >24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: >1 year post~* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.~† Including primary as well as secondary late ST; secondary late ST is after a target segment revascularization." (NCT00307047)
Timeframe: 0-758 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 0.48 |
TAXUS™ EXPRESS 2™ | 1.32 |
"ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: >24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: >1 year post~* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.~† Including primary as well as secondary late ST; secondary late ST is after a target segment revascularization." (NCT00307047)
Timeframe: 31-393 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 0.13 |
TAXUS™ EXPRESS 2™ | 0.42 |
Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 1 years
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 4.2 |
TAXUS™ EXPRESS 2™ | 6.9 |
Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 180 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 2.6 |
TAXUS™ EXPRESS 2™ | 5.3 |
Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 2 years
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 7.2 |
TAXUS™ EXPRESS 2™ | 10.2 |
Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 270 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 3.5 |
TAXUS™ EXPRESS 2™ | 6.2 |
Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 3 years
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 9.8 |
TAXUS™ EXPRESS 2™ | 12.3 |
Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 30 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 1.6 |
TAXUS™ EXPRESS 2™ | 2.7 |
Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR). (NCT00307047)
Timeframe: 1 year
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 4.2 |
TAXUS™ EXPRESS 2™ | 6.8 |
Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR). (NCT00307047)
Timeframe: 180 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 2.5 |
TAXUS™ EXPRESS 2™ | 5.1 |
Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR). (NCT00307047)
Timeframe: 2 years
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 7.0 |
TAXUS™ EXPRESS 2™ | 10.0 |
Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR). (NCT00307047)
Timeframe: 270 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 3.4 |
TAXUS™ EXPRESS 2™ | 6.1 |
Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR). (NCT00307047)
Timeframe: 3 years
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 9.5 |
TAXUS™ EXPRESS 2™ | 11.9 |
Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR). (NCT00307047)
Timeframe: 30 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 1.6 |
TAXUS™ EXPRESS 2™ | 2.7 |
"Revascularization of a target lesion associated with any of the following:~positive functional ischemia study~ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 1 year
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® | 2.5 |
TAXUS™ EXPRESS 2™ | 4.6 |
"Revascularization of a target lesion associated with any of the following:~positive functional ischemia study~ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 180 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® | 1.1 |
TAXUS™ EXPRESS 2™ | 3.2 |
"Revascularization of a target lesion associated with any of the following:~positive functional ischemia study~ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 2 years
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® | 4.4 |
TAXUS™ EXPRESS 2™ | 6.9 |
"Revascularization of a target lesion associated with any of the following:~positive functional ischemia study~ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 270 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® | 1.9 |
TAXUS™ EXPRESS 2™ | 4.1 |
"Revascularization of a target lesion associated with any of the following:~positive functional ischemia study~ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 3 years
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® | 6.3 |
TAXUS™ EXPRESS 2™ | 7.9 |
"Revascularization of a target lesion associated with any of the following:~positive functional ischemia study~ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 30 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® | 0.4 |
TAXUS™ EXPRESS 2™ | 1.1 |
Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 1 year
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® | 5.6 |
TAXUS™ EXPRESS 2™ | 7.9 |
Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 180 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® | 3.4 |
TAXUS™ EXPRESS 2™ | 6.2 |
Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 2 years
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® | 9.6 |
TAXUS™ EXPRESS 2™ | 11.8 |
Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 270 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® | 4.6 |
TAXUS™ EXPRESS 2™ | 7.2 |
Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 3 years
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® | 13.3 |
TAXUS™ EXPRESS 2™ | 14.5 |
Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 30 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® | 1.9 |
TAXUS™ EXPRESS 2™ | 3.1 |
"Revascularization of a lesion within the target vessel associated with any of the following:~positive functional ischemia study~ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 1 year
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® | 3.9 |
TAXUS™ EXPRESS 2™ | 5.9 |
"Revascularization of a lesion within the target vessel associated with any of the following:~positive functional ischemia study~ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 180 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® | 1.9 |
TAXUS™ EXPRESS 2™ | 4.3 |
"Revascularization of a lesion within the target vessel associated with any of the following:~positive functional ischemia study~ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 2 years
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® | 7.0 |
TAXUS™ EXPRESS 2™ | 8.9 |
"Revascularization of a lesion within the target vessel associated with any of the following:~positive functional ischemia study~ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 270 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® | 3.0 |
TAXUS™ EXPRESS 2™ | 5.3 |
"Revascularization of a lesion within the target vessel associated with any of the following:~positive functional ischemia study~ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 3 years
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® | 10.1 |
TAXUS™ EXPRESS 2™ | 10.6 |
"Revascularization of a lesion within the target vessel associated with any of the following:~positive functional ischemia study~ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 30 days
Intervention | percentage of participants (Number) |
---|---|
XIENCE V® | 0.7 |
TAXUS™ EXPRESS 2™ | 1.6 |
"ST will be categorized as acute (≤ 1day), subacute (>1 day to ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of ST~In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00307047)
Timeframe: 0-1123 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 0.79 |
TAXUS™ EXPRESS 2™ | 1.99 |
"ST will be categorized as acute (≤ 1day), subacute (>1 day to ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of ST~In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00307047)
Timeframe: 0-30 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 0.12 |
TAXUS™ EXPRESS 2™ | 0.57 |
"ST will be categorized as acute (≤ 1day), subacute (>1 day to ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of ST~In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00307047)
Timeframe: 0-393 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 0.17 |
TAXUS™ EXPRESS 2™ | 0.85 |
"ST will be categorized as acute (≤ 1day), subacute (>1 day to ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of ST~In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00307047)
Timeframe: 0-758 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 0.52 |
TAXUS™ EXPRESS 2™ | 1.23 |
"ST will be categorized as acute (≤ 1day), subacute (>1 day to ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of ST~In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00307047)
Timeframe: 31-393 days
Intervention | Percentage of participants (Number) |
---|---|
XIENCE V® | 0.04 |
TAXUS™ EXPRESS 2™ | 0.34 |
Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat [mITT] population) (NCT01156571)
Timeframe: 48 hours after randomization
Intervention | participants (Number) |
---|---|
Cangrelor Treatment Arm | 257 |
Clopidogrel Treatment Arm | 322 |
GUSTO = Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial (NCT01156571)
Timeframe: 48 hours after randomization
Intervention | participants (Number) | ||||||
---|---|---|---|---|---|---|---|
GUSTO severe/life threatening | GUSTO moderate | GUSTO severe or moderate | TIMI major | TIMI minor | TIMI major or minor | Any blood transfusion | |
Cangrelor Treatment Arm | 9 | 22 | 31 | 5 | 9 | 14 | 25 |
Clopidogrel Treatment Arm | 6 | 13 | 19 | 5 | 3 | 8 | 16 |
CEC-adjudicated results (mITT population) (NCT01156571)
Timeframe: 48 hours after randomization
Intervention | participants (Number) | |||
---|---|---|---|---|
Stent Thrombosis | Death | MI (myocardial infarction) | IDR (ischemia-driven revascularization) | |
Cangrelor Treatment Arm | 46 | 18 | 207 | 28 |
Clopidogrel Treatment Arm | 74 | 18 | 255 | 38 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
Intervention | percentage of patients (Number) |
---|---|
Propensity-matched DES | 1.70 |
Propensity-matched BMS | 2.61 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
Intervention | percentage of patients (KM estimate) (Number) |
---|---|
BMS 30-month DAPT | 0.50 |
BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
Intervention | percentage of patients (KM estimate) (Number) |
---|---|
BMS 30-month DAPT | 0.50 |
BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
Intervention | percentage of patients (KM estimate) (Number) |
---|---|
DES 30-month DAPT | 0.69 |
DES 12-month DAPT | 1.45 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
Intervention | percentage of patients (KM estimate) (Number) |
---|---|
DES 30-month DAPT | 0.40 |
DES 12-month DAPT | 1.35 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
Intervention | percentage of patients (Number) |
---|---|
BMS 30-month DAPT | 2.03 |
BMS 12-month DAPT | 0.90 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
Intervention | percentage of patients (Number) |
---|---|
BMS 30-month DAPT | 2.09 |
BMS 12-month DAPT | 1.05 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
Intervention | percentage of patients (Number) |
---|---|
DES 30-month DAPT | 2.74 |
DES 12-month DAPT | 1.88 |
The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
Intervention | percentage of patients (Number) |
---|---|
DES 30-month DAPT | 2.53 |
DES 12-month DAPT | 1.57 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
Intervention | percentage of patients (Number) |
---|---|
Propensity-matched DES | 11.37 |
Propensity-matched BMS | 13.24 |
(NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
Intervention | percentage of patients (KM estimate) (Number) |
---|---|
BMS 30-month DAPT | 4.04 |
BMS 12-month DAPT | 4.69 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
Intervention | percentage of patients (KM estimate) (Number) |
---|---|
BMS 30-month DAPT | 4.68 |
BMS 12-month DAPT | 5.48 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
Intervention | percentage of patients (KM estimate) (Number) |
---|---|
DES 30-month DAPT | 5.62 |
DES 12-month DAPT | 6.49 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
Intervention | percentage of patients (KM estimate) (Number) |
---|---|
DES 30-month DAPT | 4.34 |
DES 12-month DAPT | 5.92 |
The endpoint in this measure is a combination of all-cause death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
Intervention | Participants (Number) |
---|---|
Prasugrel | 692 |
Clopidogrel | 822 |
The endpoint in this measure is a combination of CV death, nonfatal MI, nonfatal stroke, or rehospitalization for cardiac ischemic events. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
Intervention | Participants (Number) |
---|---|
Prasugrel | 797 |
Clopidogrel | 938 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
Intervention | Participants (Number) | |
---|---|---|
All ACS (Through 30 days) | All ACS (Through 90 days) | |
Clopidogrel | 502 | 573 |
Prasugrel | 389 | 462 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI). (NCT00097591)
Timeframe: Randomization up to 15 months
Intervention | Participants (Number) | ||
---|---|---|---|
UA/NSTEMI (n=5044, n=5030) | STEMI (n=1769, n=1765) | All ACS (n=6813, n=6795) | |
Clopidogrel | 565 | 216 | 781 |
Prasugrel | 469 | 174 | 643 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or UTVR. Results are reported for the All ACS subject population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
Intervention | Participants (Number) | |
---|---|---|
All ACS (Through 30 days) | All ACS (Through 90 days) | |
Clopidogrel | 504 | 588 |
Prasugrel | 399 | 472 |
TIMI classification for major and minor bleeding in the subset of subjects who did not undergo a coronary artery bypass operation (CABG) were defined as follows: Major bleeding: any intracranial hemorrhage (ICH) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL)from baseline. Minor Bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 gm/dL but <5 gm/dL from baseline. Major bleeding events were further examined as events that were deemed life threatening and/or fatal. (NCT00097591)
Timeframe: First dose of study drug up to 15 months (while at risk)
Intervention | Participants (Number) | ||||||||
---|---|---|---|---|---|---|---|---|---|
TIMI Major or Minor Bleeding | TIMI Major Bleeding | TIMI Major Bleeding - Life-threatening (LT) | LT - Fatal | LT - Symptomatic intracranial hemorrage (ICH) | LT - Requiring inotropes | LT - Requiring surgical intervention | LT - Requiring transfusion (>=4 units) | TIMI Minor Bleeding | |
Clopidogrel | 231 | 111 | 56 | 5 | 17 | 8 | 19 | 30 | 125 |
Prasugrel | 303 | 146 | 85 | 21 | 19 | 21 | 19 | 45 | 164 |
Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) (NCT00433966)
Timeframe: 3 years
Intervention | Participants (Count of Participants) |
---|---|
Pharmacology Arm - Bivalirudin | 379 |
Pharmacology Arm - Unfractionated Heparin | 377 |
Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) (NCT00433966)
Timeframe: 30 days
Intervention | Participants (Count of Participants) |
---|---|
Pharmacology Arm - Bivalirudin | 98 |
Pharmacology Arm - Unfractionated Heparin | 99 |
Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) and major bleeding (bleeding adjudicated as not related to coronary artery bypass grafting). (NCT00433966)
Timeframe: 30 Days
Intervention | Participants (Count of Participants) |
---|---|
Pharmacology Arm - Bivalirudin | 166 |
Pharmacology Arm - Unfractionated Heparin | 218 |
Number of participants with major bleeding (bleeding adjudicated as not related to coronary artery bypass grafting) (NCT00433966)
Timeframe: 30 days
Intervention | Participants (Count of Participants) |
---|---|
Pharmacology Arm - Bivalirudin | 89 |
Pharmacology Arm - Unfractionated Heparin | 149 |
Number of Participants With Death, Reinfarction, Stroke, or Stent Thrombosis (NCT00433966)
Timeframe: 1 year
Intervention | Participants (Count of Participants) |
---|---|
Stent Arm - Paclitaxel-Eluting Stent | 181 |
Stent Arm - Bare Metal Stent | 59 |
Number of Participants With Ischemic Target Lesion Revascularization (NCT00433966)
Timeframe: 1 year
Intervention | Participants (Count of Participants) |
---|---|
Stent Arm - Paclitaxel-Eluting Stent | 98 |
Stent Arm - Bare Metal Stent | 54 |
Number of Participants With Segment Binary Angiographic Restenosis (13-month Angiographic Subset). (NCT00433966)
Timeframe: 13 months
Intervention | Participants (Count of Participants) |
---|---|
Stent Arm - Paclitaxel-Eluting Stent | 102 |
Stent Arm - Bare Metal Stent | 76 |
Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization
Intervention | Participants (Count of Participants) |
---|---|
Placebo + Ticagrelor | 141 |
Aspirin + Ticagrelor | 250 |
Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization
Intervention | Participants (Count of Participants) |
---|---|
Placebo + Ticagrelor | 135 |
Aspirin + Ticagrelor | 137 |
Overall costs expressed in US dollars at 18 months of follow up between Oral Sirolimus Plus BMS vs DES implantation in denovo coronary lesions. (NCT00552669)
Timeframe: Follow up will be conducted by the coordinating Center at 18 months of follow up
Intervention | US dollars (Mean) |
---|---|
Oral Sirolimus + Bare Metal Stent | 5483 |
Drug Eluting Stents | 7658.2 |
Efficacy end point was TVR as revasacularization of the treated vessel. (NCT00552669)
Timeframe: 18 months
Intervention | vessels (Number) |
---|---|
Oral Sirolimus + Bare Metal Stent | 14 |
Drug Eluting Stents | 15 |
Death from any cause, myocardial infarction and stroke. Safety was analyzed as MACCE (major adverse cardiovascular events) including death, MI and stroke. (NCT00552669)
Timeframe: 18 Months
Intervention | participants (Number) | |||
---|---|---|---|---|
MACCE | Death | Acute Myocardial Infarction | Stroke | |
Drug Eluting Stents | 15 | 7 | 9 | 1 |
Oral Sirolimus + Bare Metal Stent | 9 | 3 | 6 | 0 |
Assessment of vascular healing 6 months after Resolute Integrity placement in non-diabetic patients and patients with non-insulin dependent diabetes presenting with acute coronary syndrome (ACS) using optical frequency domain imaging (OFDI). Vascular healing will be measured by percent covered stents as determined by OFDI. A higher percentage of stent coverage indicates increased endothelial regrowth, which is an essential component for the maintenance of long-term luminal patency. (NCT01794949)
Timeframe: 6 months
Intervention | Participants (Count of Participants) | ||
---|---|---|---|
85% up to 90% stent coverage | 90% up to 95% stent coverage | 95% or greater percent stent coverage | |
NIDDM Patients Receiving the Resolute Stent | 0 | 1 | 0 |
Non-diabetic Patients Receiving the Resolute Stent | 1 | 3 | 1 |
85 reviews available for ticlopidine and Coronary Thrombosis
Article | Year |
---|---|
Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; | 2017 |
Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Administration Schedule; | 2017 |
Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.
Topics: Aryl Hydrocarbon Hydroxylases; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Cytochrome | 2013 |
Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons.
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Hemorrhage; Humans | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
New antiplatelet agents in the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; | 2014 |
How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer?
Topics: Algorithms; Animals; Blood Platelets; Clopidogrel; Coronary Thrombosis; Decision Support Techniques; | 2015 |
Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis?
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Co | 2016 |
Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
Topics: Adenosine; Antithrombins; Bayes Theorem; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Cor | 2016 |
Antiplatelet treatment of cardiovascular disease: a translational research perspective.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Resistance; Humans; Platele | 2008 |
Coronary artery stents: II. Perioperative considerations and management.
Topics: Anesthesia, Conduction; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel; | 2008 |
Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Thrombosis; Electro | 2008 |
Emergence of the concept of platelet reactivity monitoring of response to thienopyridines.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug Resistance; Humans; Platelet | 2009 |
[Resistance to desaggregants: causes, clinical implication, methods of diagnosis and correction].
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Resistance; Drug T | 2008 |
Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; C | 2009 |
Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Dia | 2009 |
[Clopidogrel resistance].
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug Resistance; Drug Therapy, Combination; Humans; Plate | 2009 |
Coronary stent thrombosis in patients with chronic renal insufficiency.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Huma | 2010 |
Combined mechanical and pharmacological approach to a thrombus-containing lesion.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Corona | 2010 |
[Discontinuation of treatment with platelet aggregation inhibitors in surgical patients with cardiac stents].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Dru | 2010 |
New antithrombotic agents--insights from clinical trials.
Topics: Adenosine; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Coumarins; Fibrinolytic Agents | 2010 |
Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis.
Topics: Alleles; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 Enzyme System; Humans; Myocardial Ischem | 2010 |
Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update.
Topics: Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Drug-Eluting Sten | 2010 |
Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development.
Topics: Animals; Clopidogrel; Coronary Thrombosis; Humans; Piperazines; Platelet Aggregation Inhibitors; Pra | 2011 |
Platelet function testing in clinical diagnostics.
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Hemorrhage; Humans; Intracranial Embolism; Intracranial T | 2011 |
[New approaches and indications for the analysis of platelet function in cardiology].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombos | 2011 |
Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Blood Vessel Prosthesis Implantation; Clopid | 2011 |
Platelet-mediated thrombosis and drug-eluting stents.
Topics: Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Equipment Design; Humans; Piperazines; Platel | 2011 |
Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Dr | 2013 |
Pharmacogenetics of clopidogrel.
Topics: Aryl Hydrocarbon Hydroxylases; Biotransformation; Blood Platelets; Clopidogrel; Coronary Thrombosis; | 2012 |
Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug | 2012 |
Clinical impact of genetically determined platelet reactivity.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Biotransformation; Blood Platelets; Clopidogrel; Coronary Th | 2013 |
The discovery of a new class of synaptic transmitters in smooth muscle 50 years ago and amelioration of coronary artery thrombosis.
Topics: Adenosine; Animals; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; History, 20th Century | 2013 |
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Female; Humans; Intracra | 2013 |
Preventing thrombosis: update of first-line therapy in the management of non-ST segment elevation acute coronary syndromes.
Topics: Acute Disease; Algorithms; Clopidogrel; Coronary Disease; Coronary Thrombosis; Enoxaparin; Fibrinoly | 2002 |
Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.
Topics: Acute Disease; Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clop | 2003 |
[Stent thrombosis in patients with myocardial infarction].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Thrombosis; Fibrinolytic Age | 2003 |
[Treatment of ischemic heart disease with the platelet aggregation inhibitor clopidogrel].
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Therapy, Combination; Humans; Myoc | 2004 |
Combined antithrombotic therapy for acute coronary syndrome.
Topics: Administration, Oral; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; D | 2003 |
Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Antithrombins; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery D | 2004 |
Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials.
Topics: Anticoagulants; Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Hu | 2004 |
What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis.
Topics: Aged; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Blood Vessel Prost | 2005 |
Platelet inhibition in percutaneous coronary interventions.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Platelet Aggregat | 2005 |
Therapeutic approaches in arterial thrombosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atherosclerosis; Blood Pl | 2005 |
[Place of ticlopidine in antiplatelet treatment].
Topics: Animals; Cardiovascular Diseases; Coronary Thrombosis; Humans; Platelet Aggregation Inhibitors; Ticl | 2005 |
[Cardiological (pharmaco)therapy and dental practice].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Thrombosis; Defibrillators, Implantable; Hea | 2006 |
Multiple coronary thrombosis and stent implantation to the subtotally occluded right renal artery in a patient with essential thrombocytosis: a case report with review.
Topics: Angina, Unstable; Angioplasty; Clopidogrel; Coronary Thrombosis; Female; Humans; Hypertension; Middl | 2006 |
Drug insight: Clopidogrel nonresponsiveness.
Topics: Clopidogrel; Coronary Thrombosis; Drug Resistance; Humans; Platelet Aggregation; Platelet Aggregatio | 2006 |
[Pathogenesis and therapy of the acute coronary syndrome: differentiated advantage of glycoprotein IIb/IIIa receptor antagonists for high-risk patients].
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Thrombosis; Diabetes Complic | 2006 |
[Antiplatelet agents--problem for cardiac surgeon].
Topics: Anticoagulants; Aspirin; Coronary Thrombosis; Dipyridamole; Fibrinolytic Agents; Humans; Myocardial | 2006 |
Platelet P2 receptors: old and new targets for antithrombotic drugs.
Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Coronar | 2007 |
[Antiplatelet drugs and intraoperative hemorrhage].
Topics: Algorithms; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combinati | 2006 |
Oral antiplatelet therapy for percutaneous coronary revascularization.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therap | 2007 |
Role of clopidogrel in managing atherothrombotic cardiovascular disease.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Dr | 2007 |
[Stents in interventional cardiology].
Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aspirin; Clop | 2007 |
Clopidogrel resistance--the cardiologist's perspective.
Topics: Blood Platelets; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Resistance; Humans; Platel | 2007 |
[Very late intrastent thrombosis--at 27 months!].
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Fatal Outcome; Flurbiprofen; Follow-Up Studies; Hernia, I | 2007 |
[Dual platelet aggregation inhibition in coronary artery stent implantation--what is evidence-based?].
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Drug Therapy, Combination; Evidence-Bas | 2007 |
Contemporary use of clopidogrel in patients with coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Coro | 2007 |
Perioperative use of anti-platelet drugs.
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Elective Surgical Procedures; Hemorrhage; Humans; Periope | 2007 |
[Management coronary syndrome in the acute phase].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidog | 2007 |
Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Th | 2007 |
Aspirin and clopidogrel resistance.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; | 2007 |
[Late coronary stent thrombosis and clopidogrel].
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Plate | 2007 |
Increased incidence of in-stent thrombosis related to cocaine use: case series and review of literature.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cocaine; Cocaine-Related Disorders; Cor | 2007 |
[Clopidogrel and statins or once more on the danger of direct transfer of results of experimental studies in clinical practice].
Topics: Atorvastatin; Clopidogrel; Coronary Thrombosis; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; | 2008 |
[Antiplatelet therapy during coronary endoprosthesis placement].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Coronary Thrombosis; Drug Therapy, Combin | 1996 |
Ticlopidine and aspirin therapy following implantation of coronary artery stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thromb | 1997 |
[Pharmacology of ticlopidine and clopidogrel in comparison with acetylsalicylic acid].
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Coronary Thrombosis; Death, Sudden, Cardiac; Humans | 1997 |
Beyond aspirin.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Myocardial Infarc | 1998 |
Clopidogrel with aspirin is the optimal antiplatelet regimen for intracoronary stenting.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Co | 1999 |
Aspirin and ticlopidine after routine coronary stenting: the gold standard as of 1999.
Topics: Anemia, Aplastic; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Co | 1999 |
Future directions in thrombolysis.
Topics: Clopidogrel; Coronary Disease; Coronary Thrombosis; Cyclooxygenase 2; Enzyme Inhibitors; Fibrinolyti | 1999 |
Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention.
Topics: Coronary Thrombosis; Humans; Platelet Aggregation Inhibitors; Purpura, Thrombotic Thrombocytopenic; | 1999 |
Use of clopidrogel in coronary stenting: what was the question?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Humans; Plat | 1999 |
[Acute complications of coronary angioplasty: prevention and management].
Topics: Angioplasty, Balloon, Coronary; Coronary Artery Bypass; Coronary Disease; Coronary Thrombosis; Human | 1999 |
Treatment of unstable angina: the role of platelet inhibitors and anticoagulants.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Clopidogrel; Coronary Thrombosi | 1999 |
Antiplatelet agents in cardiology: the choice of therapy.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Humans; | 2000 |
The thienopyridines in coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Humans; | 1999 |
Antiplatelet medications and their indications in preventing and treating coronary thrombosis.
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Platelet Aggregation Inhibitors; Platelet Glycopr | 2000 |
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End | 2001 |
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End | 2001 |
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End | 2001 |
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End | 2001 |
Ticlopidine versus oral anticoagulation for coronary stenting.
Topics: Administration, Oral; Anticoagulants; Aspirin; Coronary Thrombosis; Drug Therapy, Combination; Fibri | 2001 |
Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Therapy, Combination; Humans; Odds | 2002 |
Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Thrombosis; Heparin, Low-Molecular-Weight; Humans; | 2002 |
Clinical pharmacology of bivalirudin.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Clinical Trials as | 2002 |
92 trials available for ticlopidine and Coronary Thrombosis
Article | Year |
---|---|
Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug | 2017 |
6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedu | 2017 |
Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents.
Topics: Aged; Aspirin; Clinical Decision-Making; Clopidogrel; Coronary Disease; Coronary Thrombosis; Decisio | 2017 |
Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease.
Topics: Adenosine; Aged; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Coronary Thrombosis; Cross-O | 2017 |
Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aged; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Female; He | 2017 |
Telephone contact to improve adherence to dual antiplatelet therapy after drug-eluting stent implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Counseling; Drug Prescriptions; Drug Therapy, Combi | 2013 |
Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Coronary Angiography; C | 2013 |
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem | 2013 |
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem | 2013 |
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem | 2013 |
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem | 2013 |
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem | 2013 |
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem | 2013 |
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem | 2013 |
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem | 2013 |
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem | 2013 |
Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-plate
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, | 2013 |
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment
Topics: Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; D | 2014 |
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment
Topics: Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; D | 2014 |
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment
Topics: Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; D | 2014 |
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment
Topics: Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; D | 2014 |
Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Thrombosis; Creatin | 2014 |
Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Artery Bypass; Coronary Thrombosis; | 2014 |
Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.
Topics: Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug-Elutin | 2014 |
High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention.
Topics: Aged; China; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule | 2015 |
Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
Topics: Aged; Angina, Stable; Aspirin; Belgium; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coron | 2014 |
Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations.
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-El | 2014 |
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
Topics: Adenosine Monophosphate; Aged; Anticoagulants; Chi-Square Distribution; Clopidogrel; Coronary Artery | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; | 2015 |
Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention: The RECLOSE-3 Study (REsponsiveness to CLOpidogrel and StEnt Thrombosis).
Topics: Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thr | 2015 |
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Femora | 2016 |
Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Topics: Adenosine; Aged; Chi-Square Distribution; China; Clopidogrel; Coronary Thrombosis; Drug Therapy, Com | 2016 |
Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODI
Topics: Aged; Aged, 80 and over; Aspirin; Clinical Decision-Making; Clopidogrel; Coronary Thrombosis; Drug T | 2016 |
6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
Topics: Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug | 2016 |
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial.
Topics: Adenosine Monophosphate; Aged; Brazil; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Do | 2016 |
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; C | 2016 |
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angina, Stable; Chi-Square Distribution; Clo | 2016 |
Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Aspirin; Clopidogrel; Coronary Thrombosis; Double-Bli | 2017 |
Effect of 150-mg vs 300-mg loading doses of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Asian People; Clopidogrel; Coronary Art | 2008 |
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial I
Topics: Administration, Oral; Aged; Clopidogrel; Coronary Thrombosis; Diabetes Mellitus, Type 1; Diabetes Me | 2008 |
Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis; | 2008 |
Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis.
Topics: Acute Disease; Aged; Angina Pectoris; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary T | 2009 |
Temporal relation between Clopidogrel cessation and stent thrombosis after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Female; | 2009 |
Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual
Topics: Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Dose-Response Relations | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Dis | 2009 |
Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; C | 2009 |
Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thromb | 2010 |
Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Blood Loss, Surgical; Clopidogrel; C | 2010 |
High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Dose-Resp | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
A case-control study on platelet reactivity in patients with coronary stent thrombosis.
Topics: Aged; Aspirin; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Thrombosis; Female; Flow | 2011 |
Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Clopidogrel; Coronary Restenosi | 2011 |
Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. - Impact on intracoronary thrombus burden and myocardial perfusion-.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Circulation; Co | 2011 |
Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Co | 2011 |
A novel regimen of alternate day clopidogrel would provide a cost-effective strategy to prevent very late stent thrombosis.
Topics: Aspirin; Clopidogrel; Cohort Studies; Coronary Thrombosis; Drug-Eluting Stents; Equipment Safety; Hu | 2012 |
The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Circulati | 2012 |
Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Angina, Stable; Angioplasty, Balloon, Coronary; Aspirin; Cl | 2012 |
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2012 |
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2012 |
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2012 |
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2012 |
Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention.
Topics: Adult; Aged; Asian People; Clopidogrel; Cohort Studies; Coronary Thrombosis; Female; Humans; Male; M | 2012 |
Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention.
Topics: Adolescent; Adult; Aged; Aryl Hydrocarbon Hydroxylases; Asian People; China; Clopidogrel; Coronary T | 2013 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial.
Topics: Aged; Asian People; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy | 2014 |
Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel.
Topics: Administration, Oral; Adult; Aspirin; Clopidogrel; Coronary Thrombosis; Cross-Over Studies; Dose-Res | 2013 |
Sustained platelet activation following intracoronary beta irradiation.
Topics: Angioplasty, Balloon, Coronary; Beta Particles; Blood Platelets; Brachytherapy; CD40 Ligand; Clopido | 2002 |
Effects of diltiazem on platelet activation and cytosolic calcium during percutaneous transluminal coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Calcium; Calcium Channel Blockers; C | 2003 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Effects of pretreatment with clopidogrel on platelet and coagulation activation in patients undergoing elective coronary stenting.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; beta-Thromboglobulin; Blood Vessel Prosthesis; Clop | 2003 |
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen | 2005 |
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen | 2005 |
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen | 2005 |
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen | 2005 |
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen | 2005 |
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen | 2005 |
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen | 2005 |
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen | 2005 |
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen | 2005 |
What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis.
Topics: Aged; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Blood Vessel Prost | 2005 |
Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Thera | 2005 |
Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Double-Bli | 2006 |
[Prevention of atherothrombotic incidents. CHARISMA Study (The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance].
Topics: Aged; Aspirin; Cause of Death; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Embolism | 2006 |
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli | 2006 |
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli | 2006 |
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli | 2006 |
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli | 2006 |
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli | 2006 |
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli | 2006 |
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli | 2006 |
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli | 2006 |
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli | 2006 |
Comparison of two antiplatelet regimens (aspirin alone versus aspirin + ticlopidine or clopidogrel) after intracoronary implantation of a carbofilm-coated stent.
Topics: Aspirin; Carbon; Cause of Death; Clopidogrel; Coated Materials, Biocompatible; Coronary Disease; Cor | 2007 |
Comparison of sarpogrelate and ticlopidine in bare metal coronary stent implantation.
Topics: Aged; Coronary Restenosis; Coronary Thrombosis; Coronary Vessels; Female; Follow-Up Studies; Humans; | 2008 |
TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug-Elutin | 2007 |
Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary A | 2008 |
Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Catheterization; Coronary Angiography; Coronar | 1995 |
Combined antiplatelet therapy with ticlopidine and aspirin. A simplified approach to intracoronary stent management.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Coronary Artery Disea | 1996 |
High pressure assisted coronary stent implantation accomplished without intravascular ultrasound guidance and subsequent anticoagulation.
Topics: Anticoagulants; Aspirin; Case-Control Studies; Coronary Angiography; Coronary Disease; Coronary Thro | 1997 |
Coronary stenting (Cordis) without anticoagulation.
Topics: Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Coronary Thrombosis; Evaluation Stu | 1997 |
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T | 1997 |
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T | 1997 |
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T | 1997 |
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T | 1997 |
Silicon carbide-coated stents: clinical experience in coronary lesions with increased thrombotic risk.
Topics: Adult; Aged; Angioplasty, Balloon; Carbon Compounds, Inorganic; Coronary Disease; Coronary Thrombosi | 1998 |
Clinical outcome at six months of coronary stenting followed by ticlopidine monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Electro | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Low-molecular-weight heparins in coronary stenting (the ENTICES trial). ENoxaparin and TIClopidine after Elective Stenting.
Topics: Aged; Aspirin; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Enoxaparin; Fem | 1998 |
Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).
Topics: Adult; Aged; Anticoagulants; Aspirin; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Patien | 1998 |
Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Thrombosis; Diarrhea; D | 1999 |
Comparison of cilostazol versus ticlopidine therapy after stent implantation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Disease; Coronary Thrombo | 1999 |
Clopidogrel as adjunctive antiplatelet therapy during coronary stenting.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiograp | 1999 |
Clopidogrel versus ticlopidine after intracoronary stent placement.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosi | 1999 |
[Acute coronary syndrome, stent and cardiac insufficiency. Advances in thrombosis prevention].
Topics: Acute Disease; Clopidogrel; Coronary Disease; Coronary Thrombosis; Coumarins; Humans; Platelet Aggre | 1999 |
A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Drug Therapy, Combination; Female | 2000 |
[Subacute thrombosis with antiplatelet treatment in a non-selected population of intracoronary stents: incidence and predictors].
Topics: Acute Disease; Aspirin; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Platelet Aggregation | 2000 |
Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Thrombosis; Drug T | 2000 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
A safe and effective regimen without heparin therapy after successful primary coronary stenting in patients with acute myocardial infarction.
Topics: Aged; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis; Coronary Vessel | 2000 |
Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population.
Topics: Abciximab; Antibodies, Monoclonal; Clopidogrel; Coronary Disease; Coronary Thrombosis; Eptifibatide; | 2001 |
Inhibition by combined therapy with ticlopidine and aspirin of enhanced platelet aggregation during physical exercise in patients with coronary artery disease.
Topics: Adenine Nucleotides; Adult; Aged; Aspirin; Coronary Disease; Coronary Thrombosis; Drug Administratio | 2001 |
A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial.
Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Coronary Disease; Coronary Thrombosis; Double-B | 2001 |
Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (
Topics: Coronary Thrombosis; Enoxaparin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Platelet Ag | 2002 |
320 other studies available for ticlopidine and Coronary Thrombosis
Article | Year |
---|---|
Dual antiplatelet therapy after percutaneous coronary intervention: entering the final chapter?
Topics: Coronary Restenosis; Coronary Thrombosis; Drug Therapy, Combination; Humans; Percutaneous Coronary I | 2019 |
Stent thrombosis: prevention is the only effective treatment.
Topics: Coronary Thrombosis; Humans; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine | 2020 |
Stent thrombosis in patients undergoing coronary stenting after return of spontaneous circulation. Does the choice of antiplatelet drug matter?
Topics: Aspirin; Coronary Thrombosis; Drug-Eluting Stents; Humans; Platelet Aggregation Inhibitors; Stents; | 2017 |
Potentially increased incidence of scaffold thrombosis in patients treated with Absorb BVS who terminated DAPT before 18 months.
Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Biocompati | 2017 |
Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Computer Simulation; Coronary Thrombosis; Cost-Benefi | 2017 |
Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Thr | 2017 |
Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Drug Resi | 2017 |
Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Combined Modal | 2018 |
Long-term outcome after angiographically proven coronary stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug-E | 2013 |
Safety and efficacy of intense antithrombotic treatment and percutaneous coronary intervention deferral in patients with large intracoronary thrombus.
Topics: Acute Coronary Syndrome; Angiography; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopi | 2013 |
Thrombocytosis as a potential cause of a very late stent thrombosis in the left main coronary artery.
Topics: Adult; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary Thrombosis; Drug-Eluting Stent | 2013 |
Antiplatelet therapy. Cangrelor succeeds, at last, in PCI.
Topics: Adenosine Monophosphate; Administration, Intravenous; Administration, Oral; Blood Platelets; Clopido | 2013 |
Relationship between aspirin/clopidogrel resistance and intra-stent thrombi assessed by follow-up optical coherence tomography after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Confidence Intervals; Co | 2013 |
Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction.
Topics: Abciximab; Aged; Aged, 80 and over; Antibodies, Monoclonal; Clopidogrel; Coronary Thrombosis; Cost S | 2013 |
[Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
Topics: Acute Coronary Syndrome; Aged; Alleles; Angina, Unstable; Aryldialkylphosphatase; Biotransformation; | 2014 |
P2Y12 Receptor Blockade and Myocardial Perfusion.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary T | 2013 |
The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subf | 2013 |
Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Area Under Curve; Biomarkers; Cell Adhesion Molecu | 2013 |
Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; Blood Coagulation; Clopidogrel; Co | 2014 |
[The CHAMPION PHOENIX study].
Topics: Adenosine Monophosphate; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Coronary Thrombosis; D | 2013 |
Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clopidogrel; Coronary Artery Diseas | 2013 |
Impact of mild hypothermia on platelet responsiveness to aspirin and clopidogrel: an in vitro pharmacodynamic investigation.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; | 2014 |
Fixed-dose aspirin-clopidogrel combination enhances compliance to aspirin after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Dose-Re | 2014 |
A cautionary tale on the use of antiplatelet treatment following TURP.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Hematuria; Humans; Male; Myoca | 2014 |
A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
Topics: Aged; Aged, 80 and over; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Thrombosis; Dr | 2014 |
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Th | 2014 |
Subacute bioresorbable vascular scaffold thrombosis: a report of 2 cases.
Topics: Absorbable Implants; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis; | 2015 |
Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY).
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; France; Hemorrha | 2014 |
Fixed combination dual antiplatelet therapy and the risk of stent thrombosis.
Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-Elutin | 2014 |
Acute coronary thrombosis and multiple coronary aneurysms in a 22-year-old man with the human immunodeficiency virus.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Aneurysm; Coronary An | 2014 |
Letter by Roguin and Musallam regarding article, "Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial".
Topics: Acute Coronary Syndrome; Adenosine; Coronary Thrombosis; Female; Humans; Internationality; Male; Ste | 2014 |
Response to letter regarding article, "Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial".
Topics: Acute Coronary Syndrome; Adenosine; Coronary Thrombosis; Female; Humans; Internationality; Male; Ste | 2014 |
An atypical presentation of an extremely late stent thrombosis after more than 7 years (2634 days) of DES implantation in a patient without obvious risk factors on regular dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Drug-Elu | 2014 |
Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study.
Topics: Aged; Clopidogrel; Coronary Thrombosis; Denmark; Drug Administration Schedule; Drug Prescriptions; D | 2014 |
Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry.
Topics: Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Thrombosis; Female; Germany; Hemorrh | 2014 |
Changes in thrombus composition and profilin-1 release in acute myocardial infarction.
Topics: Analysis of Variance; Blood Platelets; Clopidogrel; Coronary Thrombosis; Female; Fibrinogen; Humans; | 2015 |
Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study.
Topics: Acute Coronary Syndrome; Aged; Biotransformation; Blood Platelets; Clopidogrel; Coronary Angiography | 2014 |
Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti | 2014 |
Tailored antiplatelet therapy in a patient with ITP and clopidogrel resistance.
Topics: Adenosine; Clopidogrel; Coronary Thrombosis; Drug Resistance; Drug Substitution; Humans; Male; Middl | 2015 |
Intrastent thrombus – what you see is what you get?
Topics: Angioscopy; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Female; | 2015 |
Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction.
Topics: Absorbable Implants; Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Everolimu | 2015 |
Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy.
Topics: Aged; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; D | 2015 |
Plasma fibrin clot phenotype independently affects intracoronary thrombus ultrastructure in patients with acute myocardial infarction.
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Coronary | 2015 |
Characterization of patients with angioscopically-detected in-stent mural thrombi – genetics of clopidogrel responsiveness and generations of drug-eluting stents.
Topics: Activation, Metabolic; Aged; Alleles; Angina Pectoris; Angioscopy; Aspirin; Clopidogrel; Coronary An | 2015 |
A case of repetitive and simultaneous stent thromboses.
Topics: Coronary Angiography; Coronary Thrombosis; Diagnosis, Differential; Electrocardiography; Graft Occlu | 2015 |
Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies.
Topics: Adenosine; Adult; Animals; Arteriovenous Shunt, Surgical; Aspirin; Blood Coagulation; Clopidogrel; C | 2015 |
Cardioembolic acute myocardial infarction associated with apical ballooning: Considerations.
Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Echocardiog | 2015 |
Very late bioresorbable vascular scaffold thrombosis: a new clinical entity.
Topics: Absorbable Implants; Aged, 80 and over; Anterior Wall Myocardial Infarction; Brachytherapy; Clopidog | 2015 |
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
Topics: Activation, Metabolic; Acute Coronary Syndrome; Aged; Alleles; Angina Pectoris; Aspirin; Clopidogrel | 2015 |
Prasugrel in Clopidogrel Nonresponders: A Way to Improve Secondary Prevention in Patients After Percutaneous Coronary Intervention?
Topics: Coronary Artery Disease; Coronary Thrombosis; Drug Substitution; Female; Humans; Male; Percutaneous | 2015 |
Successful Prasugrel Therapy for Recurrent Left Main Stent Thrombosis in a Clopidogrel Hyporesponder.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug Resis | 2015 |
Very late scaffold thrombosis of everolimus-eluting bioresorbable scaffold following implantation in STEMI after discontinuation of dual antiplatelet therapy.
Topics: Absorbable Implants; Adult; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Coronary Vessels | 2017 |
Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Drug Dosa | 2016 |
Stent thrombosis after primary percutaneous coronary intervention in comatose survivors of out-of-hospital cardiac arrest: Are the new P2Y12 inhibitors really more effective than clopidogrel?
Topics: Adenosine; Aspirin; Clopidogrel; Coma; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Comb | 2016 |
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr | 2015 |
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr | 2015 |
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr | 2015 |
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr | 2015 |
Personalized Antiplatelet Therapy: The Odyssey Continues.
Topics: Coronary Artery Disease; Coronary Thrombosis; Drug Substitution; Female; Humans; Male; Percutaneous | 2016 |
Reply: Personalized Antiplatelet Therapy: The Odyssey Continues.
Topics: Coronary Artery Disease; Coronary Thrombosis; Drug Substitution; Female; Humans; Male; Percutaneous | 2016 |
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Anemia; Aspirin; Body Mass Index; Clopidogrel; Cohort St | 2016 |
The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2016 |
CASE 11-2016 Perioperative Coronary Thrombosis in a Patient With Multiple Second-Generation Drug-Eluting Stents: Is It Time for a Paradigm Shift?
Topics: Analgesics, Opioid; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopid | 2016 |
Increased Platelet-leukocyte Aggregates Are Associated With Myocardial No-reflow in Patients With ST Elevation Myocardial Infarction.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Thrombos | 2016 |
Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug Antagonism; Drug | 2017 |
Platelet aggregation and the risk of stent thrombosis or bleeding in elective percutaneous coronary intervention patients.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Elective Surgical Procedures; Fema | 2017 |
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Aged; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Coronary Artery | 2017 |
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2017 |
Out-of-hospital cardiac arrest and stent thrombosis: Ticagrelor versus clopidogrel in patients with primary percutaneous coronary intervention under mild therapeutic hypothermia.
Topics: Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Humans; Hypothermia, Induced; Male; Middle Aged; | 2017 |
Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2017 |
Very late stent thrombosis after drug-eluting stent implantation in a patient without aspirin and clopidogrel resistance.
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Resista | 2008 |
The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow P2Y12 assay.
Topics: Angioplasty, Balloon, Coronary; Coronary Stenosis; Coronary Thrombosis; Female; Humans; Male; Platel | 2008 |
A threshold of platelet reactivity for ischaemic events?
Topics: Angioplasty, Balloon, Coronary; Coronary Stenosis; Coronary Thrombosis; Female; Humans; Male; Platel | 2008 |
Efficient tirofiban infusion resulting in resolution of intracoronary thrombus.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Clopidogrel; Coronary Angiography; Coronary Thrombo | 2008 |
Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug R | 2008 |
Very late stent thrombosis after discontinuation of clopidogrel therapy.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Follow-Up Studi | 2008 |
Safety and efficacy of low-dose clopidogrel in Japanese patients undergoing coronary stenting: preliminary 30-day clinical outcome.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Coronary Thrombosis; Female; Huma | 2008 |
Clopidogrel in a pediatric population: prescribing practice and outcomes from a single center.
Topics: Adolescent; Child; Child Welfare; Child, Preschool; Clopidogrel; Coronary Thrombosis; Drug Prescript | 2009 |
What to do with patients receiving long-term clopidogrel: reload or relax?
Topics: Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Humans; Platelet Aggregation; Random | 2008 |
[Severe myocardial infarction due to late and very late stent thrombosis after coronary artery stenting with drug-eluting stents].
Topics: Aged; Aspirin; Cardiac Catheterization; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Crea | 2008 |
Identifying clopidogrel resistance during chronic therapy: the case for a biochemical approach.
Topics: Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Humans; Platelet Aggrega | 2008 |
Overcoming "resistance" to aspirin and clopidogrel with tirofiban: fact or fiction?
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug Resistance; Humans; Platelet Aggregation Inhibitors; | 2008 |
The challenge of monitoring platelet response after clopidogrel.
Topics: Blood Platelets; Clopidogrel; Coronary Disease; Coronary Thrombosis; Humans; Platelet Aggregation In | 2008 |
Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug Resist | 2009 |
Death caused by simultaneous subacute stent thrombosis of sirolimus-eluting stents in left anterior descending artery and left circumflex artery.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Occ | 2010 |
Very late stent thrombosis after discontinuation of clopidogrel therapy.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Plate | 2009 |
Knowledge of coronary stents, thrombosis and dual antiplatelet therapy among Spanish dentists.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Cross-S | 2009 |
Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Thromb | 2009 |
Very late stent thrombosis after discontinuation of clopidogrel therapy.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Plate | 2009 |
Very late drug-eluting stent thrombosis after nonsteroidal anti-inflammatory drug treatment despite dual antiplatelet therapy.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Cyclooxygenase Inh | 2009 |
Combined, superselective pharmacological management of large coronary thrombus burden.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidog | 2009 |
Bridging with GP IIb/IIIa inhibitors after abdominal surgery in a patient presenting with late stent thrombosis of a drug-eluting stent and who cannot receive oral antiplatelet treatment.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug-Elu | 2009 |
Assessment of sirolimus-eluting coronary stent implantation with aspirin plus low dose ticlopidine administration: one year results from CYPHER Stent Japan Post-Marketing Surveillance Registry (J-PMS).
Topics: Aged; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis; Coronary Vessel | 2009 |
[Late thrombosis in paclitaxel-eluting stent after discontinuation of clopidogrel medication - a case report with 2-year follow-up].
Topics: Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Angiogra | 2009 |
Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiogra | 2008 |
A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis.
Topics: Analysis of Variance; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting S | 2009 |
Local determinants of thrombus formation following sirolimus-eluting stent implantation assessed by optical coherence tomography.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis | 2009 |
Coronary aneurysms after drug-eluting stent implantation: clinical, angiographic, and intravascular ultrasound findings.
Topics: Adult; Aged; Clopidogrel; Confidence Intervals; Coronary Aneurysm; Coronary Angiography; Coronary Re | 2009 |
Future of oral antiplatelet therapy: four challenged hypotheses.
Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Hemorr | 2009 |
Tailored medical and interventional therapy against recurrent stent thrombosis after drug-eluting stenting.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Thrombosis; Drug-Eluting Stents; Humans; Male | 2010 |
Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Combined Modality Therapy; C | 2009 |
New coating stent design for patients with high-risk coronary lesions for thrombotic events: early and long-term results of the Camouflage registry.
Topics: Aged; Argentina; Clopidogrel; Coated Materials, Biocompatible; Coronary Angiography; Coronary Diseas | 2009 |
Drug-specific thienopyridine resistance in patient with recurrent coronary stent thrombosis.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug Resistance; Humans; Male; Mid | 2009 |
Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis.
Topics: Aged; Aspirin; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary Thrombosis; Drug Resistan | 2009 |
Early stent thrombosis in patients undergoing primary coronary stenting for acute myocardial infarction: incidence, a simple risk score, and prognosis.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Female; Humans; Incid | 2010 |
Platelet antiaggregants in pregnancy.
Topics: Abciximab; Adult; Antibodies, Monoclonal; Clopidogrel; Coronary Thrombosis; Female; Humans; Immunogl | 2009 |
Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Blood Proteins | 2009 |
Time does not heal every wound: coronary stent thrombosis of a bare-metal stent more than one decade after its implantation.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis; Clopidogrel; Coronar | 2009 |
Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study).
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combi | 2009 |
Perioperative management of the patient with a coronary stent.
Topics: Algorithms; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stent | 2010 |
High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cor | 2009 |
Potential Interaction between clopidogrel and proton pump inhibitors.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Therapy, Combinat | 2009 |
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; | 2008 |
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should not be continued for more than 1 year and preferably indefinitely.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Restenosis; Cor | 2008 |
Guidelines for the management of antiplatelet therapy in patients with coronary stents undergoing non-cardiac surgery.
Topics: Anticoagulants; Aspirin; Australia; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Heparin; | 2010 |
[Antiplatelet therapy and urgent surgical procedures. Acute appendicitis two days after stent implantation--a case report].
Topics: Appendicitis; Clopidogrel; Coronary Thrombosis; Dobutamine; Humans; Intraoperative Complications; Ma | 2009 |
Subacute coronary stent thrombosis in a patient with angina treated with double antiplatelet drugs for six days.
Topics: Adult; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; D | 2009 |
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cyto | 2010 |
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cyto | 2010 |
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cyto | 2010 |
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cyto | 2010 |
Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Gene Freq | 2010 |
Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Combi | 2010 |
Very late drug-eluting stent thrombosis in the perioperative period of endoscopic choledocholithotomy.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; | 2009 |
Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Restenosis; Coronary | 2010 |
Acute myocardial infarction related to very late sirolimus-eluting stent thrombosis 6 months after discontinuation of dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiogra | 2011 |
The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response.
Topics: Aged; Amlodipine; Angioplasty; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platel | 2010 |
[Recurrent stent thrombosis in a patient with non-ST-segment elevation acute coronary syndrome].
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Resistance; El | 2010 |
[Thrombosis of pharmacoactive coronary endoprothesis after stopping antiplatelet treatment].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cholecystectomy, Laparoscopic; Cholecystolithiasis; Clopido | 2010 |
Thrombus too big for pharmacology alone?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Thrombosis; Humans; | 2010 |
Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery | 2010 |
Late and very late stent thrombosis after polymer-based sirolimus- or paclitaxel-eluting stent implantation in real-world clinical practice.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug-Eluting Stents; Humans; Paclitaxel | 2010 |
Comparison of the incidence of late stent thrombosis after implantation of different drug-eluting stents in the real world coronary heart disease patients: three-year follow-up results.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Huma | 2010 |
Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Glucose; C-Reactive Protein; Clopid | 2010 |
The evidence base for platelet function testing in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Atherectomy; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Diagnostic | 2010 |
Management of perioperative stent thrombosis in patients undergoing surgery.
Topics: Aged; Aspirin; Cardiac Surgical Procedures; Clopidogrel; Coronary Thrombosis; Humans; Male; Perioper | 2010 |
Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window.
Topics: Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Hemorrhage; Humans; Platelet Aggregation; Pur | 2010 |
Initial experience with an institutional bridging protocol for patients with recent coronary stent implantation requiring discontinuation of dual antiplatelet therapy resulting from urgent surgery.
Topics: Antithrombins; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; | 2011 |
Recurrent acute stent thrombosis due to allergic reaction secondary to clopidogrel therapy.
Topics: Acute Disease; Adult; Clopidogrel; Coronary Thrombosis; Drug Hypersensitivity; Humans; Male; Platele | 2011 |
Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary | 2010 |
Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
Topics: Adenosine; Animals; Bleeding Time; Blood Coagulation; Clopidogrel; Coronary Circulation; Coronary Th | 2010 |
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Artery | 2010 |
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Artery | 2010 |
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Artery | 2010 |
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Artery | 2010 |
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Combined Modali | 2010 |
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Combined Modali | 2010 |
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Combined Modali | 2010 |
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Combined Modali | 2010 |
[Between thrombosis and bleeding - a case of paroxysmal nocturnal hemoglobinuria].
Topics: Aged; Anticoagulants; Aspirin; Cerebral Hemorrhage; Clopidogrel; Coronary Thrombosis; Drug Therapy, | 2010 |
Significant increase in clopidogrel use across U.S. children's hospitals.
Topics: Adolescent; Child; Child, Preschool; Clopidogrel; Coronary Thrombosis; Databases, Factual; Drug Ther | 2011 |
[Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; | 2010 |
What is the optimal duration of triple anti-platelet therapy in patients with acute myocardial infarction undergoing drug-eluting stent implantation?
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Female; Follow-Up Studie | 2011 |
Clinical and angiographic outcomes with sirolimus-eluting stent for coronary bifurcation lesions. The J-PMS study.
Topics: Angioplasty; Aspirin; Calcinosis; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coro | 2011 |
Behind the paper: stepping up to the antiplatelet.
Topics: Amino Acid Sequence; Aryldialkylphosphatase; Aspirin; Clopidogrel; Coronary Thrombosis; Cytochrome P | 2011 |
Management of clopidogrel hypersensitivity without drug interruption.
Topics: Adrenal Cortex Hormones; Cardiac Catheterization; Clopidogrel; Coronary Thrombosis; Drug Hypersensit | 2011 |
Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding St
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Dos | 2011 |
Recurrent myocardial infarction due to one subacute and two very late thrombotic events of drug-eluting stent associated with clopidogrel resistance.
Topics: Adult; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug | 2011 |
Recurrent episodes of very late stent thrombosis in a patient with aspirin hypersensitivity, stent fracture and malapposition.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Occlusion; Coronary Thrombosis; Drug | 2011 |
Treatment patterns in acute coronary syndrome patients in the United Kingdom undergoing PCI.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thromb | 2011 |
[Coronary stent thrombosis in concurrent clopidogrel and proton pump inhibitor therapy].
Topics: Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Therapy, Combination; Humans; Platelet Agg | 2011 |
Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary A | 2011 |
Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting.
Topics: Aged; Calcium Channel Blockers; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary | 2011 |
Effective management of acute coronary thrombosis in a young woman with lupus using aggressive medical therapy.
Topics: Adult; Aspirin; Clopidogrel; Coronary Thrombosis; Eptifibatide; Female; Fibrinolytic Agents; Heparin | 2011 |
Serial angioscopic evaluation of neointimal coverage and incidence of thrombus formation after Paclitaxel-eluting stent implantation: comparison between 6- and 18-month follow-up.
Topics: Aged; Angioscopy; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Health | 2011 |
Comparison of two murine models of thrombosis induced by atherosclerotic plaque injury.
Topics: Animals; Apolipoproteins E; Blood Platelets; Carotid Arteries; Clopidogrel; Coronary Thrombosis; Dis | 2011 |
[Multiple arterial thrombosis and resistance to conventional antiaggregation].
Topics: Aged; Angiography; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Resistance; Electrocardiography; | 2011 |
Increased platelet turnover in patients with previous definite stent thrombosis.
Topics: Aspirin; Blood Platelets; Coronary Thrombosis; Female; Humans; Male; Ticlopidine | 2011 |
Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shock.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiopulmonary Resuscitation; Catecholamines; Clopidogrel; Co | 2011 |
Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2012 |
Influence of low-dose aspirin (81 mg) on the incidence of definite stent thrombosis in patients receiving bare-metal and drug-eluting stents.
Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Therapy, Combination; Drug-Elut | 2011 |
Recent trends in Australian percutaneous coronary intervention practice: insights from the Melbourne Interventional Group registry.
Topics: Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Australia; Clopidogrel; Comorb | 2011 |
Influence of platelet reactivity on outcome of patients with acute myocardial infarction undergoing primary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Female; Humans; Male; Myocardial I | 2011 |
Antiplatelet therapy in percutaneous coronary intervention: is variability of response clinically relevant?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Thrombosis | 2011 |
Stent-related cardiac events beyond three years after implantation of the sirolimus-eluting stent (from the EVASTENT Patients).
Topics: Clopidogrel; Cohort Studies; Coronary Artery Disease; Coronary Thrombosis; Diabetes Mellitus; Drug-E | 2011 |
Optical coherence tomography findings during "evolving" stent thrombosis.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cardiopulmonary Resuscitation; Clopidogr | 2011 |
Intravascular ultrasound and angiographic demonstration of left main stem thrombus-high-risk presentation in a young adult with anabolic steroid abuse.
Topics: Abciximab; Anabolic Agents; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Angiography; Coro | 2010 |
Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2012 |
Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel.
Topics: Aged; Aged, 80 and over; Amplified Fragment Length Polymorphism Analysis; Angioplasty, Balloon, Coro | 2011 |
Renal function assessed using cystatin C and antiplatelet efficacy of clopidogrel assessed using the vasodilator-stimulated phosphoprotein index in patients having percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Proteins; Cell Adhesion Molecules; Clopidogrel; Coronary | 2012 |
Low mean corpuscular hemoglobin level is a predictor of discontinuation of antiplatelet therapy in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cl | 2011 |
"Conversations in cardiology": How do you pick the best antiplatelet drug--clopidogrel, prasugrel, ticagrelor for your PCI patient?
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Decision Making; Humans | 2012 |
The safety of major head and neck surgery in patients taking clopidogrel (Plavix).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Thrombosis; Female; Head and Neck | 2012 |
Acute stent thrombosis: technical complication or inadequate antithrombotic therapy? An optical coherence tomography study.
Topics: Acute Disease; Aged; Antithrombins; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Eptifibat | 2012 |
Short thromboelastography and the identification of high platelet reactivity while on and off therapy.
Topics: Clopidogrel; Coronary Thrombosis; Drug Resistance; Female; Graft Occlusion, Vascular; Humans; Male; | 2012 |
Personalised antiplatelet therapy in stent thrombosis: observations from the Clopidogrel Resistance in Stent Thrombosis (CREST) registry.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Resistance; | 2012 |
Very late thrombosis of a paclitaxel-eluting stent after 72 months in a patient on dual anti-platelet therapy.
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Echocardiography; Electrocardiograph | 2012 |
Pharmacodynamic effect of clopidogrel therapy and switching to cilostazol in patients with the CYP2C19 loss-of-function allele (ACCEL-SWITCH) study.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Asian People; Aspirin; Cilostazol; Cl | 2012 |
Simultaneous subacute thrombosis of bare metal coronary stents in two different arteries early after clopidogrel cessation.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coron | 2012 |
Simultaneous thromboses of two coronary arteries in a heavy smoker woman: a singular case of acute myocardial infarction.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Antibodies | 2012 |
Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Animals; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Humans; | 2012 |
Early and late outcome associated with bleeding events in the setting of dual antiplatelet therapy following stent placement.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Hem | 2012 |
Less may be more: insights on dual antiplatelet therapy duration after drug-eluting stent implantation from the MATRIX registry.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Hum | 2012 |
Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clopidogrel; Cohort Studies | 2013 |
Understand the power of Plavix. This antiplatelet drug prevents in-stent clots in women as well as men.
Topics: Angioplasty, Balloon; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug-Eluting S | 2010 |
Predictors of early, late, and very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Confidence Intervals; Coronary Restenosis; Corona | 2012 |
Effects of pre-hospital clopidogrel administration on early and late residual platelet reactivity in ST-segment elevation myocardial infarction patients undergoing primary intervention.
Topics: Aged; Belgium; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Emer | 2013 |
A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study.
Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; China; Clopidogrel; Coronary Artery Disea | 2012 |
Current antiplatelet therapy for Japanese patients with ST elevation acute myocardial infarction: J-AMI registry.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Femal | 2013 |
Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cass | 2013 |
A case of in-stent thrombosis in a patient with drug eluting stents during perioperative management with glycoprotein IIb/IIIa inhibitors.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug | 2013 |
Ambulatory use of ticlopidine and clopidogrel in association with percutaneous coronary revascularization procedures in a national managed care organization.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; | 2002 |
Clopidogrel as an antiplatelet agent in transplant heart coronary stenting.
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Heart Transplantation; Humans; | 2002 |
Large intracoronary thrombi with good TIMI flow during acute myocardial infarction: four cases of successful aggressive medical management in patients without angiographically detectable coronary atherosclerosis.
Topics: Abciximab; Adult; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Coronary Circulation | 2002 |
Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cor | 2002 |
Influence of residual stenosis after percutaneous coronary intervention with stent implantation on development of restenosis and stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Restenosis; Coronary T | 2003 |
Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Antigens, CD; Clopidogrel; Collagen; Coronary Disease; Coronar | 2003 |
Introduction to "Optimizing management of non-ST-segment elevation acute coronary syndromes". Harmonizing advances in mechanical and pharmacologic intervention.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Clopidogre | 2003 |
Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Cell Adhesio | 2003 |
[Effects of antiaggregants on concentration of plasma cytokines in patients with acute coronary syndrome].
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cytokines; Female | 2003 |
Clopidogrel versus ticlopidine after the placement of coronary artery stents.
Topics: Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Dose-Response Relationship, Drug; Humans | 2003 |
Influence of residual stenosis after coronary stent implantation on development of restenosis and stent thrombosis.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Restenosis; Coronary Thrombo | 2003 |
Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation.
Topics: Aged; Aspirin; Atherectomy, Coronary; Catheterization; Cilostazol; Combined Modality Therapy; Corona | 2004 |
Are we making efficient use of clopidogrel?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Humans; Platelet Aggregation Inhib | 2004 |
Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disea | 2004 |
Resistance to antiplatelet drugs: is it real or relevant?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Brachytherapy; Clopid | 2004 |
Late stent thrombosis (> 1 year) following clopidogrel withdrawal after brachytherapy treatment: need to assess aspirin resistance?
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Brachytherapy; | 2004 |
PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation.
Topics: Abciximab; Adenosine Diphosphate; Aged; Amino Acid Substitution; Antibodies, Monoclonal; Aspirin; Bl | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
[New antiplatelet agents (platelet receptor blockers): has aspirin come out of place?].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Huma | 2004 |
[What should one pay attention to during surgery shortly after brachytherapy with coated stents?].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Brachytherapy; Clopidogrel; Contraindications; Coronary Thr | 2004 |
Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Administration, Oral; Aspirin; Clopidogrel; Coronary Thrombosis; Evidence-Based Medicine; Humans; My | 2004 |
Late coronary thrombosis after drug-eluting stent: stent vs patient-driven prescription of aspirin-clopidogrel combination.
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; Humans; Middle Aged; P | 2004 |
[Antiplatelet strategies in the acute and chronic therapy of cardiovascular disease].
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Humans; Long-Term Care; Myocar | 2004 |
Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery B | 2004 |
A case of life-saving pharmacologic and mechanical coronary dethrombosis.
Topics: Angioplasty, Balloon; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis; | 2004 |
Subacute coronary stent thrombosis in a patient developing clopidogrel associated thrombotic thrombocytopenic purpura.
Topics: Aged; Angina, Unstable; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis | 2005 |
Dual antiplatelet therapy for coronary stenting: a clear path for a research agenda.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug A | 2005 |
[Exercise-induced left arm pain and thrombocytosis].
Topics: Angioplasty, Balloon, Coronary; Bone Marrow Examination; Clopidogrel; Coronary Angiography; Coronary | 2005 |
Very late thrombosis after implantation of sirolimus eluting stent.
Topics: Adult; Aspirin; Blood Vessel Prosthesis; Catheterization; Clopidogrel; Coronary Angiography; Coronar | 2005 |
Validation of predictors of intraprocedural stent thrombosis in the drug-eluting stent era.
Topics: Acute Disease; Anticoagulants; Antineoplastic Agents, Phytogenic; Blood Vessel Prosthesis Implantati | 2005 |
Increased long term rates of stent thrombosis and mortality in patients given clopidogrel as compared to ticlopidine following coronary stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; D | 2005 |
What is the best measure of thrombotic risks--pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation?
Topics: Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Humans; P | 2005 |
Optimal antiplatelet treatment for percutaneous coronary intervention: clopidogrel vs. ticlopidine.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Resistance | 2007 |
Antiplatelet therapy after percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug Resistan | 2006 |
Potent low dose platelet inhibitory effects of clopidogrel and aspirin on coronary thrombus formation in an animal model of acute unstable angina.
Topics: Acute Disease; Angina, Unstable; Animals; Aspirin; Clopidogrel; Coronary Thrombosis; Disease Models, | 2006 |
Successful lysis of coronary thrombi by long term warfarin treatment after a failed course of tirofiban infusion.
Topics: Angina Pectoris; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combinatio | 2006 |
Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis.
Topics: Animals; Bleeding Time; Clopidogrel; Coronary Thrombosis; Disease Models, Animal; Dogs; Dose-Respons | 2006 |
Suspected clopidogrel resistance in a patient with acute stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary | 2006 |
Combined aspirin and clopidogrel resistance associated with recurrent coronary stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Rest | 2006 |
Late in-stent thrombosis in a patient with systemic lupus erythematosus and hyperhomocysteinemia while on clopidogrel and aspirin.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Coagulation Disorders; Clopidogrel; Coronary Artery D | 2006 |
Subacute thrombosis after coronary stenting occurring with resistance to ticlopidine.
Topics: Aged; Angioplasty, Balloon, Coronary; Atherectomy, Coronary; Coronary Thrombosis; Drug Resistance; H | 2006 |
Clopidogrel-associated thrombotic thrombocytopenic purpura presenting with coronary artery thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Female; Humans; L-Lactate De | 2006 |
Use of ticlopidine and cilostazol after intracoronary drug-eluting stent placement in a patient with previous clopidogrel-induced thrombotic thrombocytopenic purpura: a case report.
Topics: ADAM Proteins; ADAMTS1 Protein; Aged; Apoptosis; Aspirin; Autoantibodies; Cilostazol; Clopidogrel; C | 2006 |
[Combination of clopidogrel and aspirin was no better than aspirin alone for prevention of atherothrombotic events in stable patients. Results of CHARISMA].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug T | 2006 |
Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study.
Topics: Aged; Aspirin; Coronary Restenosis; Coronary Thrombosis; Disease Progression; Female; Humans; Immuno | 2006 |
Clinical, biochemical and genetical resistance to clopidogrel in a patient with recurrent stent thrombosis.
Topics: Clopidogrel; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance | 2007 |
The CHARISMA trial and the REACH registry outcomes.
Topics: Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Humans; Inciden | 2006 |
Clinical and angiographic outcomes of sirolimus-eluting stents implantation in Japanese patients in daily practice.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Coronary Restenosis; C | 2006 |
Late thrombosis of drug-eluting stents after discontinuation of clopidogrel: report of two cases and review of the literature.
Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Male; Middle Aged; Myocardial | 2006 |
Late angiographic stent thrombosis in a drug-eluting stent that occurred 20 months after premature discontinuation of clopidogrel administration.
Topics: Adult; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary Thrombosis; Humans; Male; Plat | 2006 |
A current problem in cardiology: very late thrombosis after implantation of sirolimus eluting stent.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Huma | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T | 2007 |
Late ischemic events after clopidogrel cessation following drug-eluting stenting: should we be worried?
Topics: Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Delivery Systems; Humans; Immunosuppressiv | 2006 |
A new caution for patients with drug-coated stents.
Topics: Clopidogrel; Coronary Disease; Coronary Thrombosis; Humans; Platelet Aggregation Inhibitors; Stents; | 2006 |
Stent thrombosis: consider also low response to antiplatelets.
Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Implants; Humans; Platelet Aggr | 2007 |
Stent thrombosis: patient card on discontinuing clopidogrel is available.
Topics: Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Implants; Humans; Medical Records; Plate | 2007 |
Response to letter of Dr van Werkum et al.
Topics: Clopidogrel; Coronary Thrombosis; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Ticlopid | 2007 |
Incidence of side-effects of ticlopidine after sirolimus-eluting stent implantation.
Topics: Aged; Blood Vessel Prosthesis Implantation; Chemical and Drug Induced Liver Injury; Coronary Thrombo | 2007 |
Double-trouble: three cases with simultaneous stent thrombosis in different coronary arteries.
Topics: Aged; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis; Clopid | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro | 2007 |
A case report of simultaneous thrombosis of two coronary artery stents in association with clopidogrel resistance.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Resi | 2007 |
Late thrombosis of a drug-eluting stent during combined anti-platelet therapy in a clopidogrel nonresponsive diabetic patient: shall we routinely test platelet function?
Topics: Aged; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Diabetic Angiopathies; Drug Resistance; Hu | 2007 |
Increased incidence of stent thrombosis in patients with cocaine use.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cocaine-Related Disorders; Co | 2007 |
[Treatment of intrastent restenosis by drug eluting stents: experience from one cardiology centre].
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Clopidogrel; Coronary Angiography; Coronar | 2007 |
Timing of thrombotic events in patients receiving 2 weeks of clopidogrel therapy post bare metal coronary artery stenting: a New Zealand retrospective study.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary | 2007 |
Clopidogrel and stent thrombosis after percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Restenosis; Coronary Thrombo | 2007 |
Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Angi | 2007 |
Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; Corona | 2008 |
Confined late stent thrombosis following clopidogrel withdrawal in a patient with multi-segment sirolimus-eluting stent implants.
Topics: Abciximab; Aged; Angioplasty, Balloon; Antibodies, Monoclonal; Anticoagulants; Clopidogrel; Coronary | 2007 |
Comparison of drug-eluting stents with bare metal stents in unselected patients with acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cardiovascular Diseases; Clopidogrel; C | 2007 |
Very late paclitaxel-eluting stent thrombosis despite 21 months of clopidogrel treatment after percutaneous coronary intervention.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Clopidogrel; Coronary Angiogra | 2007 |
[Suspected clopidogrel resistance associated with recurrent coronary stent thrombosis--a case report].
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombos | 2007 |
Perioperative thrombotic risk of coronary artery stents: possible role for intravenous platelet blockade.
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Injections, Intravenous; Perioperative Care; Plat | 2007 |
Sirolimus-eluting stent thrombosis several years after clopidogrel discontinuation.
Topics: Adult; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug Deliver | 2007 |
Angiographic and procedural correlates of stent thrombosis after intracoronary implantation of drug-eluting stents.
Topics: Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stents; He | 2007 |
Triple antithrombotic therapy with aspirin, clopidogrel and warfarin--a persisting dilemma.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Fibrinoly | 2007 |
Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany.
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Clopidogrel; Cohort Studies; Coronary Thrombosis; | 2008 |
[Prasugrel, a new thienopyridine].
Topics: Clinical Trials, Phase II as Topic; Clopidogrel; Coronary Thrombosis; Humans; Piperazines; Platelet | 2007 |
Perioperative complications in patients with drug-eluting stents: a three-year audit at Geelong Hospital.
Topics: Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Intraoperative Complications; Male; M | 2007 |
The success of clopidogrel treatment for recurrent coronary thrombosis in a patient with aortic and mitral valve replacement.
Topics: Aortic Valve; Clopidogrel; Coronary Thrombosis; Female; Heart Valve Prosthesis; Humans; Middle Aged; | 2008 |
[Four years of circulatory support with the INCOR axial pump from Berlin Heart].
Topics: Clopidogrel; Coronary Thrombosis; Enoxaparin; Fibrinolytic Agents; Heart Failure; Heart-Assist Devic | 2007 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Very late thrombosis in a bare metal stent: an under-recognized problem.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Humans; Male; | 2008 |
Which patients receiving warfarin can be treated safely with a drug-eluting stent?
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Restenosis; Cor | 2008 |
Clinical outcomes after multilesion percutaneous coronary intervention: comparison between exclusive and selective use of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Cor | 2008 |
Drug-eluting versus bare-metal stents: when and for whom?
Topics: Angioplasty, Balloon, Coronary; Canada; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2008 |
Very very late thrombosis of a sirolimus-eluting stent: does suboptimal stent expansion take its toll even after three years?
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Male; Middle Aged; Platelet | 2008 |
Simultaneous subacute coronary drug-eluting stent thrombosis in two different vessels of a patient with factor V Leiden mutation.
Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosi | 2008 |
Resistance to what, does it matter? How do we study it?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Resistance | 2008 |
Clinical, procedural, and pharmacologic correlates of acute and subacute stent thrombosis: results of a multicenter case-control study with 145 thrombosis events.
Topics: Acute Disease; Aged; Analysis of Variance; Case-Control Studies; Clopidogrel; Coronary Angiography; | 2008 |
Stent thrombosis--a complication best avoided.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Th | 2008 |
Percutaneous coronary intervention in neurosurgical patients.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombos | 2008 |
Resistance to platelet antiaggregants: an important cause of very late thrombosis of drug eluting stents? Observations from five cases.
Topics: Aged; Aged, 80 and over; Aspirin; Cell Adhesion Molecules; Clopidogrel; Coronary Thrombosis; Drug Re | 2008 |
Acute stent thrombosis in a patient with giant cell arteritis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Di | 2008 |
Commentary for "Comparison of drug eluting stents with bare metal stents in unselected patients with acute myocardial infarction".
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Metal | 2008 |
Antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 male mice with myocardial infarction and systemic lupus erythematosus.
Topics: Analysis of Variance; Animals; Antigen-Antibody Complex; Blood Urea Nitrogen; Coronary Disease; Coro | 1995 |
[Pilot study of the efficacy of ticlopidine in early patency of coronary endoprostheses].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Disease; Coron | 1994 |
Relation of thrombotic occlusion of coronary stents to the indication for stenting, stent size, and anticoagulation.
Topics: Angioplasty, Balloon, Coronary; Coronary Disease; Coronary Thrombosis; Female; Heparin; Humans; Male | 1995 |
Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance of thromboxane A2 and thrombin.
Topics: Anesthesia; Animals; Aspirin; Biphenyl Compounds; Blood Coagulation Tests; Coronary Circulation; Cor | 1994 |
Clopidogrel is more effective than aspirin in preventing coronary artery reocclusion after thrombolysis.
Topics: Animals; Aspirin; Blood Coagulation; Clopidogrel; Coronary Thrombosis; Disease Models, Animal; Dogs; | 1993 |
Ticlopidine and subcutaneous heparin as an alternative regimen following coronary stenting.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Thrombosis; Female; Heparin | 1994 |
Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis.
Topics: Animals; Aspirin; Clopidogrel; Coronary Thrombosis; Dogs; Drug Therapy, Combination; Fibrinolytic Ag | 1994 |
Improved outcome of coronary stenting by utilizing a modified treatment protocol.
Topics: Aged; Angioplasty, Balloon, Coronary; Clinical Protocols; Combined Modality Therapy; Coronary Diseas | 1996 |
Reduction of thrombotic and hemorrhagic complications after stent implantation.
Topics: Acute Disease; Aged; Anticoagulants; Coronary Angiography; Coronary Thrombosis; Female; Follow-Up St | 1996 |
Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome.
Topics: Anticoagulants; Aspirin; Case-Control Studies; Causality; Coronary Angiography; Coronary Disease; Co | 1997 |
Ticlopidine in the prevention of thrombus formation after percutaneous transluminal coronary angioplasty (PTCA).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Disease; Coronary Thrombosis | 1997 |
Antiplatelet therapy alone is safe and effective after coronary stenting: observations of a transition in practice.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Ar | 1997 |
Neutropenia with ticlopidine plus aspirin.
Topics: Aspirin; Chemoprevention; Coronary Thrombosis; Coronary Vessels; Drug Combinations; Fibrinolytic Age | 1997 |
Micro stent implantation in patients with acute myocardial infarction without anticoagulation: clinical experience with two different antithrombotic protocols.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Angiograp | 1998 |
[Thrombocyte aggregation inhibition].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Thrombosis; Humans; Intracranial Embolism | 1998 |
Emergency coronary artery bypass grafting (CABG) after failed coronary artery intervention--caution regarding the combined use of aspirin, ticlopidine and abciximab.
Topics: Abciximab; Adult; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 1998 |
Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting.
Topics: Aged; Coronary Disease; Coronary Thrombosis; Fatal Outcome; Female; Humans; Male; Middle Aged; Neutr | 1999 |
Preliminary experience with intravascular ultrasound guided Palmaz-Schatz coronary stenting: the acute and short-term results on a consecutive series of patients.
Topics: Aged; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Evaluation Studies as Topi | 1994 |
Toward the elimination of stent thrombosis.
Topics: Coronary Thrombosis; Fibrinolytic Agents; Humans; Registries; Stents; Ticlopidine | 1999 |
[Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation].
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Humans; Platelet Aggregation I | 1999 |
Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Dise | 1999 |
Vale, warfarin: a stentorian farewell.
Topics: Animals; Anticoagulants; Aspirin; Coronary Thrombosis; Dogs; Humans; Platelet Aggregation Inhibitors | 1999 |
Studies published on clopidogrel-aspirin for coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Drug Combinations; Humans; Platelet Agg | 2000 |
[Imputable cutaneous eruption caused by ticlopidine after implantation of a coronary endoprosthesis: why not continue treatment?].
Topics: Angioplasty, Balloon, Coronary; Coronary Disease; Coronary Thrombosis; Dose-Response Relationship, D | 2000 |
Ticlopidine plus aspirin for coronary thrombosis in Kawasaki disease.
Topics: Aspirin; Coronary Thrombosis; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Infant; Male; | 2000 |
Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine.
Topics: Abciximab; Adult; Aged; Antibodies, Monoclonal; Blood Vessel Prosthesis Implantation; Cardiac Cathet | 2000 |
Extensive thrombus prior to elective percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Coronary Thrombosis; Elective Surgical | 2001 |
Late acute thrombosis after paclitaxel eluting stent implantation.
Topics: Acute Disease; Angiogenesis Inhibitors; Aspirin; Coronary Disease; Coronary Thrombosis; Drug Implant | 2001 |
Adjunctive therapies in the cath lab. Subacute stent thrombosis developing twelve days after discontinuation of ticlopidine treatment.
Topics: Acute Disease; Aged; Coronary Thrombosis; Female; Humans; Platelet Aggregation Inhibitors; Stents; S | 2001 |
Coronary stent thrombosis: insights from the porcine coronary stent model.
Topics: Animals; Anticoagulants; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Coronary Vess | 2001 |
Aspirin plus clopidogrel for everyone: panacea comes true in the 21st century.
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Platelet Aggregation Inhibitors; Postoperative Co | 2001 |
Thrombostatin inhibits cyclic flow variations in stenosed canine coronary arteries.
Topics: Animals; Aspirin; Blood Coagulation Tests; Bradykinin; Clopidogrel; Coronary Stenosis; Coronary Thro | 2001 |
Thrombus formation on guide wires during routine PTCA procedures: a scanning electron microscopic evaluation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coated Materials, Biocompatible; Coronary Thrombosis; | 2002 |
[Two platelet inhibitors after acute coronary syndrome. Many colleagues are not aware of this].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug T | 2002 |
[A case of hypertrophic obstructive cardiomyopathy with left atrial giant thrombus during anti-platelet therapy].
Topics: Aged; Cardiomyopathy, Hypertrophic; Coronary Disease; Coronary Thrombosis; Echocardiography; Female; | 1989 |
Intracoronary thrombodynamics in the early phase of acute myocardial infarction.
Topics: Animals; Blood Pressure; Coronary Circulation; Coronary Disease; Coronary Thrombosis; Death, Sudden; | 1988 |